{"questions": [{"body": "Is there a role of proton beam therapy in medulloblastoma treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25927402", "http://www.ncbi.nlm.nih.gov/pubmed/26548600", "http://www.ncbi.nlm.nih.gov/pubmed/24187330", "http://www.ncbi.nlm.nih.gov/pubmed/25403752", "http://www.ncbi.nlm.nih.gov/pubmed/23433794", "http://www.ncbi.nlm.nih.gov/pubmed/22553304"], "ideal_answer": ["Yes, proton beam therapy is used for treatment of medulloblastoma."], "exact_answer": "yes", "type": "yesno", "id": "58850ac7e56acf5176000012", "snippets": [{"offsetInBeginSection": 746, "offsetInEndSection": 952, "text": "All papers directly compared outcomes from protons with photons, five papers included medulloblastoma, four papers each included craniopharyngioma and low grade gliomas and three papers included ependymoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25927402", "endSection": "abstract"}, {"offsetInBeginSection": 1872, "offsetInEndSection": 2212, "text": "There are many indications of protontherapy for paediatric brain tumours in curative intent, either for localized treatment of ependymomas, germ-cell tumours, craniopharyngiomas, low-grade gliomas; or panventricular irradiation of pure non-secreting germinoma; or craniospinal irradiation of medulloblastomas and metastatic pure germinomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26548600", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Cost-effectiveness analysis of cochlear dose reduction by proton beam therapy for medulloblastoma in childhood.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187330", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 360, "text": "BACKGROUND: The aim of this study is to evaluate the cost-effectiveness of proton beam therapy with cochlear dose reduction compared with conventional X-ray radiotherapy for medulloblastoma in childhood.METHODS: We developed a Markov model to describe health states of 6-year-old children with medulloblastoma after treatment with proton or X-ray radiotherapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187330", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Evaluation of permanent alopecia in pediatric medulloblastoma patients treated with proton radiation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25403752", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "BACKGROUND: To precisely calculate skin dose and thus to evaluate the relationship between the skin dose and permanent alopecia for pediatric medulloblastoma patients treated with proton beams.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25403752", "endSection": "abstract"}, {"offsetInBeginSection": 1139, "offsetInEndSection": 1314, "text": "CONCLUSIONS: Our results based on 12 patients provide a relationship between the skin dose and permanent alopecia for pediatric medulloblastoma patients treated with protons. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25403752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23433794", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "PURPOSE: Efficacy and acute toxicity of proton craniospinal irradiation (p-CSI) were compared with conventional photon CSI (x-CSI) for adults with medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23433794", "endSection": "abstract"}, {"offsetInBeginSection": 1235, "offsetInEndSection": 1358, "text": "CONCLUSIONS: This report is the first analysis of clinical outcomes for adult medulloblastoma patients treated with p-CSI. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23433794", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Dilemmas concerning dose distribution and the influence of relative biological effect in proton beam therapy of medulloblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553304", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "OBJECTIVE: To improve medulloblastoma proton therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553304", "endSection": "abstract"}]}, {"body": "Which protein complexes recognize centromeric (CEN) DNA in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23620291", "http://www.ncbi.nlm.nih.gov/pubmed/22693454", "http://www.ncbi.nlm.nih.gov/pubmed/3464952"], "ideal_answer": ["The Schizosaccharomyces pombe centromere-linked genes, LYS1 and CYH1 on chromosome I and TPS13 and RAN1 on chromosome II, have been isolated. In budding yeast, as well as in other eukaryotes, the Cse4 histone variant (known in vertebrates as CENP-A) is believed to substitute for histone H3 at the centromeric nucleosome.", "The Schizosaccharomyces pombe centromere-linked genes, LYS1 and CYH1 on chromosome I and TPS13 and RAN1 on chromosome II, have been isolated Histone H3 localizes to the centromeric DNA in budding yeast  In budding yeast, as well as in other eukaryotes, the Cse4 histone variant (known in vertebrates as CENP-A) is believed to substitute for histone H3 at the centromeric nucleosome", "The Schizosaccharomyces pombe centromere-linked genes, LYS1 and CYH1 on chromosome I and TPS13 and RAN1 on chromosome II, have been isolated"], "exact_answer": [["Lys1"], ["Cyh1"], ["Tps13"], ["Ran1"], ["H3"], ["Cse4"]], "type": "list", "id": "58a71f7460087bc10a00002e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "The Schizosaccharomyces pombe centromere-linked genes, LYS1 and CYH1 on chromosome I and TPS13 and RAN1 on chromosome II, have been isolated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3464952", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "Histone H3 localizes to the centromeric DNA in budding yeast", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693454", "endSection": "title"}, {"offsetInBeginSection": 503, "offsetInEndSection": 682, "text": " In budding yeast, as well as in other eukaryotes, the Cse4 histone variant (known in vertebrates as CENP-A) is believed to substitute for histone H3 at the centromeric nucleosome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693454", "endSection": "abstract"}, {"offsetInBeginSection": 915, "offsetInEndSection": 1142, "text": "Surprisingly, we observed a strong interaction of H3, as well as Cse4, H4, H2A, and H2B, but not histone chaperone Scm3 (HJURP in human) with the centromeric DNA. H3 localizes to centromeric DNA at all stages of the cell cycle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693454", "endSection": "abstract"}, {"offsetInBeginSection": 1246, "offsetInEndSection": 1325, "text": "Our results favor a H3-Cse4 heterotypic octamer at the budding yeast centromere", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693454", "endSection": "abstract"}, {"offsetInBeginSection": 92, "offsetInEndSection": 257, "text": "In budding yeast, a single right-handed cenH3/H4/H2A/H2B tetramer wraps the \u223c80-bp Centromere DNA Element II (CDE II) sequence of each centromere into a 'hemisome'. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23620291", "endSection": "abstract"}, {"offsetInBeginSection": 446, "offsetInEndSection": 559, "text": "Here, we show that Cse4 octamers remain intact under conditions of low salt and urea that dissociate H3 octamers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23620291", "endSection": "abstract"}]}, {"body": "Are there canonical marks of active chromatin in developmentally regulated genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26280901"], "ideal_answer": ["No. The transcription of genes temporally regulated during fly and worm development occurs in the absence of canonically active histone modifications. Conversely, strong chromatin marking is related to transcriptional and post-transcriptional stability, an association also observed in mammals. Consequently, chromatin marking is associated with the stable production of RNA, whereas unmarked chromatin would permit rapid gene activation and deactivation during development. In the latter case, regulation by transcription factors would have a comparatively more important regulatory role than chromatin marks."], "exact_answer": "no", "type": "yesno", "id": "588383172305cd7e21000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Absence of canonical marks of active chromatin in developmentally regulated genes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280901", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 823, "text": "The interplay of active and repressive histone modifications is assumed to have a key role in the regulation of gene expression. In contrast to this generally accepted view, we show that the transcription of genes temporally regulated during fly and worm development occurs in the absence of canonically active histone modifications. Conversely, strong chromatin marking is related to transcriptional and post-transcriptional stability, an association that we also observe in mammals. Our results support a model in which chromatin marking is associated with the stable production of RNA, whereas unmarked chromatin would permit rapid gene activation and deactivation during development. In the latter case, regulation by transcription factors would have a comparatively more important regulatory role than chromatin marks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280901", "endSection": "abstract"}]}, {"body": "Which cells express CIDEC protein in humans?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26927378", "http://www.ncbi.nlm.nih.gov/pubmed/25418138", "http://www.ncbi.nlm.nih.gov/pubmed/25477509", "http://www.ncbi.nlm.nih.gov/pubmed/26099526", "http://www.ncbi.nlm.nih.gov/pubmed/23220584"], "ideal_answer": ["The cell death-inducing DNA fragmentation factor alpha-like effector c (CIDEC) is a lipid droplet-associated protein that promotes intracellular triglyceride (TAG) storage. CIDEC is highly expressed in adipocytes, but undetectable in normal liver. However, its hepatic expression rises during fasting or under genetic or diet-induced hepatosteatosis in patients."], "type": "summary", "id": "58ca746d02b8c6095300002d", "snippets": [{"offsetInBeginSection": 976, "offsetInEndSection": 1170, "text": "The expression levels of related adipocyte markers (PPAR\u03b3, C/EBP\u03b1), mature white adipose tissue specific markers (Cidec, RIP140) increased at the presence of NPY (10(-7), 10(-9), 10(-11) mol/L).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26927378", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 458, "text": "The cell death-inducing DNA fragmentation factor alpha-like effector c (CIDEC; also known in rodents as FSP27 or fat-specific protein 27) is a lipid droplet-associated protein that promotes intracellular triglyceride (TAG) storage. CIDEC/Fsp27 is highly expressed in adipose tissue, but undetectable in normal liver. However, its hepatic expression rises during fasting or under genetic or diet-induced hepatosteatosis in both mice and patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418138", "endSection": "abstract"}, {"offsetInBeginSection": 1187, "offsetInEndSection": 1363, "text": " Our results also suggest that patients taking fibrates likely have elevated levels of hepatic CIDEC, which may limit the efficient mobilization and catabolism of hepatic TAGs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418138", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 365, "text": "Fat-specific protein 27 (FSP27, CIDEC in humans) is a lipid-coating protein highly expressed in mature white adipocytes that contributes to unilocular lipid droplet formation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25477509", "endSection": "abstract"}, {"offsetInBeginSection": 158, "offsetInEndSection": 460, "text": "We studied mouse models and human tissues to identify molecules associated with ASH progression and focused on the mouse fat-specific protein 27 (FSP-27)/human cell death-inducing DFF45-like effector C (CIDEC) protein, which is expressed in white adipose tissues and promotes formation of fat droplets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26099526", "endSection": "abstract"}, {"offsetInBeginSection": 2073, "offsetInEndSection": 2230, "text": "Hepatic CIDEC mRNA expression was increased in patients with AH and correlated with the degree of hepatic steatosis and disease severity including mortality.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26099526", "endSection": "abstract"}, {"offsetInBeginSection": 2382, "offsetInEndSection": 2580, "text": "Hepatic expression of FSP27/CIDEC is highly up-regulated in mice following chronic-plus-binge ethanol feeding and in patients with AH; this up-regulation contributes to alcohol-induced liver damage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26099526", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "FSP27 [cell death-inducing DFFA-like effector c (CIDEC) in humans] is a protein associated with lipid droplets that downregulates the fatty acid oxidation (FAO) rate when it is overexpressed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23220584", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Fsp27/CIDEC is a CREB target gene induced during early fasting in liver and regulated by FA oxidation rate.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23220584", "endSection": "title"}, {"offsetInBeginSection": 951, "offsetInEndSection": 1393, "text": "Similarly, CIDEC expression was upregulated in HepG2 cells by either etomoxir or HMGCS2 interference. Our data indicate that there is a kinetic mechanism of autoregulation between short- and long-term fasting, by which free FAs delivered to the liver during early fasting are accumulated/exported by FSP27/CIDEC, whereas over longer periods of fasting, they are degraded in the mitochondria through the carnitine palmitoyl transferase system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23220584", "endSection": "abstract"}]}, {"body": "What is the function of BAX", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26252372", "http://www.ncbi.nlm.nih.gov/pubmed/26395559", "http://www.ncbi.nlm.nih.gov/pubmed/27164337"], "ideal_answer": ["BAX is a central death regulator that controls apoptosis in normal and cancer cells", "pro-apoptotic protein Bax"], "exact_answer": [["bax promotes Apoptosis"]], "type": "factoid", "id": "58bde18b02b8c60953000014", "snippets": [{"offsetInBeginSection": 545, "offsetInEndSection": 570, "text": "pro-apoptotic protein Bax", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252372", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "Bax, a central cell death regulator, is an indispensable gateway to mitochondrial dysfunction and a major proapoptotic member of the B-cell lymphoma 2 (Bcl-2) family proteins that control apoptosis in normal and cancer cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26395559", "endSection": "abstract"}]}, {"body": "Which is the relation between coffee consumption and stroke risk?", "documents": [], "ideal_answer": ["The coffee paradox in stroke: Increased consumption linked with fewer strokes."], "exact_answer": [["The coffee paradox in stroke: Increased consumption linked with fewer strokes."]], "type": "factoid", "id": "58ce363b02b8c60953000046", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "The coffee paradox in stroke: Increased consumption linked with fewer strokes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098738", "endSection": "title"}, {"offsetInBeginSection": 1331, "offsetInEndSection": 1410, "text": "Heavier daily coffee consumption is associated with decreased stroke prevalence", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098738", "endSection": "abstract"}, {"offsetInBeginSection": 1180, "offsetInEndSection": 1268, "text": "Daily coffee consumption is associated with reduced risk of cerebral microbleeds in men.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26255558", "endSection": "abstract"}, {"offsetInBeginSection": 450, "offsetInEndSection": 854, "text": "The majority of prospective studies have reported a weak inverse association between moderate consumption of coffee and risk of stroke. However, there are yet no clear biological mechanisms whereby coffee might provide cardiovascular health benefits. Awaiting the results from further long-term RCTs and prospective studies, moderate consumption of filtered coffee, tea, and dark chocolate seems prudent.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24326448", "endSection": "abstract"}, {"offsetInBeginSection": 946, "offsetInEndSection": 1065, "text": "In summary, for most healthy people, moderate coffee consumption is unlikely to adversely affect cardiovascular health.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23990273", "endSection": "abstract"}, {"offsetInBeginSection": 1038, "offsetInEndSection": 1129, "text": "Coffee and tea can generally be recommended as health-promoting additions to an adult diet.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24071782", "endSection": "abstract"}, {"offsetInBeginSection": 655, "offsetInEndSection": 807, "text": " In addition, coffee intake is associated with risks of heart failure, stroke, diabetes mellitus and some cancers in an inverse dose-dependent fashion. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24071782", "endSection": "abstract"}]}, {"body": "What is the purpose of the Orpington Prognostic Scale?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16634344", "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "http://www.ncbi.nlm.nih.gov/pubmed/16690572", "http://www.ncbi.nlm.nih.gov/pubmed/16097508", "http://www.ncbi.nlm.nih.gov/pubmed/16418057", "http://www.ncbi.nlm.nih.gov/pubmed/15083439", "http://www.ncbi.nlm.nih.gov/pubmed/15595254", "http://www.ncbi.nlm.nih.gov/pubmed/11300243", "http://www.ncbi.nlm.nih.gov/pubmed/9731605", "http://www.ncbi.nlm.nih.gov/pubmed/8463526", "http://www.ncbi.nlm.nih.gov/pubmed/17903924"], "ideal_answer": ["The Orpington Prognostic Scale (OPS) is used to predict futue functional status of stroke patients, to asses stroke severity, outcome and response to subacute rehabilitation. In patients with stroke, OPS and NIHSS had significant contribution to the estimation of the functional status and OPS was more effective than NIHSS. However, other reported that the OPS has limited predictive accuracy for discharge destination and is a poor predictor of follow-up services."], "type": "summary", "id": "58861f8b3b87a8a738000003", "snippets": [{"offsetInBeginSection": 339, "offsetInEndSection": 407, "text": "Stroke severity was determined using the Orpington Prognostic Scale.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16634344", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Predicting response to rehabilitation in elderly patients with stroke using the Orpington Prognostic Scale and selected clinical variables.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "title"}, {"offsetInBeginSection": 130, "offsetInEndSection": 315, "text": " The purpose of this study was to determine the ability of the Orpington Prognostic Scale (OPS) to predict outcome and response to subacute rehabilitation in older patients with stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "abstract"}, {"offsetInBeginSection": 794, "offsetInEndSection": 1005, "text": "The OPS scores were strong predictors of response to subacute rehabilitation and discharge FIM motor subscale scores. The OPS may warrant a broader application as a prognostic indicator for patients with stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 239, "text": "PURPOSE: The aim of our study is to compare the Orpington Prognostic Scale (OPS) and the National Institutes of Health Stroke Scale (NIHSS) and to evaluate whether they help us estimate the future functional status of patients with stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690572", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Comparison of the Orpington Prognostic Scale (OPS) and the National Institutes of Health Stroke Scale (NIHSS) for the prediction of the functional status of patients with stroke.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690572", "endSection": "title"}, {"offsetInBeginSection": 1089, "offsetInEndSection": 1250, "text": "CONCLUSION: In patients with stroke, OPS and NIHSS had significant contribution to the estimation of the functional status and OPS was more effective than NIHSS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690572", "endSection": "abstract"}, {"offsetInBeginSection": 180, "offsetInEndSection": 332, "text": "The Orpington Prognostic Score (OPS) is a clinically derived stroke severity scale that can be used to stratify patients into different severity groups.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16097508", "endSection": "abstract"}, {"offsetInBeginSection": 1539, "offsetInEndSection": 1613, "text": "The OPS is a valid measure of stroke severity in Irish stroke in-patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16097508", "endSection": "abstract"}, {"offsetInBeginSection": 1158, "offsetInEndSection": 1337, "text": "CONCLUSIONS: Despite high inter-rater and test-retest reliability, the OPS has limited predictive accuracy for discharge destination and is a poor predictor of follow-up services.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16418057", "endSection": "abstract"}, {"offsetInBeginSection": 345, "offsetInEndSection": 536, "text": "PARTICIPANTS: Sixty-four patients with recent stroke admitted for inpatient rehabilitation were randomized within severity strata (Orpington Prognostic Scale) into 1 of 3 intervention groups.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15083439", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Predicting final disposition after stroke using the Orpington Prognostic Score.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15595254", "endSection": "title"}, {"offsetInBeginSection": 256, "offsetInEndSection": 374, "text": "In Calgary, the Orpington Prognostic Score (OPS) has been used to predict outcome as an aid to rehabilitation triage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15595254", "endSection": "abstract"}, {"offsetInBeginSection": 1301, "offsetInEndSection": 1370, "text": "CONCLUSIONS: The first week OPS can be used to predict final outcome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15595254", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Predicting stroke recovery: three- and six-month rates of patient-centered functional outcomes based on the orpington prognostic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11300243", "endSection": "title"}, {"offsetInBeginSection": 1536, "offsetInEndSection": 1657, "text": "CONCLUSION: OPS scores can predict widely differing rates of functional recovery in five important functional abilities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11300243", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Prediction of functional outcome after stroke: comparison of the Orpington Prognostic Scale and the NIH Stroke Scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9731605", "endSection": "title"}, {"offsetInBeginSection": 1550, "offsetInEndSection": 1806, "text": "CONCLUSIONS: Our results demonstrate that in a sample of mostly mild and moderate strokes, the Orpington Prognostic Scale compared with the NIH Stroke Scale is simpler to use and is a slightly better predictor of ADL and higher levels of physical function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9731605", "endSection": "abstract"}, {"offsetInBeginSection": 1400, "offsetInEndSection": 1631, "text": "CONCLUSIONS: The Orpington score when assessed at 2-weeks post-stroke is a useful prognostic indicator with special suitability for the elderly and may help to select patients most likely to benefit from stroke unit rehabilitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8463526", "endSection": "abstract"}, {"offsetInBeginSection": 1211, "offsetInEndSection": 1456, "text": "The OPS at 48 hours is a good predictor of outcome at 6 months and 2 years after ischemic stroke and allows early identification of 3 prognostic groups, which may help in identifying patients most likely to benefit from intensive rehabilitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17903924", "endSection": "abstract"}]}, {"body": "Do IEG create a ripple effect of transcription?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19160492"], "ideal_answer": ["Rapid induction of immediate-early genes (IEGs) in response to growth factor stimulations is accompanied by co-upregulation of their neighbouring genes. Profiling the primary transcripts in the nucleus with whole-genome tiling arrays delineated simultaneous activation of transcription centred on IEGs.", "rapid induction of immediate-early genes (iegs) in response to growth factor stimulations is accompanied by co-upregulation of their neighbouring genes.", "Rapid induction of immediate-early genes (IEGs) in response to growth factor stimulations is accompanied by co-upregulation of their neighbouring genes. Even in surrounding intergenic regions, transcriptional activation took place at the same time.", "Rapid induction of immediate-early genes (IEGs) in response to growth factor stimulations is accompanied by co-upregulation of their neighbouring genes.", "Here we show that intensive transcription at one locus frequently spills over into its physical neighbouring loci. Rapid induction of immediate-early genes (IEGs) in response to growth factor stimulations is accompanied by co-upregulation of their neighbouring genes."], "exact_answer": "yes", "type": "yesno", "id": "58c276bc02b8c60953000020", "snippets": [{"offsetInBeginSection": 524, "offsetInEndSection": 676, "text": "Rapid induction of immediate-early genes (IEGs) in response to growth factor stimulations is accompanied by co-upregulation of their neighbouring genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19160492", "endSection": "abstract"}, {"offsetInBeginSection": 827, "offsetInEndSection": 923, "text": "Even in surrounding intergenic regions, transcriptional activation took place at the same time. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19160492", "endSection": "abstract"}, {"offsetInBeginSection": 409, "offsetInEndSection": 523, "text": "Here we show that intensive transcription at one locus frequently spills over into its physical neighbouring loci.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19160492", "endSection": "abstract"}]}, {"body": "Which R package is used for the analysis of genome-wide DNA methylation profiles?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23034086"], "ideal_answer": ["MethylKit is a comprehensive R package for the analysis of genome-wide DNA methylation profiles. MethylKit includes functions for clustering, sample quality visualization, differential methylation analysis and annotation features, thus automating and simplifying many of the steps for discerning statistically significant bases or regions of DNA methylation."], "exact_answer": [["methylKit"]], "type": "factoid", "id": "588f8e9794c1512c50000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034086", "endSection": "title"}, {"offsetInBeginSection": 144, "offsetInEndSection": 592, "text": " Here, we describe an R package, methylKit, that rapidly analyzes genome-wide cytosine epigenetic profiles from high-throughput methylation and hydroxymethylation sequencing experiments. methylKit includes functions for clustering, sample quality visualization, differential methylation analysis and annotation features, thus automating and simplifying many of the steps for discerning statistically significant bases or regions of DNA methylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034086", "endSection": "abstract"}]}, {"body": "Is butterfly rash a symptom of Systemic lupus erythematosus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20120828", "http://www.ncbi.nlm.nih.gov/pubmed/17569152", "http://www.ncbi.nlm.nih.gov/pubmed/17728372", "http://www.ncbi.nlm.nih.gov/pubmed/25516474", "http://www.ncbi.nlm.nih.gov/pubmed/24948869", "http://www.ncbi.nlm.nih.gov/pubmed/23019977"], "ideal_answer": ["Yes, butterfly rash is symptom of Systemic lupus erythematosus."], "exact_answer": "yes", "type": "yesno", "id": "58bfeb2b02b8c6095300001a", "snippets": [{"offsetInBeginSection": 374, "offsetInEndSection": 605, "text": "Diagnosing SLE can be challenging because of the myriad of clinical features and substantial variability between patients. Cutaneous involvement is present in about 60% of cases and typically manifests as a malar or butterfly rash.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120828", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "The prevalence of systemic lupus erythematosus (SLE) is 28 per 100,000. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120828", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "We report a 12 years old female patient with an overlap syndrome involving autoimmune hepatitis (AIH) and systemic lupus erythematosus (SLE). The patient presented with jaundice, hepatosplenomegaly, malaise, polyarthralgia, arthritis and butterfly rash on the face.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17569152", "endSection": "abstract"}, {"offsetInBeginSection": 486, "offsetInEndSection": 764, "text": "Some of the clinical characteristics of SLE patients observed were nephritis (53.7%), fever (53.26%), neuropsychological disorder (36.18%), malar/butterfly rash (27.6%), pulmonary disorder (22.6%), photosensitivity (21.6%), cardiac involvement (21.1%) and oral ulcers (19.09%). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17728372", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Systemic lupus erythematosus and infections: a retrospective study in Saudis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17728372", "endSection": "title"}, {"offsetInBeginSection": 801, "offsetInEndSection": 1123, "text": "The prevalence of the following manifestations was significantly higher for pediatric than for adult-onset disease including: lupus nephritis (43% pediatric vs 26.4% for adult-onset), hematological disorders (57% vs 36.4%), photosensitivity (20% vs 9%), butterfly rash (61% vs 35.5%) and mucosal ulceration (11.4% vs 4%). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516474", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease with highest prevalence among women of childbearing age. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516474", "endSection": "abstract"}, {"offsetInBeginSection": 462, "offsetInEndSection": 1069, "text": "We described a unique case of a 25-year-old Arab young woman who was diagnosed with SLE, depending on clinical, laboratory investigations and after she had fulfilled the diagnostic criteria for SLE and had presented the following findings: constitutional findings (fatigue, fever, and arthralgia); dermatologic finding (photosensitivity and butterfly rash); chronic renal failure (proteinuria up to 400 mg in 24 hours); hematologic and antinuclear antibodies (positivity for antinuclear factor (ANF), anti-double-stranded DNA antibodies, direct Coombs, ANA and anti-DNA, low C4 and C3, aCL by IgG and IgM). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24948869", "endSection": "abstract"}, {"offsetInBeginSection": 492, "offsetInEndSection": 771, "text": "Grade 1 and 2-3 inflammatory process occurred in 53 (63%) and 31 (37%) patients respectively. Symptom complexes \"systemic inflammation\", \"butterfly rash\", \"wrist petechiae\", \"enanthema of the oral mucous membrane\", and other lesions were regarded as the markers of SLE activity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019977", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Systemic lupus erythematosus (SLE) remains a challenging medical problem. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019977", "endSection": "abstract"}]}, {"body": "Do T-Cells regulate neuropathic pain?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25608762", "http://www.ncbi.nlm.nih.gov/pubmed/25787078"], "ideal_answer": ["Macrophage-T cell interactions can mediate neuropathic pain through the glucocorticoid-induced TNF"], "exact_answer": "yes", "type": "yesno", "id": "58c0825502b8c6095300001b", "snippets": [{"offsetInBeginSection": 346, "offsetInEndSection": 501, "text": "here is evidence for a considerable impact of the immune system also in neuropathic pain. However, the role of the adaptive immune system is still unclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25608762", "endSection": "abstract"}, {"offsetInBeginSection": 1806, "offsetInEndSection": 1927, "text": " Our investigation revealed a clear shift of T-cell subsets towards anti-inflammation in patients with neuropathic pain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25608762", "endSection": "abstract"}, {"offsetInBeginSection": 1209, "offsetInEndSection": 1346, "text": " GITRL expressed on macrophages drives cytokine release and T cell activation, resulting in neuropathic pain via GITR-dependent actions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25787078", "endSection": "abstract"}]}, {"body": "Can telomere length shortening be reversed by telomerase?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26903545", "http://www.ncbi.nlm.nih.gov/pubmed/27154402", "http://www.ncbi.nlm.nih.gov/pubmed/27029895", "http://www.ncbi.nlm.nih.gov/pubmed/27483324", "http://www.ncbi.nlm.nih.gov/pubmed/27401551"], "ideal_answer": ["Yes, telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia."], "exact_answer": "yes", "type": "yesno", "id": "58cd675c02b8c6095300003b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 284, "text": "Telomere length is regulated around an equilibrium set point. Telomeres shorten during replication and are lengthened by telomerase. Disruption of the length equilibrium leads to disease; thus, it is important to understand the mechanisms that regulate length at the molecular level. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401551", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 455, "text": "High telomerase activity is detected in nearly all human cancers but most human cells are devoid of telomerase activity. There is well-documented evidence that reactivation of telomerase occurs during cellular transformation. In humans, tumors can rely in reactivation of telomerase or originate in a telomerase positive stem/progenitor cell, or rely in alternative lengthening of telomeres, a telomerase-independent telomere-length maintenance mechanism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27483324", "endSection": "abstract"}, {"offsetInBeginSection": 1019, "offsetInEndSection": 1247, "text": " Together, these observations may provoke a re-evaluation of telomere and telomerase based therapies, both in telomerase inhibition for cancer therapy and telomerase activation for tissue regeneration and anti-ageing strategies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27483324", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 253, "text": "Telomeres progressively shorten throughout life. A hallmark of advanced malignancies is the ability for continuous cell divisions that almost universally correlates with the stabilization of telomere length by the reactivation of telomerase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27029895", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "Telomerase-mediated telomere elongation provides cell populations with the ability to proliferate indefinitely. Telomerase is capable of recognizing and extending the shortest telomeres in cells;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27154402", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26903545", "endSection": "title"}]}, {"body": "What are clinical features of the de Morsier syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26842535", "http://www.ncbi.nlm.nih.gov/pubmed/27136085", "http://www.ncbi.nlm.nih.gov/pubmed/24678945", "http://www.ncbi.nlm.nih.gov/pubmed/23422579"], "ideal_answer": ["Classic triad of the De Morsier syndrome (septooptic dysplasia) includes optic nerve hypoplasia, the absence of septum pellucidum, and pituitary hypoplasia."], "exact_answer": [["optic nerve hypoplasia"], ["absence of septum pellucidum"], ["pituitary hypoplasia"]], "type": "list", "id": "588f952994c1512c50000007", "snippets": [{"offsetInBeginSection": 76, "offsetInEndSection": 228, "text": " SOD was formerly known as de Morsier syndrome, which associated a midline brain defect such as an absent septum pellucidum with optic nerve hypoplasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26842535", "endSection": "abstract"}, {"offsetInBeginSection": 323, "offsetInEndSection": 506, "text": "The triad consists of optic nerve hypoplasia, pituitary hormone abnormalities, and midline brain defects, although it can vary in the severity of clinical presentation and phenotype. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26842535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "INTRODUCTION: Previous studies have described septooptic dysplasia (SOD) to describe patients who have optic nerve hypoplasia, the absence of septum pellucidum, and pituitary hypoplasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136085", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "BACKGROUND: Septo-optic dysplasia, also referred to as de Morsier syndrome, is a congenital condition characterized by classic triad features: midline brain abnormalities, optic nerve hypoplasia and pituitary endocrine dysfunction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24678945", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 235, "text": "Septo-optic dysplasia (SOD), otherwise called De Morsier syndrome, is a developmental anomaly of mid-line brain structures and includes optic nerve hypoplasia, absence of the septum pellucidum and hypothalamo-pituitary abnormalities). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23422579", "endSection": "abstract"}]}, {"body": "Which is the largest metabolic gene cluster in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15951822"], "ideal_answer": ["The DAL cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source.", "the dal cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable saccharomyces cerevisiae to use allantoin as a nitrogen source.", "The DAL cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source. The DAL cluster is located in a domain of modified chromatin involving both H2A.Z histone exchange and Hst1-Sum1-mediated histone deacetylation, and it may be a coadapted gene complex formed by epistatic selection.", "The DAL cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source. Six of the eight genes involved in allantoin degradation, which were previously scattered around the genome, became relocated to a single subtelomeric site in an ancestor of S. cerevisiae and Saccharomyces castellii."], "exact_answer": [["The DAL cluster"]], "type": "factoid", "id": "58d0dc878acda34529000004", "snippets": [{"offsetInBeginSection": 217, "offsetInEndSection": 408, "text": "The DAL cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15951822", "endSection": "abstract"}]}, {"body": "Is there any involvement of the long non-coding RNA Gomafu in schizophrenia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23628989"], "ideal_answer": ["Yes. The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing."], "exact_answer": "yes", "type": "yesno", "id": "588fbedced9bbee70d000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989", "endSection": "title"}, {"offsetInBeginSection": 308, "offsetInEndSection": 1154, "text": "Here, we profile these transcriptomic responses and show that long non-coding RNAs (lncRNAs) are dynamically regulated by neuronal activation, including acute downregulation of the lncRNA Gomafu, previously implicated in brain and retinal development. Moreover, we demonstrate that Gomafu binds directly to the splicing factors QKI and SRSF1 (serine/arginine-rich splicing factor 1) and dysregulation of Gomafu leads to alternative splicing patterns that resemble those observed in SZ for the archetypal SZ-associated genes DISC1 and ERBB4. Finally, we show that Gomafu is downregulated in post-mortem cortical gray matter from the superior temporal gyrus in SZ. These results functionally link activity-regulated lncRNAs and alternative splicing in neuronal function and suggest that their dysregulation may contribute to neurological disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989", "endSection": "abstract"}]}, {"body": "Which are the main brain dysfunctions caused by hyperbilirubinemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25534357", "http://www.ncbi.nlm.nih.gov/pubmed/26480925", "http://www.ncbi.nlm.nih.gov/pubmed/25524299", "http://www.ncbi.nlm.nih.gov/pubmed/23086523", "http://www.ncbi.nlm.nih.gov/pubmed/23283699", "http://www.ncbi.nlm.nih.gov/pubmed/21163242"], "ideal_answer": ["Bilirubin-induced neurologic dysfunction (BIND) and classical kernicterus are the main dysfunctions of hyperbilirubinemia, whenever bilirubin levels exceed the capacity of the brain defensive mechanisms in preventing its entrance and cytotoxicity. Bilirubin accumulation may lead to deficits in auditory, cognitive, and motor processing, due to neuronal cell death, reduced myelination and glial activation."], "type": "summary", "id": "58c66a4b02b8c60953000025", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 616, "text": "Bilirubin-induced neurologic dysfunction (BIND) and classical kernicterus are clinical manifestations of moderate to severe hyperbilirubinemia whenever bilirubin levels exceed the capacity of the brain defensive mechanisms in preventing its entrance and cytotoxicity. In such circumstances and depending on the associated co-morbidities, bilirubin accumulation may lead to short- or long-term neurodevelopmental disabilities, which may include deficits in auditory, cognitive, and motor processing. Neuronal cell death, astrocytic reactivity, and microglia activation are part of the bilirubin-induced pathogenesis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534357", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Reduced Myelination and Increased Glia Reactivity Resulting from Severe Neonatal Hyperbilirubinemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26480925", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 239, "text": "Bilirubin-induced neurologic dysfunction (BIND) and kernicterus has been used to describe moderate to severe neurologic dysfunction observed in children exposed to excessive levels of total serum bilirubin (TSB) during the neonatal period.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26480925", "endSection": "abstract"}, {"offsetInBeginSection": 584, "offsetInEndSection": 769, "text": "Histologic studies of brain tissue demonstrate that the onset of severe neonatal hyperbilirubinemia, characterized by seizures, leads to alterations in myelination and glia reactivity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26480925", "endSection": "abstract"}, {"offsetInBeginSection": 1467, "offsetInEndSection": 1702, "text": "Thus, kernicterus in this model displays not only axonal damage but also myelination deficits and glial activation in different brain regions that are usually related to the neurologic sequelae observed after severe hyperbilirubinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26480925", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 388, "text": "Advances in the care of neonatal hyperbilirubinemia have led to a decreased incidence of kernicterus. However, neonatal exposure to high levels of bilirubin continues to cause severe motor symptoms and cerebral palsy (CP). Exposure to moderate levels of unconjugated bilirubin may also cause damage to the developing central nervous system, specifically the basal ganglia and cerebellum. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25524299", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "High levels of serum unconjugated bilirubin (UCB) in newborns are associated with axonal damage and glial reactivity that may contribute to subsequent neurologic injury and encephalopathy (kernicterus). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23086523", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 295, "text": "Hyperbilirubinemia remains one of the most frequent clinical diagnoses in the neonatal period. This condition may lead to the deposition of unconjugated bilirubin (UCB) in the central nervous system, causing nerve cell damage by molecular and cellular mechanisms that are still being clarified. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23283699", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 254, "text": "\"Kernicterus\" is a term currently used to describe bilirrubin induced brain injury in the neuro-pathological studies. This is a confusing term and nowadays we prefer bilirrubin encephalopathy or bilirrubin induced neurological dysfunction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21163242", "endSection": "abstract"}]}, {"body": "What is the incidence of new cases of X-linked adrenoleukodystrophy (ALD) in Australian and New Zealand in the late 1990's?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9556302"], "ideal_answer": ["cases of ALD diagnosed in Australia and New Zealand between 1981 and 1996 and their families. We estimate that the combined incidence of ALD and its variants in Australasia is at least 1.6 per 100,000. ", "cases of ALD diagnosed in Australia and New Zealand between 1981 and 1996 and their families. We estimate that the combined incidence of ALD and its variants in Australasia is at least 1.6 per 100,000.", "When looking cases of  ALD diagnosed in Australia and New Zealand between 1981 and 1996, it was estimated that the combined incidence of ALD and its variants in Australasia is at least 1.6 per 100,000."], "exact_answer": [["1.6 per 100,000 people"]], "type": "factoid", "id": "58cc5bae02b8c60953000037", "snippets": [{"offsetInBeginSection": 453, "offsetInEndSection": 655, "text": "cases of ALD diagnosed in Australia and New Zealand between 1981 and 1996 and their families. We estimate that the combined incidence of ALD and its variants in Australasia is at least 1.6 per 100,000. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9556302", "endSection": "abstract"}]}, {"body": "Is ABCE1 involved in ribosomal recycling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27824037", "http://www.ncbi.nlm.nih.gov/pubmed/25659154", "http://www.ncbi.nlm.nih.gov/pubmed/26276635", "http://www.ncbi.nlm.nih.gov/pubmed/25001285", "http://www.ncbi.nlm.nih.gov/pubmed/25128630"], "ideal_answer": ["Yes, recent studies have identified ABCE1 as a ribosome-recycling factor important for translation termination in mammalian cells, yeast and also archaea"], "exact_answer": "yes", "type": "yesno", "id": "58ce5a1602b8c60953000049", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "Ribosome recycling orchestrated by the ATP binding cassette (ABC) protein ABCE1 can be considered as the final-or the first-step within the cyclic process of protein synthesis, connecting translation termination and mRNA surveillance with re-initiation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27824037", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 260, "text": " Recent studies have identified ABCE1 as a ribosome-recycling factor important for translation termination in mammalian cells, yeast and also archaea.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25659154", "endSection": "abstract"}, {"offsetInBeginSection": 502, "offsetInEndSection": 560, "text": "d a termination/prerecycling complex containing eRF1-ABCE1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25001285", "endSection": "abstract"}, {"offsetInBeginSection": 653, "offsetInEndSection": 698, "text": "ABCE1, a eukaryotic ribosome recycling factor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25128630", "endSection": "abstract"}]}, {"body": "Describe Exploding head syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25773787", "http://www.ncbi.nlm.nih.gov/pubmed/24703829", "http://www.ncbi.nlm.nih.gov/pubmed/24907167", "http://www.ncbi.nlm.nih.gov/pubmed/23467433"], "ideal_answer": ["Exploding head syndrome is characterized by the perception of abrupt, loud noises when going to sleep or waking up."], "type": "summary", "id": "588f9756ed9bbee70d000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Exploding head syndrome is characterized by the perception of loud noises during sleep-wake or wake-sleep transitions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Exploding head syndrome is characterized by the perception of abrupt, loud noises when going to sleep or waking up.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24703829", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "BACKGROUND: Exploding head syndrome (EHS) is characterized by attacks of a sudden noise or explosive feeling experienced in the head occurring during the transition from wake to sleep or from sleep to wake.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24907167", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "INTRODUCTION: Exploding head syndrome (EHS) is a rare parasomnia in which affected individuals awaken from sleep with the sensation of a loud bang.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23467433", "endSection": "abstract"}]}, {"body": "How are looped genes identified in yest?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24124207"], "ideal_answer": ["Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB.", "gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as tfiib.", "Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB", "Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB. . . . . "], "type": "summary", "id": "58d4d7578acda34529000007", "snippets": [{"offsetInBeginSection": 249, "offsetInEndSection": 361, "text": "Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24124207", "endSection": "abstract"}]}, {"body": "What is REVIGO?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21789182"], "ideal_answer": ["REVIGO summarizes and visualizes long lists of gene ontology terms.", "REVIGO is a Web server that summarizes long, unintelligible lists of GO terms by finding a representative subset of the terms using a simple clustering algorithm that relies on semantic similarity measures. Furthermore, REVIGO visualizes this non-redundant GO term set in multiple ways to assist in interpretation: multidimensional scaling and graph-based visualizations accurately render the subdivisions and the semantic relationships in the data, while treemaps and tag clouds are also offered as alternative views. REVIGO is freely available at http://revigo.irb.hr/.", "Outcomes of high-throughput biological experiments are typically interpreted by statistical testing for enriched gene functional categories defined by the Gene Ontology (GO). The resulting lists of GO terms may be large and highly redundant, and thus difficult to interpret.REVIGO is a Web server that summarizes long, unintelligible lists of GO terms by finding a representative subset of the terms using a simple clustering algorithm that relies on semantic similarity measures. Furthermore, REVIGO visualizes this non-redundant GO term set in multiple ways to assist in interpretation: multidimensional scaling and graph-based visualizations accurately render the subdivisions and the semantic relationships in the data, while treemaps and tag clouds are also offered as alternative views. REVIGO is freely available at http://revigo.irb.hr/."], "type": "summary", "id": "5891c754621ea6ff7e000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "REVIGO summarizes and visualizes long lists of gene ontology terms.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789182", "endSection": "title"}, {"offsetInBeginSection": 274, "offsetInEndSection": 845, "text": "REVIGO is a Web server that summarizes long, unintelligible lists of GO terms by finding a representative subset of the terms using a simple clustering algorithm that relies on semantic similarity measures. Furthermore, REVIGO visualizes this non-redundant GO term set in multiple ways to assist in interpretation: multidimensional scaling and graph-based visualizations accurately render the subdivisions and the semantic relationships in the data, while treemaps and tag clouds are also offered as alternative views. REVIGO is freely available at http://revigo.irb.hr/.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789182", "endSection": "abstract"}]}, {"body": "Which are the typical symptoms of M\u00e9ni\u00e8re's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23418296", "http://www.ncbi.nlm.nih.gov/pubmed/12806289", "http://www.ncbi.nlm.nih.gov/pubmed/15198043", "http://www.ncbi.nlm.nih.gov/pubmed/11936909", "http://www.ncbi.nlm.nih.gov/pubmed/1896669", "http://www.ncbi.nlm.nih.gov/pubmed/3631415"], "ideal_answer": ["The typical symptoms of M\u00e9ni\u00e8re's disease are:\n1) sensorineural hearing loss, \n2) vertigo and \n3) tinnitus."], "exact_answer": [["sensorineural hearing loss", "hypoacusia"], ["vertigo", "dizziness"], ["tinnitus"]], "type": "list", "id": "58c6a6c502b8c60953000027", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 156, "text": "To evaluate the onset of vertigo, hearing loss and tinnitus in M\u00e9ni\u00e8re's disease and the associated endolymphatic hydrops (EH) of the inner ear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418296", "endSection": "abstract"}, {"offsetInBeginSection": 1554, "offsetInEndSection": 1783, "text": "We suggest that a 3T MRI measurement should be carried out in patients with sensory-neural hearing loss, vertigo and tinnitus, 4 h after the intravenous injection of a gadolinium-contrast agent to verify the inner ear pathology. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418296", "endSection": "abstract"}, {"offsetInBeginSection": 519, "offsetInEndSection": 819, "text": "Eleven of the 17425 veterans appeared to have typical M\u00e9ni\u00e8re's Disease. Their symptoms included attacks of vertigo, lasting between half an hour and a few hours and no more than 24 hours; the sensation of aural fullness; and tinnitus accompanied by a fluctuating or permanent low-tone hearing loss. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12806289", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "Diagnosis of Meni\u00e8re's Disease is based upon the wellknown labyrinthic syndrome (hypoacusia, tinnitus and dizziness) which manifests with the typical abscessual, recurrent and unforeseeable course. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15198043", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 814, "text": "Typical clinical manifestations of M\u00e9ni\u00e8re's disease (vertigo, sensorineural hearing loss and tinnitus) were found in 6/11 patients (54.5%) in the Lyme disease group.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11936909", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 428, "text": "Among 93 patients presenting the typical symptoms of a M\u00e9ni\u00e8re's disease associating an unilateral fluctuating hearing loss of sensorineural type, tinnitus and vertiginous attacks lasting minutes to hours, 40 patients (43%) presented in their personal history a particular otologic insult in the ear which later on developed into the full M\u00e9ni\u00e8re's symptomatology, or a particular systemic disease with otologic manifestations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1896669", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "Fourteen children (aged 14 years or younger) with typical M\u00e9ni\u00e8re's triad with cochlear sensorineural hearing loss, tinnitus, and intermittent vertigo attacks lasting from minutes to hours were investigated in four different neuro-otologic centers. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3631415", "endSection": "abstract"}]}, {"body": "What are Degrons?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26732515", "http://www.ncbi.nlm.nih.gov/pubmed/26456660"], "ideal_answer": ["Specific signals (degrons) regulate protein turnover mediated by the ubiquitin-proteasome system.", "Portable degradation sequences, or degrons, have the ability to bind to E3 ligases and promote substrate ubiquitination when the sequence is presented in isolation or appended to other entities such as fluorescent peptide-based reporters.", "portable degradation sequences, or degrons, have the ability to bind to e3 ligases and promote substrate ubiquitination when the sequence is presented in isolation or appended to other entities such as fluorescent peptide-based reporters."], "type": "summary", "id": "58cdbaf302b8c60953000044", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Specific signals (degrons) regulate protein turnover mediated by the ubiquitin-proteasome system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732515", "endSection": "abstract"}, {"offsetInBeginSection": 672, "offsetInEndSection": 911, "text": "Portable degradation sequences, or degrons, have the ability to bind to E3 ligases and promote substrate ubiquitination when the sequence is presented in isolation or appended to other entities such as fluorescent peptide-based reporters. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26456660", "endSection": "abstract"}]}, {"body": "List metalloenzyme inhibitors.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24074025", "http://www.ncbi.nlm.nih.gov/pubmed/22308350", "http://www.ncbi.nlm.nih.gov/pubmed/21189019", "http://www.ncbi.nlm.nih.gov/pubmed/21046516", "http://www.ncbi.nlm.nih.gov/pubmed/19949750", "http://www.ncbi.nlm.nih.gov/pubmed/18666306", "http://www.ncbi.nlm.nih.gov/pubmed/17314045", "http://www.ncbi.nlm.nih.gov/pubmed/11551755"], "ideal_answer": ["Foscarnet\nVT-1129\nVT-1161 \nBB-3497\nhydroxamate molecules\nsiderophores"], "exact_answer": [["VT-1129"], ["VT-1161"], ["BB-3497"], ["hydroxamate molecules"], ["siderophores"], ["Foscarnet"]], "type": "list", "id": "58ce5c7c1f5fb2b734000001", "snippets": [{"offsetInBeginSection": 123, "offsetInEndSection": 401, "text": " Clinically approved inhibitors were selected as well as several other reported metalloprotein inhibitors in order to represent a broad range of metal binding groups (MBGs), including hydroxamic acid, carboxylate, hydroxypyridinonate, thiol, and N-hydroxyurea functional groups.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24074025", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 293, "text": "A total of 21 different raltegravir-chelator derivative (RCD) compounds were prepared that differed only in the nature of the MBG. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22308350", "endSection": "abstract"}, {"offsetInBeginSection": 863, "offsetInEndSection": 1055, "text": "At least two compounds (RCD-4, RCD-5) containing a hydroxypyrone MBG were found to display superior strand-transfer inhibition when compared to an abbreviated analogue of raltegravir (RCD-1). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22308350", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "By screening a library of metalloenzyme inhibitors, the N-formyl-hydroxylamine derivative BB-3497 was identified as a potent inhibitor of Escherichia coli peptide deformylase with antibacterial activity both in vitro and in vivo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11551755", "endSection": "abstract"}, {"offsetInBeginSection": 984, "offsetInEndSection": 1172, "text": " The 8-hydroxyquinoline represents a promising new chelator scaffold for the development of MMP inhibitors that was discovered by use of a metalloprotein-focused chelator fragment library.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21189019", "endSection": "abstract"}, {"offsetInBeginSection": 568, "offsetInEndSection": 647, "text": " the metalloenzyme inhibitors VT-1129 and VT-1161 (both Viamet Pharmaceuticals)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21046516", "endSection": "abstract"}, {"offsetInBeginSection": 24, "offsetInEndSection": 161, "text": "Based on their ability to chelate metals, hydroxamate molecules and siderophores have been successfully used as metalloenzyme inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19949750", "endSection": "abstract"}, {"offsetInBeginSection": 881, "offsetInEndSection": 1073, "text": " Using this model, we identified two nitrogen donor compounds--2,2'-dipyridylamine (DPA) and triazacyclononane (TACN)--as the most selective ZBGs for zinc metalloenzyme inhibitor development. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18666306", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Foscarnet (phosphonoformate trisodium salt), an antiviral used for the treatment of HIV and herpes virus infections, also acts as an activator or inhibitor of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17314045", "endSection": "abstract"}]}, {"body": "Which gene is mutated in the Karak syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26001724", "http://www.ncbi.nlm.nih.gov/pubmed/24130795", "http://www.ncbi.nlm.nih.gov/pubmed/20938027"], "ideal_answer": ["PLA2G6 gene is mutated in the Karak syndrome."], "exact_answer": [["PLA2G6"]], "type": "factoid", "id": "588f9950ed9bbee70d000002", "snippets": [{"offsetInBeginSection": 163, "offsetInEndSection": 333, "text": "Mutations in PLA2G6 have been associated with disorders such as infantile neuroaxonal dystrophy, neurodegeneration with brain iron accumulation type II and Karak syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26001724", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "Mutations in PLA2G6 gene have variable phenotypic outcome including infantile neuroaxonal dystrophy, atypical neuroaxonal dystrophy, idiopathic neurodegeneration with brain iron accumulation and Karak syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24130795", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "BACKGROUND: PLA2G6 is the causative gene for infantile neuroaxonal dystrophy, neurodegeneration associated with brain iron accumulation, and Karak syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20938027", "endSection": "abstract"}]}, {"body": "Which proteins remove H2A.Z in the yeast Saccharomyces cerevisiae?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26142279"], "ideal_answer": ["Removal of H2A.Z by INO80 promotes homologous recombination Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. Here, we show that H2A.Z in human cells is indeed rapidly removed from chromatin flanking DNA damage by INO80.", "Here, we show that H2A.Z in human cells is indeed rapidly removed from chromatin flanking DNA damage by INO80. We also report that the histone chaperone ANP32E, which is implicated in removing H2AZ from chromatin, similarly promotes HR and appears to work on the same pathway as INO80 in these assays. Importantly, we demonstrate that the HR defect in cells depleted of INO80 or ANP32E can be rescued by H2A.Z co-depletion, suggesting that H2A.Z removal from chromatin is the primary function of INO80 and ANP32E in promoting homologous recombination.", "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. Here, we show that H2A.Z in human cells is indeed rapidly removed from chromatin flanking DNA damage by INO80. We also report that the histone chaperone ANP32E, which is implicated in removing H2AZ from chromatin, similarly promotes HR and appears to work on the same pathway as INO80 in these assays.", "we also report that the histone chaperone anp32e, which is implicated in removing h2az from chromatin, similarly promotes hr and appears to work on the same pathway as ino80 in these assays.", "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. Removal of H2A.Z by INO80 promotes homologous recombination H2A.Z removal from chromatin is the primary function of INO80 and ANP32E in promoting homologous recombination.", "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. Removal of H2A.Z by INO80 promotes homologous recombination", "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. H2A.Z removal from chromatin is the primary function of INO80 and ANP32E in promoting homologous recombination."], "exact_answer": [["INO80"], ["ANP32E"]], "type": "list", "id": "58de71fa8acda3452900002c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Removal of H2A.Z by INO80 promotes homologous recombination", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "title"}, {"offsetInBeginSection": 135, "offsetInEndSection": 235, "text": "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "abstract"}, {"offsetInBeginSection": 403, "offsetInEndSection": 513, "text": "Here, we show that H2A.Z in human cells is indeed rapidly removed from chromatin flanking DNA damage by INO80.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "abstract"}, {"offsetInBeginSection": 514, "offsetInEndSection": 704, "text": "We also report that the histone chaperone ANP32E, which is implicated in removing H2AZ from chromatin, similarly promotes HR and appears to work on the same pathway as INO80 in these assays.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "abstract"}, {"offsetInBeginSection": 843, "offsetInEndSection": 954, "text": "H2A.Z removal from chromatin is the primary function of INO80 and ANP32E in promoting homologous recombination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "abstract"}]}, {"body": "Are there methods for generating highly multiplexed ChIP-seq libraries?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24885602"], "ideal_answer": ["Yes. There are methods for generating highly multiplexed ChIP-seq libraries."], "exact_answer": "yes", "type": "yesno", "id": "589206fc49702f2e01000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "A method for generating highly multiplexed ChIP-seq libraries.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24885602", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 817, "text": "The barcoding of next generation sequencing libraries has become an essential part of the experimental design. Barcoding not only allows the sequencing of more than one sample per lane, but also reduces technical bias. However, current barcoding strategies impose significant limitations and/or technical barriers in their implementation for ChIP-sequencing.FINDINGS: Converting Y-shaped sequencing adapters to double stranded DNA prior to agarose gel size selection reduces adapter dimer contamination and quantitating the number of cycles required for amplification of the library with qPCR prior to library amplification eliminates library over-amplification.CONCLUSIONS: We describe an efficient and cost effective method for making barcoded ChIP-seq libraries for sequencing on the Illumina platform.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24885602", "endSection": "abstract"}]}, {"body": "Which diseases are associated with Primary intestinal lymphangiectasia (PIL)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26908672", "http://www.ncbi.nlm.nih.gov/pubmed/26934740", "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "http://www.ncbi.nlm.nih.gov/pubmed/20812055", "http://www.ncbi.nlm.nih.gov/pubmed/18294365", "http://www.ncbi.nlm.nih.gov/pubmed/15229406"], "ideal_answer": ["Primary intestinal lymphangiectasia (PIL) is associated with:\n1) Waldmann's disease and\n2) Hennekam syndrome (HS)."], "exact_answer": [["Waldmann's disease"], ["Hennekam syndrome", "HS"]], "type": "list", "id": "58ca6d3902b8c6095300002c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is an exudative enteropathy resulting from morphologic abnormalities in the intestinal lymphatics. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908672", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Secondary hypogammaglobulinemia in Waldmann's disease treated with subcutaneous immunoglobulins.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26934740", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Octreotide in Hennekam syndrome-associated intestinal lymphangiectasia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "endSection": "title"}, {"offsetInBeginSection": 97, "offsetInEndSection": 250, "text": "Primary intestinal lymphangiectasia (PIL) is one mechanism leading to PLE. Few syndromes are associated with PIL; Hennekam syndrome (HS) is one of them. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "endSection": "abstract"}, {"offsetInBeginSection": 530, "offsetInEndSection": 617, "text": "There are no publications on the treatment of PIL with octreotide in patients with HS. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "endSection": "abstract"}, {"offsetInBeginSection": 1169, "offsetInEndSection": 1275, "text": "To the best of our knowledge, this is the first case report on the use of octreotide in HS-associated PIL.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is a rare disorder characterized by dilated intestinal lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20812055", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Primary intestinal lymphangiectasia (Waldmann's disease).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18294365", "endSection": "title"}, {"offsetInBeginSection": 1, "offsetInEndSection": 101, "text": "Limb lymphedema as a first manifestation of primary intestinal lymphangiectasia (Waldmann's disease)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15229406", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Primary intestinal lymphangiectasia (Waldmann's disease) is characterized by protein-losing enteropathy occurring more frequently in childhood. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15229406", "endSection": "abstract"}]}, {"body": "Is there a relationship between B cells and Multiple Sclerosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25666875", "http://www.ncbi.nlm.nih.gov/pubmed/25620021", "http://www.ncbi.nlm.nih.gov/pubmed/26604134"], "ideal_answer": ["MS patients with high neurodegeneration have changes in B cells characterized by down-regulation of B-cell-specific genes and increased activation status"], "exact_answer": "yes", "type": "yesno", "id": "58c0836102b8c6095300001c", "snippets": [{"offsetInBeginSection": 1682, "offsetInEndSection": 1896, "text": "These results suggest that RRMS patients with radiological phenotypes showing high neurodegeneration have changes in B cells characterized by down-regulation of B-cell-specific genes and increased activation status", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26604134", "endSection": "abstract"}, {"offsetInBeginSection": 517, "offsetInEndSection": 744, "text": "Although the exact etiology is still obscure, the leading hypothesis behind MS relapses is acute inflammatory attacks on CNS myelin and axons. This complex process involves B and T cells together with macrophages and microglia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25620021", "endSection": "abstract"}, {"offsetInBeginSection": 545, "offsetInEndSection": 878, "text": "It is currently known that CD24 serves as a costimulatory factor of T cells that regulate their homeostasis and proliferation, while in B cells, CD24 is functionally involved in cell activation and differentiation. CD24 can enhance autoimmune diseases in terms of its protective role in the clonal deletion of autoreactive thymocytes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25666875", "endSection": "abstract"}]}, {"body": "Which disease is associated with mutated Sox2?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26130484", "http://www.ncbi.nlm.nih.gov/pubmed/26893459", "http://www.ncbi.nlm.nih.gov/pubmed/25542770", "http://www.ncbi.nlm.nih.gov/pubmed/26250054"], "ideal_answer": ["SOX2 anophthalmia syndrome is an uncommon autosomal dominant syndrome caused by mutations in the SOX2 gene and clinically characterized by severe eye malformations (anophthalmia/microphthalmia) and extraocular anomalies mainly involving brain, esophagus, and genitalia."], "exact_answer": [["SOX2 anophthalmia syndrome"]], "type": "factoid", "id": "58ce9bf1d46b5c2951000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "Anophthalmia and microphthalmia (A/M) are developmental ocular malformations defined as the complete absence or reduction in size of the eye. A/M is a highly heterogeneous disorder with SOX2 and FOXE3 playing major roles in dominant and recessive pedigrees, respectively;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26130484", "endSection": "abstract"}, {"offsetInBeginSection": 45, "offsetInEndSection": 296, "text": "anophthalmia/microphthalmia (AM) or anterior segment dysgenesis (ASD) have an estimated combined prevalence of 3.7 in 10,000 births. Mutations in SOX2 are the most frequent contributors to severe ODA, yet account for a minority of the genetic drivers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26893459", "endSection": "abstract"}, {"offsetInBeginSection": 477, "offsetInEndSection": 548, "text": "Three causative SOX2 mutations were found in subjects with syndromic A.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25542770", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "SOX2 anophthalmia syndrome is an uncommon autosomal dominant syndrome caused by mutations in the SOX2 gene and clinically characterized by severe eye malformations (anophthalmia/microphthalmia) and extraocular anomalies mainly involving brain, esophagus, and genitalia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26250054", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of onartuzumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27349303", "http://www.ncbi.nlm.nih.gov/pubmed/27401892", "http://www.ncbi.nlm.nih.gov/pubmed/27918718", "http://www.ncbi.nlm.nih.gov/pubmed/27918764", "http://www.ncbi.nlm.nih.gov/pubmed/27937096", "http://www.ncbi.nlm.nih.gov/pubmed/25818471"], "ideal_answer": ["Onartuzumab is monoclonal antibody targeting MET. It works by inhibiting MET. Onartuzumab was tested for treatment of non-small cell lung carcinoma, adenocarcinoma of the stomach and gastroesophageal Junction, and recurrent glioblastoma."], "type": "summary", "id": "5890dcba621ea6ff7e000003", "snippets": [{"offsetInBeginSection": 316, "offsetInEndSection": 503, "text": " In this study, e-training was used to train board-certified pathologists to evaluate non-small cell lung carcinoma for eligibility for treatment with onartuzumab, a MET-inhibiting agent.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27349303", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892", "endSection": "title"}, {"offsetInBeginSection": 238, "offsetInEndSection": 331, "text": "MET immunohistochemistry expression as a biomarker of onartuzumab activity was also examined.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892", "endSection": "abstract"}, {"offsetInBeginSection": 1721, "offsetInEndSection": 2173, "text": "CONCLUSION: The addition of onartuzumab to mFOLFOX6 in gastric cancer did not improve efficacy in an unselected population or in a MET immunohistochemistry-positive population.IMPLICATIONS FOR PRACTICE: The YO28252 study demonstrated that the addition of the anti-MET agent onartuzumab to mFOLFOX6 for treatment of gastric cancer did not improve efficacy in an overall study population or those selected for positive MET status by immunohistochemistry.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892", "endSection": "abstract"}, {"offsetInBeginSection": 251, "offsetInEndSection": 433, "text": " The phase II study GO27819 investigated the monovalent MET inhibitor onartuzumab plus bevacizumab (Ona + Bev) versus placebo plus bevacizumab (Pla + Bev) in recurrent glioblastoma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27918718", "endSection": "abstract"}, {"offsetInBeginSection": 167, "offsetInEndSection": 376, "text": "We report results of METGastric, a phase 3 trial of the MET inhibitor onartuzumab plus standard first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative, MET-positive, advanced GEC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27918764", "endSection": "abstract"}, {"offsetInBeginSection": 1678, "offsetInEndSection": 1872, "text": "Conclusion Onartuzumab plus erlotinib did not improve clinical outcomes, with shorter OS in the onartuzumab arm, compared with erlotinib in patients with MET-positive non-small-cell lung cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27937096", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 657, "text": "A recent example of a failed trial is the Phase III MetLung trial that compared the effects of the c-MET monovalent antibody onartuzumab with erlotinib versus erlotinib alone in late-stage non-small-cell lung cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25818471", "endSection": "abstract"}]}, {"body": "Is the mouse Sry gene locus free of repetitive sequences?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8747544", "http://www.ncbi.nlm.nih.gov/pubmed/8566785"], "ideal_answer": ["We demonstrate that the presence of long inverted repeats (IR) flanking the mouse Sry gene leads to the formation of the Sry circular transcript in cultured cells. We have found that in an in vitro assay, the SRY protein binds to several sites of the Sry gene and especially to a (CA)25 sequence and to a (CAG)30 repeat.", "The presence of long inverted repeats (IR) flanking the mouse Sry gene leads to the formation of the Sry circular transcript in cultured cells.", "We demonstrate that the presence of long inverted repeats (IR) flanking the mouse Sry gene leads to the formation of the Sry circular transcript in cultured cells Circularization requires the presence of both IR.", "We demonstrate that the presence of long inverted repeats (IR) flanking the mouse Sry gene leads to the formation of the Sry circular transcript in cultured cells We have found that in an in vitro assay, the SRY protein binds to several sites of the Sry gene and especially to a (CA)25 sequence and to a (CAG)30 repeat", "We demonstrate that the presence of long inverted repeats (IR) flanking the mouse Sry gene leads to the formation of the Sry circular transcript in cultured cells"], "exact_answer": "no", "type": "yesno", "id": "58de34608acda3452900002b", "snippets": [{"offsetInBeginSection": 446, "offsetInEndSection": 608, "text": "We demonstrate that the presence of long inverted repeats (IR) flanking the mouse Sry gene leads to the formation of the Sry circular transcript in cultured cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8566785", "endSection": "abstract"}, {"offsetInBeginSection": 610, "offsetInEndSection": 721, "text": "Circularization requires the presence of both IR. As few as 400 complementary nt are necessary for this process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8566785", "endSection": "abstract"}, {"offsetInBeginSection": 723, "offsetInEndSection": 830, "text": "The presence of the IR does not significantly stimulate intermolecular annealing and trans-splicing in vivo", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8566785", "endSection": "abstract"}, {"offsetInBeginSection": 397, "offsetInEndSection": 552, "text": "We have found that in an in vitro assay, the SRY protein binds to several sites of the Sry gene and especially to a (CA)25 sequence and to a (CAG)30 repeat", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8747544", "endSection": "abstract"}]}, {"body": "Is Meis1 implicated in microphthalmia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26253404"], "ideal_answer": ["Yes. Meis1 coordinates a network of genes implicated in eye development and microphthalmia. Haploinsufficiency of Meis1, which encodes a transcription factor with evolutionarily conserved expression in the embryonic trunk, brain and sensory organs, including the eye, causes microphthalmic traits and visual impairment in adult mice."], "exact_answer": "yes", "type": "yesno", "id": "5892783d49702f2e01000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Meis1 coordinates a network of genes implicated in eye development and microphthalmia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "title"}, {"offsetInBeginSection": 328, "offsetInEndSection": 587, "text": "Here we show that haploinsufficiency of Meis1, which encodes a transcription factor with evolutionarily conserved expression in the embryonic trunk, brain and sensory organs, including the eye, causes microphthalmic traits and visual impairment in adult mice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "abstract"}, {"offsetInBeginSection": 1310, "offsetInEndSection": 1502, "text": "We propose that Meis1 is at the core of a genetic network implicated in eye patterning/microphthalmia, and represents an additional candidate for syndromic cases of these ocular malformations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "abstract"}]}, {"body": "Does oculocutaneous albinism show an autosomal recessive inheritance?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26165494", "http://www.ncbi.nlm.nih.gov/pubmed/22817390", "http://www.ncbi.nlm.nih.gov/pubmed/20019752", "http://www.ncbi.nlm.nih.gov/pubmed/23112997", "http://www.ncbi.nlm.nih.gov/pubmed/17768386"], "ideal_answer": ["Yes, oculocutaneous albinism shows an autosomal recessive inheritance."], "exact_answer": "yes", "type": "yesno", "id": "58cbb55402b8c60953000033", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Oculocutaneous albinism (OCA) is an autosomal recessive disorder characterized by hypopigmentation in eyes, hair and skin, accompanied with vision loss. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26165494", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Autosomal-recessive albinism is a hypopigmentation disorder with a broad phenotypic range. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395477", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Mutations in c10orf11, a melanocyte-differentiation gene, cause autosomal-recessive albinism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395477", "endSection": "title"}, {"offsetInBeginSection": 1389, "offsetInEndSection": 1533, "text": "In conclusion, we have identified a melanocyte-differentiation gene, C10orf11, which when mutated causes autosomal-recessive albinism in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395477", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 152, "text": "Oculocutaneous albinism (OCA) is an autosomal recessive hereditary pigmentation disorder affecting humans and several other animal species. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22817390", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Oculocutaneous albinism type 2 (OCA2) is a human autosomal-recessive hypopigmentation disorder associated with pathological mutations of the OCA2 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20019752", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 186, "text": "Oculocutaneous albinism type1 (OCA1) is characterized by the absence of melanin pigmentation. The mutation on TYR gene makes OCA1 as an autosomal recessive genetic disorder. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23112997", "endSection": "abstract"}, {"offsetInBeginSection": 804, "offsetInEndSection": 953, "text": "Our patients were diagnosed as affected with Oculocutaneous albinism type1a. Analysis of pedigree pattern showed an autosomal recessive inheritance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23112997", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 174, "text": "Oculocutaneous albinism (OCA) is an autosomal recessive disorder of melanin biosynthesis that results in congenital hypopigmentation of ocular and cutaneous tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17768386", "endSection": "abstract"}]}, {"body": "List 3 indications for Bupropion", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27038550", "http://www.ncbi.nlm.nih.gov/pubmed/25895022", "http://www.ncbi.nlm.nih.gov/pubmed/26137782", "http://www.ncbi.nlm.nih.gov/pubmed/25223901"], "ideal_answer": ["Bupropion is used to treat Obesity, for smoking cessation and for depression"], "exact_answer": [["weight loss in obesity"], ["smoking cessation"], ["depression"]], "type": "list", "id": "58c1b2f702b8c6095300001e", "snippets": [{"offsetInBeginSection": 710, "offsetInEndSection": 806, "text": " recurrent MDD. Non-responders to an 8-week trial are switched double blind to either bupropion ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27038550", "endSection": "abstract"}, {"offsetInBeginSection": 407, "offsetInEndSection": 699, "text": " For genotype, genes associated with nicotinic acetylcholine receptors (nAChRs) and related proteins have been found to predict response to first-line medications (e.g. nicotine replacement therapy [NRT], bupropion, or varenicline) or quitting over time without a controlled treatment trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25895022", "endSection": "abstract"}, {"offsetInBeginSection": 1633, "offsetInEndSection": 1851, "text": "The approval of drug combinations, such as phentermine/topiramate and bupropion/naltrexone are also noteworthy, the components of which have been previously approved, but not necessarily for obesity as main indication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137782", "endSection": "abstract"}, {"offsetInBeginSection": 148, "offsetInEndSection": 374, "text": "Two drugs, phentermine plus topiramate and lorcaserin, have recently been approved by the US Food and Drug Administration for the indication of obesity; a third, bupropion plus naltrexone, is under consideration for approval. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25223901", "endSection": "abstract"}]}, {"body": "Is the enzyme EPRS phosphorylated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27729295", "http://www.ncbi.nlm.nih.gov/pubmed/23071094", "http://www.ncbi.nlm.nih.gov/pubmed/21220307", "http://www.ncbi.nlm.nih.gov/pubmed/19647514"], "ideal_answer": ["Yes, EPRS is dually phosphorylated by cyclin-dependent kinase 5 (Cdk5) at Ser(886) and then by a Cdk5-dependent-AGC kinase at Ser(999)"], "exact_answer": "yes", "type": "yesno", "id": "58cd522902b8c60953000038", "snippets": [{"offsetInBeginSection": 368, "offsetInEndSection": 560, "text": "Phosphorylation of glutamyl-prolyl tRNA synthetase (EPRS) has been investigated extensively in our laboratory for more than a decade, and has served as an archetype for studies of other AARSs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729295", "endSection": "abstract"}, {"offsetInBeginSection": 448, "offsetInEndSection": 579, "text": "EPRS is dually phosphorylated by cyclin-dependent kinase 5 (Cdk5) at Ser(886) and then by a Cdk5-dependent-AGC kinase at Ser(999); ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071094", "endSection": "abstract"}, {"offsetInBeginSection": 800, "offsetInEndSection": 997, "text": "Diphosphorylated EPRS is released from its residence in the tRNA multisynthetase complex for immediate binding to NS1-associated protein and subsequent binding to ribosomal protein L13a and GAPDH. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21220307", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Two-site phosphorylation of EPRS coordinates multimodal regulation of noncanonical translational control activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19647514", "endSection": "title"}]}, {"body": "Can Pentraxin 3 predict outcomes of sepsis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26872435", "http://www.ncbi.nlm.nih.gov/pubmed/25048752", "http://www.ncbi.nlm.nih.gov/pubmed/26717657", "http://www.ncbi.nlm.nih.gov/pubmed/25001601", "http://www.ncbi.nlm.nih.gov/pubmed/20119647"], "ideal_answer": ["Yes, Pentraxin 3 s an objective biochemical marker in diagnosis of sepsis; it is helpful in assessment of severity and prognosis of sepsis; it also has a certain clinical value in the assessment of sepsis cardiovascular function damage."], "exact_answer": "yes", "type": "yesno", "id": "5890eb22621ea6ff7e000006", "snippets": [{"offsetInBeginSection": 1447, "offsetInEndSection": 1708, "text": "As compared with low serum PTX3and sTWEAK cases, cirrhotic patients with high serum PTX3/sTWEAK levels a have higher probability of new severe infections, severe sepsis, septic shock, type 1 hepatorenal syndrome, in-hospital, and 3-month follow-up mortalities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26872435", "endSection": "abstract"}, {"offsetInBeginSection": 1350, "offsetInEndSection": 1543, "text": "Neonates with high nPTX3 concentrations also have lowered APGAR scores, increased rate of respiratory distress syndrome, clinical sepsis, IVH, necrotizing enterocolitis and prolonged NICU stay.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25048752", "endSection": "abstract"}, {"offsetInBeginSection": 3688, "offsetInEndSection": 4106, "text": "In terms of predicting the prognosis of sepsis with heart failure complications, the PTX3 value's area under ROC curve was larger than that of BNP (respectively 0. 844, 0. 472).CONCLUSION: The PTX3 is an objective biochemical marker in diagnosis of sepsis; it is helpful in assessment of severity and prognosis of sepsis; it also has a certain clinical value in the assessment of sepsis cardiovascular function damage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26717657", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Severe Acinetobacter baumannii sepsis is associated with elevation of pentraxin 3.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25001601", "endSection": "title"}, {"offsetInBeginSection": 1636, "offsetInEndSection": 1755, "text": "Together, these results suggest that elevation of PTX3 is associated with fulminant disease during A. baumannii sepsis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25001601", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20119647", "endSection": "title"}, {"offsetInBeginSection": 231, "offsetInEndSection": 332, "text": "PTX3, as a mediator of inflammation, may represent an early marker of severity and outcome in sepsis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20119647", "endSection": "abstract"}, {"offsetInBeginSection": 1413, "offsetInEndSection": 1645, "text": "CONCLUSIONS: Persisting high levels of circulating PTX3 over the first days from sepsis onset may be associated with mortality. PTX3 correlates with severity of sepsis and with sepsis-associated coagulation/fibrinolysis dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20119647", "endSection": "abstract"}]}, {"body": "Which polymerase transcribes pri-miRNAs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26149087", "http://www.ncbi.nlm.nih.gov/pubmed/21702984", "http://www.ncbi.nlm.nih.gov/pubmed/20655920", "http://www.ncbi.nlm.nih.gov/pubmed/15525708", "http://www.ncbi.nlm.nih.gov/pubmed/18829588", "http://www.ncbi.nlm.nih.gov/pubmed/18042145"], "ideal_answer": ["Recent evidence indicates that miRNA genes are transcribed by RNA polymerase II (Pol II) we have established a robust in vivo system in which pri-miRNA is transcribed by RNAP II and processed to pre-miRNA in HeLa cell nuclear extracts.", "Previous studies in vivo reported that processing of primary microRNA (pri-miRNA) is coupled to transcription by RNA polymerase II (RNAP II) and can occur co-transcriptionally. ", "The non-protein-encoding pri-miRNAs are synthesized by RNA polymerase II and post-transcriptionally modified by addition of a 5'-cap and a 3'-poly (A) tail.", " Analogously to mRNAs, the non-protein-encoding pri-miRNAs are synthesized by RNA polymerase II and post-transcriptionally modified by addition of a 5'-cap and a 3'-poly (A) tail. Recent evidence indicates that miRNA genes are transcribed by RNA polymerase II (Pol II)", "Previous studies in vivo reported that processing of primary microRNA (pri-miRNA) is coupled to transcription by RNA polymerase II (RNAP II) and can occur co-transcriptionally. we have established a robust in vivo system in which pri-miRNA is transcribed by RNAP II and processed to pre-miRNA in HeLa cell nuclear extracts.", "Because the transcripts of most miRNA genes are the products of type-II RNA polymerase, pri-miRNA has a poly(A) tail and appears in expressed sequence tags (EST). Analogously to mRNAs, the non-protein-encoding pri-miRNAs are synthesized by RNA polymerase II and post-transcriptionally modified by addition of a 5'-cap and a 3'-poly (A) tail."], "exact_answer": [["RNA polymerase II"], ["RNAPII"]], "type": "factoid", "id": "589d965a78275d0c4a000049", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Previous studies in vivo reported that processing of primary microRNA (pri-miRNA) is coupled to transcription by RNA polymerase II (RNAP II) and can occur co-transcriptionally. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26149087", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 328, "text": "we have established a robust in vivo system in which pri-miRNA is transcribed by RNAP II and processed to pre-miRNA in HeLa cell nuclear extracts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26149087", "endSection": "abstract"}, {"offsetInBeginSection": 628, "offsetInEndSection": 873, "text": "In addition, obvious enrichments of three histone modifications (H2BK5me1, H3K36me3 and H4K20me1) as well as RNA Polymerase II (RNAPII) were observed on pre-miRNA genomic sequences corresponding to the active-promoter miRNAs and expressed miRNAs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21702984", "endSection": "abstract"}, {"offsetInBeginSection": 252, "offsetInEndSection": 413, "text": "Because the transcripts of most miRNA genes are the products of type-II RNA polymerase, pri-miRNA has a poly(A) tail and appears in expressed sequence tags (EST)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20655920", "endSection": "abstract"}, {"offsetInBeginSection": 310, "offsetInEndSection": 398, "text": "Recent evidence indicates that miRNA genes are transcribed by RNA polymerase II (Pol II)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18829588", "endSection": "abstract"}, {"offsetInBeginSection": 400, "offsetInEndSection": 688, "text": "Since Pol II transcripts are capped, we hypothesized that CBP (cap-binding protein) 20 and 80 may bind to capped primary miRNA (pri-miRNA) transcripts and play a role in their processing. Here, we show that cbp20 and cbp80 mutants have reduced miRNA levels and increased pri-miRNA levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18829588", "endSection": "abstract"}, {"offsetInBeginSection": 120, "offsetInEndSection": 299, "text": " Analogously to mRNAs, the non-protein-encoding pri-miRNAs are synthesized by RNA polymerase II and post-transcriptionally modified by addition of a 5'-cap and a 3'-poly (A) tail.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18042145", "endSection": "abstract"}]}, {"body": "What is the role of Lysine 2-hydroxyisobutyrylation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24681537"], "ideal_answer": ["Lysine 2-hydroxyisobutyrylation (Khib) is a widely distributed active histone mark. This histone mark was initially identified by MS and then validated by chemical and biochemical methods. Histone Khib shows distinct genomic distributions from histone Kac or histone Kcr during male germ cell differentiation. In male germ cells, H4K8hib is associated with active gene transcription in meiotic and post-meiotic cells. In addition, H4K8ac-associated genes are included in and constitute only a subfraction of H4K8hib-labeled genes. The histone Khib mark is conserved and widely distributed, has high stoichiometry and induces a large structural change."], "type": "summary", "id": "589474467d9090f353000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Lysine 2-hydroxyisobutyrylation is a widely distributed active histone mark.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24681537", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1048, "text": "We report the identification of a new type of histone mark, lysine 2-hydroxyisobutyrylation (Khib), and identify the mark at 63 human and mouse histone Khib sites, including 27 unique lysine sites that are not known to be modified by lysine acetylation (Kac) and lysine crotonylation (Kcr). This histone mark was initially identified by MS and then validated by chemical and biochemical methods. Histone Khib shows distinct genomic distributions from histone Kac or histone Kcr during male germ cell differentiation. Using chromatin immunoprecipitation sequencing, gene expression analysis and immunodetection, we show that in male germ cells, H4K8hib is associated with active gene transcription in meiotic and post-meiotic cells. In addition, H4K8ac-associated genes are included in and constitute only a subfraction of H4K8hib-labeled genes. The histone Khib mark is conserved and widely distributed, has high stoichiometry and induces a large structural change. These findings suggest its critical role on the regulation of chromatin functions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24681537", "endSection": "abstract"}]}, {"body": "Which mutated enzyme is responsible for oculocutaneous 1 (OCA1)-type albinism?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23242301", "http://www.ncbi.nlm.nih.gov/pubmed/19208379", "http://www.ncbi.nlm.nih.gov/pubmed/12829739", "http://www.ncbi.nlm.nih.gov/pubmed/10713140", "http://www.ncbi.nlm.nih.gov/pubmed/10671066"], "ideal_answer": ["Mutations in the gene for tyrosinase (TYR), the key enzyme in melanin synthesis, are responsible for oculocutaneous 1 (OCA1)-type albinism."], "exact_answer": [["tyrosinase"], ["TYR"]], "type": "factoid", "id": "58cbb98c02b8c60953000034", "snippets": [{"offsetInBeginSection": 1, "offsetInEndSection": 89, "text": "An overview of oculocutaneous albinism: TYR gene mutations in five Colombian individuals", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23242301", "endSection": "title"}, {"offsetInBeginSection": 173, "offsetInEndSection": 385, "text": "To date, 230 mutations in the TYR gene have been reported as responsible for oculocutaneus albinism type 1 worldwide. TYR gene encodes the enzyme tyrosinase involved in the metabolic pathway of melanin synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23242301", "endSection": "abstract"}, {"offsetInBeginSection": 397, "offsetInEndSection": 644, "text": "Mutations were identified in the TYR gene as responsible for oculocutaneous albinism type 1 in five Colombian individuals, and a new ophthalmic system was tested that corrected visual defects and symptoms in a patient with oculocutaneous albinism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23242301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Mutations in the gene for tyrosinase, the key enzyme in melanin synthesis, are responsible for oculocutaneous albinism type 1, and more than 100 mutations of this gene have been identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19208379", "endSection": "abstract"}, {"offsetInBeginSection": 346, "offsetInEndSection": 522, "text": "The Q402 allele has been associated with autosomal recessive ocular albinism when it is in trans with a tyrosinase gene mutation associated with oculocutaneous albinism type 1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19208379", "endSection": "abstract"}, {"offsetInBeginSection": 353, "offsetInEndSection": 503, "text": "The disruption of tyrosinase trafficking occurs at the level of the endoplasmic reticulum (ER) in OCA1 and OCA3, but at the post-Golgi level in OCA2. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12829739", "endSection": "abstract"}, {"offsetInBeginSection": 89, "offsetInEndSection": 308, "text": "Mutations at a single N-glycosylation sequon of tyrosinase have been reported to be responsible for oculocutaneous albinism type IA in humans, characterized by inactive tyrosinase and the total absence of pigmentation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10713140", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Mutations of the human tyrosinase gene associated with tyrosinase related oculocutaneous albinism (OCA1). ", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10671066", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 582, "text": "Mutations in the human tyrosinase gene produce tyrosinase-related oculocutaneous albinism (OCA1, MIM #203100). Tyrosinase is a copper containing enzyme and is responsible for catalyzing the rate limiting step in melanin biosynthesis, the hydroxylation of tyrosine to dopaquinone. We report 13 new mutations in the tyrosinase gene associated with OCA1A (without pigment) and OCA1B (with pigment) including 9 missense mutations (H19Q, R521, R77C, G97R, C289R, L312V, P313R, F340L and H404P), two nonsense mutations (W80X and R116X) and two frameshift mutations (53delG and 223 delG). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10671066", "endSection": "abstract"}]}, {"body": "Please list 2 treatments for a torn roator cuff", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26254089", "http://www.ncbi.nlm.nih.gov/pubmed/26564215", "http://www.ncbi.nlm.nih.gov/pubmed/26847487", "http://www.ncbi.nlm.nih.gov/pubmed/26912284"], "ideal_answer": ["to compare clinical outcomes between conventional en masse repair and separate double-layer double-row repair for the treatment of delaminated rotator cuff tears.", "Surgical repair earlier or later than 3 months after injury may result in similar outcomes and patient satisfaction."], "exact_answer": [["early surgery"], ["later surgery(3 months after injury)"], ["en masse repair"], ["double-layer double-row repair"], ["arthroscopic"], ["open"], ["knotless transosseous-equivalent"]], "type": "list", "id": "58c99acf02b8c60953000028", "snippets": [{"offsetInBeginSection": 408, "offsetInEndSection": 569, "text": "To compare clinical outcomes between conventional en masse repair and separate double-layer double-row repair for the treatment of delaminated rotator cuff tears", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26912284", "endSection": "abstract"}, {"offsetInBeginSection": 467, "offsetInEndSection": 594, "text": " To systematically review and evaluate the effectiveness of grafts in the augmentation of large-to-massive rotator cuff repairs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26847487", "endSection": "abstract"}, {"offsetInBeginSection": 506, "offsetInEndSection": 576, "text": "early (<6 weeks after surgery) versus delayed (\u22656 weeks after surgery)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25943112", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 150, "text": "To evaluate the effectiveness of arthroscopic debridement (DB), partial (PR), and complete repair (CR) for massive rotator cuff tears (mRCT) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26254089", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 163, "text": "The purpose was to investigate whether surgical repair earlier or later than 3\u00a0months after injury may result in similar outcomes and patient satisfaction", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26564215", "endSection": "abstract"}]}, {"body": "List diseases associated with the  Dopamine Receptor D4 (DRD4).", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25659462", "http://www.ncbi.nlm.nih.gov/pubmed/25983551", "http://www.ncbi.nlm.nih.gov/pubmed/22610946"], "ideal_answer": ["The 5-repeat allele of a common length polymorphism in the gene that encodes the dopamine D4 receptor (DRD4) is robustly associated with the risk of attention deficit hyperactivity disorder (ADHD)."], "exact_answer": [["attention deficit hyperactivity disorder", "ADHD"], ["susceptibility to neuropsychiatric diseases"]], "type": "list", "id": "58cd59cb02b8c60953000039", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 279, "text": "The 5-repeat allele of a common length polymorphism in the gene that encodes the dopamine D4 receptor (DRD4) is robustly associated with the risk of attention deficit hyperactivity disorder (ADHD) and substantially exists in Asian populations, which have a lower ADHD prevalence.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25659462", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 296, "text": "The variable number of tandem repeats (VNTR) of the dopamine receptor D4 (DRD4) gene among humans may elucidate individual differences in susceptibility to neuropsychiatric diseases. Dopamine dysfunction may be involved with Attention Deficit Hyperactivity Disorder (ADHD) symptoms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25983551", "endSection": "abstract"}, {"offsetInBeginSection": 505, "offsetInEndSection": 720, "text": "This review summarized the ongoing research of DA receptor genes in ADHD pathogenesis and gathered the past published data with meta-analysis and revealed the high risk of DRD5, DRD2, and DRD4 polymorphisms in ADHD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22610946", "endSection": "abstract"}]}, {"body": "What is the role of Laser Interstitial Thermal Therapy in glioma treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26722845", "http://www.ncbi.nlm.nih.gov/pubmed/27690658", "http://www.ncbi.nlm.nih.gov/pubmed/25727222", "http://www.ncbi.nlm.nih.gov/pubmed/26113069", "http://www.ncbi.nlm.nih.gov/pubmed/24810945", "http://www.ncbi.nlm.nih.gov/pubmed/25434378", "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "http://www.ncbi.nlm.nih.gov/pubmed/18838327"], "ideal_answer": ["Laser Interstitial Thermal Therapy (LITT) is used in treatment of gliomas. LITT can be used effectively for treatment of difficult-to-access high-grade gliomas. More complete coverage of tumor improves progression free survival which can be translated as the extent of resection concept for surgery."], "type": "summary", "id": "5890f4ab621ea6ff7e000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "OBJECTIVE MR-guided laser-induced thermal therapy (MRgLITT) can be used to treat intracranial tumors, epilepsy, and chronic pain syndromes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26722845", "endSection": "abstract"}, {"offsetInBeginSection": 1201, "offsetInEndSection": 1346, "text": "Eight patients had glioblastoma multiforme (GBM), 1 had a previously treated GBM with radiation necrosis, and 1 had a melanoma brain metastasis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690658", "endSection": "abstract"}, {"offsetInBeginSection": 1878, "offsetInEndSection": 2087, "text": "CONCLUSIONS Laser interstitial thermal therapy followed by minimally invasive transsulcal resection, reported here for the first time, is a novel option for patients with large, DTA, malignant brain neoplasms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690658", "endSection": "abstract"}, {"offsetInBeginSection": 577, "offsetInEndSection": 739, "text": "MRI-guided laser interstitial thermal therapy is currently used as a minimally invasive treatment for brain metastases, radiation necrosis, glioma, and epilepsy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26113069", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24810945", "endSection": "title"}, {"offsetInBeginSection": 262, "offsetInEndSection": 594, "text": "We report our multicenter results of laser interstitial thermal therapy (LITT) in DTA-HGGs. We retrospectively reviewed 34 consecutive DTA-HGG patients (24 glioblastoma, 10 anaplastic) who underwent LITT at Cleveland Clinic, Washington University, and Wake Forest University (May 2011-December 2012) using the NeuroBlate(\u00ae) System. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24810945", "endSection": "abstract"}, {"offsetInBeginSection": 1484, "offsetInEndSection": 1669, "text": "LITT can be used effectively for treatment of DTA-HGGs. More complete coverage of tumor by TDT lines improves PFS which can be translated as the extent of resection concept for surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24810945", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Stereotactic laser ablation of high-grade gliomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25434378", "endSection": "title"}, {"offsetInBeginSection": 171, "offsetInEndSection": 438, "text": "Recent advances in intraoperative imaging have spurred the use of stereotactic laser ablation (laser interstitial thermal therapy [LITT]) for intracranial lesions. Among other targets, laser ablation has been used in the focal treatment of high-grade gliomas (HGGs). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25434378", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "OBJECT: Laser interstitial thermal therapy has been used as an ablative treatment for glioma; however, its development was limited due to technical issues. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "abstract"}, {"offsetInBeginSection": 1779, "offsetInEndSection": 1943, "text": "CONCLUSIONS: NeuroBlate represents new technology for delivering laser interstitial thermal therapy, allowing controlled thermal ablation of deep hemispheric rGBM. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "abstract"}, {"offsetInBeginSection": 818, "offsetInEndSection": 1118, "text": "Ongoing researches concern the adjunction of local treatments within the surgical field (photodynamic therapy, chemotherapy, convection immunotherapy...), but also the development of minimal invasive procedures (radiosurgery, high intensity focalized ultrasounds, laser interstitial thermal therapy).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18838327", "endSection": "abstract"}, {"offsetInBeginSection": 760, "offsetInEndSection": 1066, "text": "Current commercially available LITT systems have been used for the treatment of neurosurgical soft-tissue lesions, including difficult to access brain tumors, malignant gliomas, and radiosurgery-resistant metastases, as well as for the ablation of such lesions as epileptogenic foci and radiation necrosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25727222", "endSection": "abstract"}, {"offsetInBeginSection": 250, "offsetInEndSection": 403, "text": " The authors report a Phase I, thermal dose-escalation trial assessing the safety and efficacy of NeuroBlate in recurrent glioblastoma multiforme (rGBM).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "abstract"}]}, {"body": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26116819", "http://www.ncbi.nlm.nih.gov/pubmed/24507717", "http://www.ncbi.nlm.nih.gov/pubmed/23816883", "http://www.ncbi.nlm.nih.gov/pubmed/23580526", "http://www.ncbi.nlm.nih.gov/pubmed/22910211", "http://www.ncbi.nlm.nih.gov/pubmed/15045029", "http://www.ncbi.nlm.nih.gov/pubmed/20711347"], "ideal_answer": ["Saccharomyces cerevisiae Swr1, a Swi2/Snf2-related ATPase, is the catalytic core of a multisubunit chromatin remodeling enzyme, called the SWR1 complex, that efficiently replaces conventional histone H2A in nucleosomes with histone H2A.Z. We identified a complex containing 13 different polypeptides associated with a soluble pool of H2A.Z in Saccharomyces cerevisiae.", "The multisubunit nucleosome-remodeling enzyme complex SWR1, conserved from yeast to mammals, catalyzes the ATP-dependent replacement of histone H2A in canonical nucleosomes with H2A.Z. The SWR1 complex replaces the canonical histone H2A with the variant H2A.Z (Htz1 in yeast) at specific chromatin regions.", "The multisubunit nucleosome-remodeling enzyme complex SWR1, conserved from yeast to mammals, catalyzes the ATP-dependent replacement of histone H2A in canonical nucleosomes with H2A.Z.", "The chromatin remodeler SWR1 mediates site-specific incorporation of H2A.Z by a multi-step histone replacement reaction, evicting histone H2A-H2B from the canonical nucleosome and depositing the H2A.Z-H2B dimer", "The multisubunit nucleosome-remodeling enzyme complex SWR1, conserved from yeast to mammals, catalyzes the ATP-dependent replacement of histone H2A in canonical nucleosomes with H2A.Z. Saccharomyces cerevisiae Swr1, a Swi2/Snf2-related ATPase, is the catalytic core of a multisubunit chromatin remodeling enzyme, called the SWR1 complex, that efficiently replaces conventional histone H2A in nucleosomes with histone H2A.Z."], "exact_answer": [["SWR1"]], "type": "factoid", "id": "58a6db8660087bc10a00002c", "snippets": [{"offsetInBeginSection": 125, "offsetInEndSection": 335, "text": "The chromatin remodeler SWR1 mediates site-specific incorporation of H2A.Z by a multi-step histone replacement reaction, evicting histone H2A-H2B from the canonical nucleosome and depositing the H2A.Z-H2B dimer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26116819", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 333, "text": "he multisubunit nucleosome-remodeling enzyme complex SWR1, conserved from yeast to mammals, catalyzes the ATP-dependent replacement of histone H2A in canonical nucleosomes with H2A.Z.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507717", "endSection": "abstract"}, {"offsetInBeginSection": 741, "offsetInEndSection": 899, "text": "Our results show that the Swr1-Z domain can deliver the H2A.Z-H2B dimer to the DNA-(H3-H4)2 tetrasome to form the nucleosome by a histone chaperone mechanism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507717", "endSection": "abstract"}, {"offsetInBeginSection": 616, "offsetInEndSection": 801, "text": "H2A.Z is deposited into chromatin by the SWR1 complex and is subject to acetylation of its four N-terminal tail lysine residues by the NuA4 and SAGA histone acetyltransferase complexes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23816883", "endSection": "abstract"}, {"offsetInBeginSection": 99, "offsetInEndSection": 236, "text": "H2A.Z deposition is controlled by SWR-C chromatin remodeling enzymes that catalyze the nucleosomal exchange of canonical H2A with H2A.Z. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23580526", "endSection": "abstract"}, {"offsetInBeginSection": 185, "offsetInEndSection": 423, "text": "Saccharomyces cerevisiae Swr1, a Swi2/Snf2-related ATPase, is the catalytic core of a multisubunit chromatin remodeling enzyme, called the SWR1 complex, that efficiently replaces conventional histone H2A in nucleosomes with histone H2A.Z.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22910211", "endSection": "abstract"}, {"offsetInBeginSection": 749, "offsetInEndSection": 886, "text": "The system demonstrates ATP- and SWR1-complex-dependent replacement of histone H2A for histone H2A.Z on a preassembled nucleosome array. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22910211", "endSection": "abstract"}, {"offsetInBeginSection": 192, "offsetInEndSection": 414, "text": "We identified a complex containing 13 different polypeptides associated with a soluble pool of H2A.Z in Saccharomyces cerevisiae. This complex was designated SWR1-Com in reference to the Swr1p subunit, a Swi2/Snf2-paralog.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15045029", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "The SWR1 complex replaces the canonical histone H2A with the variant H2A.Z (Htz1 in yeast) at specific chromatin regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20711347", "endSection": "abstract"}]}, {"body": "Which are the key players on radial glial specification to ependymal cells?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27606337"], "ideal_answer": ["Mcidas and GemC1/Lynkeas specify embryonic radial glial cells. Both proteins were initially described as cell cycle regulators revealing sequence similarity to Geminin. They are expressed in radial glial cells committed to the ependymal cell lineage during embryogenesis, while overexpression and knock down experiments showed that are sufficient and necessary for ependymal cell generation."], "exact_answer": [["Mcidas"], ["GemC1", "Lynkeas"]], "type": "list", "id": "58948cb47d9090f353000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Mcidas and GemC1/Lynkeas specify embryonic radial glial cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27606337", "endSection": "title"}, {"offsetInBeginSection": 655, "offsetInEndSection": 1358, "text": "Here we discuss recent findings suggesting that 2 novel molecules, Mcidas and GemC1/Lynkeas are key players on radial glial specification to ependymal cells. Both proteins were initially described as cell cycle regulators revealing sequence similarity to Geminin. They are expressed in radial glial cells committed to the ependymal cell lineage during embryogenesis, while overexpression and knock down experiments showed that are sufficient and necessary for ependymal cell generation. We propose that Mcidas and GemC1/Lynkeas are key components of the molecular cascade that promotes radial glial cells fate commitment toward multiciliated ependymal cell lineage operating upstream of c-Myb and FoxJ1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27606337", "endSection": "abstract"}]}, {"body": "Is ocular melanosis a risk factor for uveal melanoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23681424", "http://www.ncbi.nlm.nih.gov/pubmed/12647250", "http://www.ncbi.nlm.nih.gov/pubmed/9442799", "http://www.ncbi.nlm.nih.gov/pubmed/8292886"], "ideal_answer": ["Yes, ocular melanosis (melanosis oculi) is a risk factor for uveal melanoma."], "exact_answer": "yes", "type": "yesno", "id": "58b5320e22d3005309000002", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 201, "text": "Ocular/oculodermal (oculo[dermal]) melanocytosis is a congenital periocular pigmentary condition that can lead to the development of uveal melanoma, estimated at 1 in 400 affected patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681424", "endSection": "abstract"}, {"offsetInBeginSection": 352, "offsetInEndSection": 582, "text": "Melanosis oculi is often underestimated as a risk factor for uveal melanoma and glaucoma. Ophthalmic surveillance, every 6 or 12 months is important, in patients with ocular melanocytosis for early detection of high risk diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12647250", "endSection": "abstract"}, {"offsetInBeginSection": 992, "offsetInEndSection": 1520, "text": " One of about 400 patients with ODM followed for life is estimated to develop uveal melanoma. Excessive melanocytes in the uveal tract in ODM may provide the biologic basis for susceptibility to the development of uveal melanoma. Patients with ODM should be monitored ophthalmoscopically, especially during the susceptible period, for the development of uveal melanoma. The authors suggest that a national registry of ODM patients be created and prospective data collected to better assess the risk of developing uveal melanoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9442799", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 132, "text": "In the white population, an association between oculo(dermal) melanocytosis (ODM) and uveal melanoma is well recognized. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9442799", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 325, "text": "Malignant melanomas may arise in the uveal tract, the conjunctiva, the skin of the eyelid, or the orbit. Risk factors so far identified include pre-existing choroidal naevi for uveal melanomas, primary acquired melanosis (PAM) for conjunctival tumours, and ocular and oculodermal melanocytosis for uveal and orbital lesions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8292886", "endSection": "abstract"}]}, {"body": "What does the human ABCC gene  product do?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16815813", "http://www.ncbi.nlm.nih.gov/pubmed/15631998"], "ideal_answer": ["The important drug resistance-conferring members belong to three subfamilies of the human ABC family; these are ABCB1 (MDR1/P-glycoprotein of subfamily ABCB), subfamily ABCC (MRPs), and ABCG2 (BCRP of subfamily ABCG), which are expressed in various organs. The ATP-binding cassette (ABC) transporters constitute a large family of membrane proteins, which transport a variety of compounds through the membrane against a concentration gradient at the cost of ATP hydrolysis"], "exact_answer": [["ATP dependent small molecule transporter"]], "type": "factoid", "id": "58c99fcc02b8c60953000029", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "The ATP-binding cassette (ABC) transporters constitute a large family of membrane proteins, which transport a variety of compounds through the membrane against a concentration gradient at the cost of ATP hydrolysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16815813", "endSection": "abstract"}, {"offsetInBeginSection": 616, "offsetInEndSection": 915, "text": "structure, function, and expression of the important drug resistance-conferring members belonging to three subfamilies of the human ABC family; these are ABCB1 (MDR1/P-glycoprotein of subfamily ABCB), subfamily ABCC (MRPs), and ABCG2 (BCRP of subfamily ABCG), which are expressed in various organs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16815813", "endSection": "abstract"}, {"offsetInBeginSection": 79, "offsetInEndSection": 455, "text": "Transport proteins, including members of the multidrug resistance protein (MRP)/ABCC subfamily, have been recognized to contribute to the latter function. MRP5 (ABCC5) was identified as transmembrane transport protein for cyclic nucleotides, especially 3',5'-cyclic GMP (cGMP), indicating an additional role in signal transduction and a potential role in placenta development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15631998", "endSection": "abstract"}]}, {"body": "What is known about telomere length shortening and stress?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25393133", "http://www.ncbi.nlm.nih.gov/pubmed/26853993", "http://www.ncbi.nlm.nih.gov/pubmed/26919486", "http://www.ncbi.nlm.nih.gov/pubmed/25070535"], "ideal_answer": ["A significant relationship between more perceived stress and shorter telomere length is consistent with theoretical frameworks positing that stress induces physiological changes that result in shortened telomeres."], "type": "summary", "id": "58cd633c02b8c6095300003a", "snippets": [{"offsetInBeginSection": 781, "offsetInEndSection": 995, "text": "A significant relationship between more perceived stress and shorter telomere length is consistent with theoretical frameworks positing that stress induces physiological changes that result in shortened telomeres. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25393133", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 175, "text": "Psychological stress contributes to numerous diseases and may do so in part through damage to telomeres, protective non-coding segments on the ends of chromosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26853993", "endSection": "abstract"}, {"offsetInBeginSection": 1340, "offsetInEndSection": 1591, "text": "Our results support the hypothesis that depression is associated with accelerated cell aging. Future studies are required to clarify whether the association is mediated through environmental stress, and whether effective treatment can halt cell aging.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26919486", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "Telomere length, a reliable predictor of disease pathogenesis, can be affected by genetics, chronic stress and health behaviors. Cross-sectionally, highly stressed postmenopausal women have shorter telomeres, but only if they are inactive. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25070535", "endSection": "abstract"}]}, {"body": "What fruit causes Jamaican vomiting sickness?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25531872", "http://www.ncbi.nlm.nih.gov/pubmed/26328472", "http://www.ncbi.nlm.nih.gov/pubmed/26324727", "http://www.ncbi.nlm.nih.gov/pubmed/23259140"], "ideal_answer": ["Jamaican Vomiting Sickness is caused by ingestion of the unripe arils of the Ackee fruit, its seeds and husks."], "exact_answer": [["Ackee fruit"]], "type": "factoid", "id": "5895f7e978275d0c4a000001", "snippets": [{"offsetInBeginSection": 187, "offsetInEndSection": 315, "text": "The aril of the unripe fruit has high concentrations of HGA, the cause of Jamaican vomiting sickness, which is very often fatal.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25531872", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 315, "text": "In 1976, over 100 years after Jamaican vomiting sickness (JVS) was first reported, the cause of JVS was linked to the ingestion of the toxin hypoglycin A produced by ackee fruit. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26328472", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Ackee apple fruit is a native fruit to Jamaica and some parts of west Africa. Its toxicity known as \"Jamaican vomiting sickness\" dates back to the nineteenth century.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26324727", "endSection": "abstract"}, {"offsetInBeginSection": 172, "offsetInEndSection": 282, "text": "Jamaican Vomiting Sickness is caused by ingestion of the unripe arils of the Ackee fruit, its seeds and husks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259140", "endSection": "abstract"}]}, {"body": "Are Ultra-conserved elements (UCEs) enriched in segmental duplications?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25340765", "http://www.ncbi.nlm.nih.gov/pubmed/22987666", "http://www.ncbi.nlm.nih.gov/pubmed/21092253", "http://www.ncbi.nlm.nih.gov/pubmed/18957701", "http://www.ncbi.nlm.nih.gov/pubmed/16998490"], "ideal_answer": ["ULEs are located in intergenic or intronic regions and are depleted from segmental duplications. In addition, here we show that these elements are preferentially found in pathogenic deletions (enrichment ratio 3.6 vs. 0.5 in duplications), and that this association is not related with a higher content of genes.", "we begin by showing that depletion for uces characterizes the most recent large-scale human cnv datasets and then find that even newly formed de novo cnvs, which have passed through meiosis at most once, are significantly depleted for uces.", "Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell. These elements are most often located either overlapping exons in genes involved in RNA processing or in introns or nearby genes involved in the regulation of transcription and development.", "Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants. Notably, of the UCEs that are found in segmental duplications or copy number variants, the majority overlap exons, indicating, along with other findings presented, that UCEs overlapping exons represent a distinct subset.", "Here we address the process by which CNVs become depleted of UCEs. We begin by showing that depletion for UCEs characterizes the most recent large-scale human CNV datasets and then find that even newly formed de novo CNVs, which have passed through meiosis at most once, are significantly depleted for UCEs.", "Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants."], "exact_answer": "no", "type": "yesno", "id": "58a71bb960087bc10a00002d", "snippets": [{"offsetInBeginSection": 227, "offsetInEndSection": 293, "text": "Here we address the process by which CNVs become depleted of UCEs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 534, "text": "We begin by showing that depletion for UCEs characterizes the most recent large-scale human CNV datasets and then find that even newly formed de novo CNVs, which have passed through meiosis at most once, are significantly depleted for UCEs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "abstract"}, {"offsetInBeginSection": 535, "offsetInEndSection": 680, "text": "In striking contrast, CNVs arising specifically in cancer cells are, as a rule, not depleted for UCEs and can even become significantly enriched.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "abstract"}, {"offsetInBeginSection": 863, "offsetInEndSection": 954, "text": "Alternatively, lack of depletion for UCEs from cancer CNVs may reflect the diseased state. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "abstract"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1045, "text": "ULEs are located in intergenic or intronic regions and are depleted from segmental duplications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22987666", "endSection": "abstract"}, {"offsetInBeginSection": 442, "offsetInEndSection": 579, "text": "Interestingly, human UCEs have been reported to be strongly depleted among segmental duplications and benign copy number variants (CNVs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092253", "endSection": "abstract"}, {"offsetInBeginSection": 1126, "offsetInEndSection": 1341, "text": "In addition, here we show that these elements are preferentially found in pathogenic deletions (enrichment ratio 3.6 vs. 0.5 in duplications), and that this association is not related with a higher content of genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092253", "endSection": "abstract"}, {"offsetInBeginSection": 1342, "offsetInEndSection": 1433, "text": "In contrast, pathogenic CNVs lacking UCEs showed almost a threefold higher content in genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092253", "endSection": "abstract"}, {"offsetInBeginSection": 362, "offsetInEndSection": 581, "text": "We have demonstrated that nonexonic UCEs are depleted among segmental duplications (SDs) and copy number variants (CNVs) and proposed that their ultraconservation may reflect a mechanism of copy counting via comparison.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18957701", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998490", "endSection": "title"}, {"offsetInBeginSection": 610, "offsetInEndSection": 936, "text": "Here, we show that UCEs are significantly depleted among segmental duplications and copy number variants. Notably, of the UCEs that are found in segmental duplications or copy number variants, the majority overlap exons, indicating, along with other findings presented, that UCEs overlapping exons represent a distinct subset.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998490", "endSection": "abstract"}]}, {"body": "What is the applicability of the MCAST algorithm?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26704599"], "ideal_answer": ["The MCAST algorithm uses a hidden Markov model with a P-value-based scoring scheme to identify candidate CRMs."], "type": "summary", "id": "5895f75aad49cff847000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "MCAST: scanning for cis-regulatory motif clusters.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704599", "endSection": "title"}, {"offsetInBeginSection": 577, "offsetInEndSection": 1340, "text": " The MCAST algorithm uses a hidden Markov model with a P-value-based scoring scheme to identify candidate CRMs. Here, we introduce a new version of MCAST that offers improved graphical output, a dynamic background model, statistical confidence estimates based on false discovery rate estimation and, most significantly, the ability to predict CRMs while taking into account epigenomic data such as DNase I sensitivity or histone modification data. We demonstrate the validity of MCAST's statistical confidence estimates and the utility of epigenomic priors in identifying CRMs.AVAILABILITY AND IMPLEMENTATION: MCAST is part of the MEME Suite software toolkit. A web server and source code are available at http://meme-suite.org and http://alternate.meme-suite.org", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704599", "endSection": "abstract"}]}, {"body": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16903824", "http://www.ncbi.nlm.nih.gov/pubmed/18823563", "http://www.ncbi.nlm.nih.gov/pubmed/19549280", "http://www.ncbi.nlm.nih.gov/pubmed/15475580", "http://www.ncbi.nlm.nih.gov/pubmed/11701639"], "ideal_answer": ["The ApoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD)."], "exact_answer": [["ApoE4 isoform"], ["Apolipoprotein E4 isoform"]], "type": "factoid", "id": "58b6cd3222d300530900000d", "snippets": [{"offsetInBeginSection": 206, "offsetInEndSection": 334, "text": "Among three isoforms, the apoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16903824", "endSection": "abstract"}, {"offsetInBeginSection": 442, "offsetInEndSection": 589, "text": "Homozygosity for ApoE epsilon4 is associated with atherosclerosis and Alzheimer's disease whereas ApoE epsilon2 and epsilon3 tend to be protective.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823563", "endSection": "abstract"}, {"offsetInBeginSection": 515, "offsetInEndSection": 715, "text": "Importantly, lipoproteins containing the apoE3 isoform had higher TGF-beta levels and bioactivity than those containing apoE4, a major genetic risk factor for atherosclerosis and Alzheimer's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19549280", "endSection": "abstract"}, {"offsetInBeginSection": 226, "offsetInEndSection": 332, "text": "ApoE4 is positively associated with atherosclerosis and late-onset and sporadic Alzheimer's disease (AD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15475580", "endSection": "abstract"}, {"offsetInBeginSection": 757, "offsetInEndSection": 1176, "text": "Isoform (allele)-specific effects include the association of apoE2 with the genetic disorder type III hyperlipoproteinemia and with both increased and decreased risk for atherosclerosis and the association of apoE4 with increased risk for both atherosclerosis and Alzheimer's disease, impaired cognitive function, and reduced neurite outgrowth; isoform-specific differences in cellular signaling events may also exist. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11701639", "endSection": "abstract"}]}, {"body": "What organism causes woolsorter's disease", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15486181"], "ideal_answer": ["Woolsorter's disease is caused by the same organism as Anthrax, bacillus Anthrax. "], "exact_answer": [["Bacillus Anthracis"]], "type": "factoid", "id": "58caf0be02b8c6095300002f", "snippets": [{"offsetInBeginSection": 279, "offsetInEndSection": 322, "text": "When its link with anthrax was established,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15486181", "endSection": "abstract"}, {"offsetInBeginSection": 661, "offsetInEndSection": 756, "text": "Today, woolsorters' disease and other industrial manifestations of anthrax are extremely rare, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15486181", "endSection": "abstract"}, {"offsetInBeginSection": 571, "offsetInEndSection": 660, "text": "anthrax meant that the bacterium was experimented upon as a potential war-winning weapon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15486181", "endSection": "abstract"}]}, {"body": "Do normal cells express the protein TERT?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21790308", "http://www.ncbi.nlm.nih.gov/pubmed/18956258", "http://www.ncbi.nlm.nih.gov/pubmed/17531113", "http://www.ncbi.nlm.nih.gov/pubmed/17346111"], "ideal_answer": ["\u039d\u03bf, telomerase activity is found in 85%-90% of all human cancers but not in their adjacent normal cells. Human telomerase reverse transcriptase (hTERT) is an essential component in the telomerase complex that plays an important role in telomerase activity."], "exact_answer": "no", "type": "yesno", "id": "58cd6d9702b8c6095300003c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Since telomerase has been recognized as a relevant factor distinguishing cancer cells from normal cells, it has become a very promising target for anti-cancer therapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21790308", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 326, "text": "Telomerase plays a pivotal role in cellular immortality and tumorigenesis. Its activity is normally not detectable in most somatic cells while it is reactivated in the vast majority of cancer cells. Therefore, inhibition of telomerase has been viewed as a promising anticancer approach due to its specificity for cancer cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 264, "text": "Telomerase activity is found in 85%-90% of all human cancers but not in their adjacent normal cells. Human telomerase reverse transcriptase (hTERT) is an essential component in the telomerase complex that plays an important role in telomerase activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17531113", "endSection": "abstract"}, {"offsetInBeginSection": 497, "offsetInEndSection": 890, "text": "elomerase activation is considered to be a critical step in carcinogenesis and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. Since only tumor cells that express telomerase activity would activate this promoter, the hTERT proximal promoter allows for preferential expression of viral genes in tumor cells, leading to selective viral replication", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17346111", "endSection": "abstract"}]}, {"body": "Is siltuximab effective for Castleman disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26634298", "http://www.ncbi.nlm.nih.gov/pubmed/26749192", "http://www.ncbi.nlm.nih.gov/pubmed/26869762", "http://www.ncbi.nlm.nih.gov/pubmed/25601959", "http://www.ncbi.nlm.nih.gov/pubmed/25873122"], "ideal_answer": ["Yes, siltuximab , a chimeric human-mouse monoclonal antibody to IL6, is approved for the treatment of patients with multicentric Castleman disease who are human immunodeficiency virus negative and human herpesvirus-8 negative."], "exact_answer": "yes", "type": "yesno", "id": "5896d3e278275d0c4a000012", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26634298", "endSection": "title"}, {"offsetInBeginSection": 317, "offsetInEndSection": 680, "text": "The recent approvals in North America, Europe and Brazil of siltuximab, a monoclonal antibody against IL-6, for iMCD now provide a safe and effective therapy that targets a key aspect of pathogenesis. In the first ever randomized, placebo-controlled trial in iMCD, siltuximab significantly reduced disease burden and symptoms in a large portion (34%) of patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26634298", "endSection": "abstract"}, {"offsetInBeginSection": 601, "offsetInEndSection": 854, "text": "Despite recent significant advances in our understanding of this disease and the increasing therapeutic experience with rituximab, tocilizumab and siltuximab, there are still difficult questions concerning its aetiology, prognosis and optimal treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26749192", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Emerging treatments in Castleman disease - a critical appraisal of siltuximab.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26869762", "endSection": "title"}, {"offsetInBeginSection": 284, "offsetInEndSection": 793, "text": " Siltuximab, a chimeric monoclonal antibody to IL-6, has thus emerged as a promising treatment option in a disease lacking efficacious therapy. Here, we review the findings of recent studies evaluating single-agent siltuximab treatment in CD, including the first-ever randomized clinical trial in this disease. Although much more work is needed to establish a standardized treatment approach, siltuximab appears to be a safe and effective treatment for patients with newly diagnosed and previously treated CD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26869762", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601959", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 328, "text": "On April 22, 2014, the FDA granted full approval to siltuximab (SYLVANT for injection; Janssen Biotech, Inc.), a chimeric human-mouse monoclonal antibody to IL6, for the treatment of patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601959", "endSection": "abstract"}, {"offsetInBeginSection": 1460, "offsetInEndSection": 1757, "text": "Currently, there are more effective therapeutic alternatives in multicentric Castleman disease: treatment with monotherapy of rituximab or in combination therapy with immunomodulatory drugs (thalidomide or lenalidomide, treatment with anti-IL-6 (siltuximab) or against its receptor (tocilizumab). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873122", "endSection": "abstract"}]}, {"body": "What is the function of yeast Clr4 on chromatin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23771057", "http://www.ncbi.nlm.nih.gov/pubmed/21060862", "http://www.ncbi.nlm.nih.gov/pubmed/19117951", "http://www.ncbi.nlm.nih.gov/pubmed/17504808", "http://www.ncbi.nlm.nih.gov/pubmed/16127433", "http://www.ncbi.nlm.nih.gov/pubmed/11273706", "http://www.ncbi.nlm.nih.gov/pubmed/9620780", "http://www.ncbi.nlm.nih.gov/pubmed/8937982"], "ideal_answer": ["Clr4 is known to regulate silencing and switching at the mating-type loci and to affect chromatin structure at centromeres. The Clr4 methyltransferase determines the subnuclear localization of the mating-type region in fission yeast. Heterochromatin assembly in fission yeast depends on the Clr4 histone methyltransferase, which targets H3K9."], "type": "summary", "id": "58ab1e19396a458e5000000f", "snippets": [{"offsetInBeginSection": 308, "offsetInEndSection": 455, "text": "Mutations in the clr4+, rik1+ and swi6+ genes dramatically reduce silencing at certain centromeric regions and cause elevated chromosome loss rates", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8937982", "endSection": "abstract"}, {"offsetInBeginSection": 918, "offsetInEndSection": 1076, "text": "The Swi6 protein was found to be delocalised from all three silent chromosomal regions, and dispersed within the nucleus, in both clr4 and rik1 mutant cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8937982", "endSection": "abstract"}, {"offsetInBeginSection": 1274, "offsetInEndSection": 1469, "text": "Mutations in clr4, rik1 and swi6 also result in elevated sensitivity to reagents which destabilise microtubules and show a synergistic interaction with a mutation in the beta-tubulin gene (nda3).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8937982", "endSection": "abstract"}, {"offsetInBeginSection": 1470, "offsetInEndSection": 1770, "text": "These observations suggest that clr4+ and rik1+ must play a role in the assembly of Swi6p into a transcriptionally silent, inaccessible chromatin structure at fission yeast centromeres which is required to facilitate interactions with spindle microtubules and to ensure normal chromosome segregation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8937982", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "The chromo and SET domains of the Clr4 protein are essential for silencing in fission yeast.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9620780", "endSection": "title"}, {"offsetInBeginSection": 752, "offsetInEndSection": 868, "text": "Like Su(var)3-9p, Clr4p contains SET and chromo domains, motifs found in proteins that modulate chromatin structure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9620780", "endSection": "abstract"}, {"offsetInBeginSection": 1052, "offsetInEndSection": 1188, "text": "Surprisingly, RNA differential display experiments demonstrated that clr4+ can mediate transcriptional activation of certain other loci.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9620780", "endSection": "abstract"}, {"offsetInBeginSection": 1189, "offsetInEndSection": 1400, "text": "These results show that clr4 plays a critical role in silencing at mating-type loci and centromeres through the organization of repressive chromatin structure and demonstrate a new, activator function for Clr4p.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9620780", "endSection": "abstract"}, {"offsetInBeginSection": 452, "offsetInEndSection": 576, "text": "Clr4 is known to regulate silencing and switching at the mating-type loci and to affect chromatin structure at centromeres. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11273706", "endSection": "abstract"}, {"offsetInBeginSection": 638, "offsetInEndSection": 743, "text": "Mutations in Cul4 result in defective localization of Clr4 and loss of silencing at heterochromatic loci.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16127433", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "The Clr4 methyltransferase determines the subnuclear localization of the mating-type region in fission yeast.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17504808", "endSection": "title"}, {"offsetInBeginSection": 623, "offsetInEndSection": 789, "text": "In a strain lacking the histone methyltransferase Clr4, crucial for the formation of heterochromatin, the mating-type region had a random localization in the nucleus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17504808", "endSection": "abstract"}, {"offsetInBeginSection": 1009, "offsetInEndSection": 1238, "text": "Cut4 and Cut9 interact directly with Swi6/HP1 and Clr4, whereas the mutant Cut4 does not, suggesting that a direct physical interaction of APC subunits Cut4 and Cut9 with Swi6 and Clr4 is instrumental in heterochromatin assembly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19117951", "endSection": "abstract"}, {"offsetInBeginSection": 1647, "offsetInEndSection": 1858, "text": "Thus, APC and heterochromatin proteins Swi6 and Clr4 play a mutually cooperative role in heterochromatin assembly, thereby ensuring chromosomal integrity, inheritance, and segregation during mitosis and meiosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19117951", "endSection": "abstract"}, {"offsetInBeginSection": 171, "offsetInEndSection": 426, "text": "Positive feedback mechanisms that link the RNAi pathway and the Clr4/Suv39h1 histone H3K9 methyltransferase complex (Clr-C) result in requirements for H3K9 methylation for full siRNA production and for siRNA production to achieve full histone methylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21060862", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Heterochromatin assembly in fission yeast depends on the Clr4 histone methyltransferase, which targets H3K9.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771057", "endSection": "abstract"}, {"offsetInBeginSection": 1166, "offsetInEndSection": 1277, "text": "These analyses place Sir2 and H3K14 deacetylation upstream of Clr4 recruitment during heterochromatin assembly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771057", "endSection": "abstract"}]}, {"body": "What is the role of LIMT lncRNA?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27485121"], "ideal_answer": ["LINC01089 (LncRNA Inhibiting Metastasis; LIMT) is a highly conserved lncRNA, which is depleted in basal-like and in HER2-positive tumors, and the low expression of which predicts poor patient prognosis. Interestingly, EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter. LIMT inhibits extracellular matrix invasion of mammary cells in vitro and tumor metastasis in vivo.", "LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer."], "type": "summary", "id": "5896381a78275d0c4a00000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27485121", "endSection": "title"}, {"offsetInBeginSection": 602, "offsetInEndSection": 1301, "text": "This led to the identification of 11 prognostic lncRNAs. Functional analyses of this group uncovered LINC01089 (here renamed LncRNA Inhibiting Metastasis; LIMT), a highly conserved lncRNA, which is depleted in basal-like and in HER2-positive tumors, and the low expression of which predicts poor patient prognosis. Interestingly, EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter. We also find that LIMT inhibits extracellular matrix invasion of mammary cells in\u00a0vitro and tumor metastasis in\u00a0vivo In conclusion, lncRNAs dynamically regulated by growth factors might act as novel drivers of cancer progression and serve as prognostic biomarkers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27485121", "endSection": "abstract"}]}, {"body": "Is infertility characteristic of individuals with Fanconi anemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25016020", "http://www.ncbi.nlm.nih.gov/pubmed/24438373", "http://www.ncbi.nlm.nih.gov/pubmed/21915857", "http://www.ncbi.nlm.nih.gov/pubmed/21951543", "http://www.ncbi.nlm.nih.gov/pubmed/20494929"], "ideal_answer": ["Yes, infertility is characteristic of individuals with Fanconi anemia."], "exact_answer": "yes", "type": "yesno", "id": "58b6d26122d300530900000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 244, "text": "PALB2 links BRCA1 and BRCA2 in homologous recombinational repair of DNA double strand breaks (DSBs). Mono-allelic mutations in PALB2 increase the risk of breast, pancreatic, and other cancers, and biallelic mutations cause Fanconi anemia (FA). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25016020", "endSection": "abstract"}, {"offsetInBeginSection": 621, "offsetInEndSection": 888, "text": "Moreover, mutant males showed reduced fertility due to impaired meiosis and increased apoptosis in germ cells. Interestingly, mutant meiocytes showed a significant defect in sex chromosome synapsis, which likely contributed to the germ cell loss and fertility defect.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25016020", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 217, "text": "In females with Fanconi anemia (FA), infertility is often accompanied by diminished ovarian reserve and hypergonadotropic amenorrhea before the age of 30 years, suggesting primary ovarian insufficiency (POI).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24438373", "endSection": "abstract"}, {"offsetInBeginSection": 1368, "offsetInEndSection": 1740, "text": "Substantially reduced AMH levels in females with FA suggest a primary ovarian defect associated with reduced fertility. Measurement of AMH at the time of FA diagnosis and subsequent monitoring of AMH levels at regular intervals may be useful for the timely management of complications related to POI such as subfertility/infertility, osteoporosis, and menopausal symptoms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24438373", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Fanconi anemia (FA) is a human disease of bone marrow failure, leukemia, squamous cell carcinoma, and developmental anomalies, including hypogonadism and infertility. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21951543", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Reduced fertility is one clinical manifestation among other well known Fanconi anemia features. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20494929", "endSection": "abstract"}]}, {"body": "What are Kupffer cells and what is their role?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27717685", "http://www.ncbi.nlm.nih.gov/pubmed/26908374", "http://www.ncbi.nlm.nih.gov/pubmed/26613891", "http://www.ncbi.nlm.nih.gov/pubmed/26553134"], "ideal_answer": ["Kupffer cells (KCs)are hepatic macrophages which can secrete matrix metalloproteinases (MMPs), and can contribute to decreased hepatic insulin sensitivity. KCs may play a role in the development of drug induced liver injury (DILI)", "Kupffer cells (KCs) play a role in the development of drug induced liver injury (DILI). Hepatic macrophages consist of Kupffer cells, which are originated from the fetal yolk-sack, and infiltrated bone marrow-derived monocytes/macrophages. "], "type": "summary", "id": "58cdb38f02b8c60953000041", "snippets": [{"offsetInBeginSection": 45, "offsetInEndSection": 132, "text": "Kupffer cells (KCs) play a role in the development of drug induced liver injury (DILI).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27717685", "endSection": "abstract"}, {"offsetInBeginSection": 159, "offsetInEndSection": 311, "text": "Hepatic macrophages consist of Kupffer cells, which are originated from the fetal yolk-sack, and infiltrated bone marrow-derived monocytes/macrophages. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908374", "endSection": "abstract"}, {"offsetInBeginSection": 920, "offsetInEndSection": 967, "text": "Kupffer cells (KCs) are the main source of MMP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26613891", "endSection": "abstract"}, {"offsetInBeginSection": 833, "offsetInEndSection": 949, "text": "liver, both Kupffer cells and recruited hepatic macrophages can contribute to decreased hepatic insulin sensitivity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26553134", "endSection": "abstract"}]}, {"body": "What is known about saponins in crops and human consumption?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20725585", "http://www.ncbi.nlm.nih.gov/pubmed/9839832", "http://www.ncbi.nlm.nih.gov/pubmed/11336236", "http://www.ncbi.nlm.nih.gov/pubmed/23533206", "http://www.ncbi.nlm.nih.gov/pubmed/8121473"], "ideal_answer": ["Saponins are considered antinutrients for humans and have a bitter taste. They should be removed from the crops before consumption."], "type": "summary", "id": "58cd729502b8c6095300003d", "snippets": [{"offsetInBeginSection": 335, "offsetInEndSection": 706, "text": "Saponins are readily soluble in water and are approved by the US FDA for inclusion in beverages intended for human consumption. The addition of saponins to existing water supplies offers a new form of intervention into the cycle of rotavirus infection. We believe that saponins will 'coat' the epithelium of the host's small intestine and prevent attachment of rotavirus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20725585", "endSection": "abstract"}, {"offsetInBeginSection": 451, "offsetInEndSection": 762, "text": "The levels of antinutrients in meal from the raw seeds were: trypsin inhibitor activity (14.6-28.7 mg trypsin inhibited/g), lectin (25.6-52.2 unit; one unit is the reverse of minimum amount of mg meal/ml assay which produced haemagglutination), saponins (1.9-2.3% as diosgenin equivalent) and phytate (8.4-10%).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9839832", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Quinoa cultivars currently grown in North America and Europe require removal of bitter-tasting saponins from the grain prior to human consumption.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11336236", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 685, "text": " Antinutrients, including phytate, glycoside, saponin and tannin, were screened and quantified. Phytate (112.82 \u00b1 0.1 mg/100 g), glycoside (2.33 \u00b1 0.00 mg/100 g), saponin (1.31 \u00b1 0.00 mg/100g) and tannin (0.21 \u00b1 0.00 mg/100 g) were present in the fruit but phlobatanin and glycosides with steroidal rings were not found.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533206", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 279, "text": "antinutritional factors (phytic acid, trypsin inhibitor activity (TIA) and saponins)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8121473", "endSection": "abstract"}]}, {"body": "Is golimumab effective for ulcerative colitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26786341", "http://www.ncbi.nlm.nih.gov/pubmed/27494322", "http://www.ncbi.nlm.nih.gov/pubmed/27723166", "http://www.ncbi.nlm.nih.gov/pubmed/27699641", "http://www.ncbi.nlm.nih.gov/pubmed/27695502", "http://www.ncbi.nlm.nih.gov/pubmed/25609972"], "ideal_answer": ["Yes. Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis."], "exact_answer": "yes", "type": "yesno", "id": "5896e4d478275d0c4a000015", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Initial experience with golimumab in clinical practice for ulcerative colitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786341", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "BACKGROUND: Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786341", "endSection": "abstract"}, {"offsetInBeginSection": 1200, "offsetInEndSection": 1341, "text": "CONCLUSIONS: In this short study, golimumab seems to be an alternative treatment in naive and non-naive anti-TNF ulcerative colitis patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786341", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27494322", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "OBJECTIVE: The objective of this study was to assess the cost-effectiveness of induction and maintenance treatment up to 1 year of ulcerative colitis with golimumab/standard care and standard care alone in Poland.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27494322", "endSection": "abstract"}, {"offsetInBeginSection": 1406, "offsetInEndSection": 1575, "text": "CONCLUSIONS: The biologic treatment of ulcerative colitis patients with golimumab/standard care is more effective but also more costly compared with standard care alone.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27494322", "endSection": "abstract"}, {"offsetInBeginSection": 246, "offsetInEndSection": 448, "text": "Currently, infliximab, adalimumab, and golimumab are available in the East Asian medical market, and these agents have been shown to be effective for inducing and maintaining long-term remission of IBD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723166", "endSection": "abstract"}, {"offsetInBeginSection": 356, "offsetInEndSection": 457, "text": "Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27699641", "endSection": "abstract"}, {"offsetInBeginSection": 1488, "offsetInEndSection": 1750, "text": "CONCLUSIONS: No significant differences in efficacy in the maintenance phase between infliximab and golimumab or adalimumab were revealed. Infliximab proved to be more effective than adalimumab but of similar efficacy to that of golimumab in the induction phase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695502", "endSection": "abstract"}, {"offsetInBeginSection": 603, "offsetInEndSection": 811, "text": "In this review, we will provide a detailed discussion of the three tumor necrosis factor-alpha (TNF-\u03b1) inhibitors currently approved for treatment of ulcerative colitis: infliximab, adalimumab, and golimumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25609972", "endSection": "abstract"}]}, {"body": "What is the role of histone variant H2A.W?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24995981", "http://www.ncbi.nlm.nih.gov/pubmed/25983206", "http://www.ncbi.nlm.nih.gov/pubmed/25781491"], "ideal_answer": ["The histone variant H2A.W defines heterochromatin and promotes chromatin condensation in Arabidopsis. The histone variant H2A.W marks heterochromatin specifically and acts in synergy with heterochromatic marks H3K9me2 and DNA methylation to maintain transposon silencing. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization. In vitro, H2A.W enhances chromatin condensation by promoting fiber-to-fiber interactions via its conserved C-terminal motif. In non-flowering land plants, we identify a new class of H2A variants and propose their possible role in the emergence of the H2A.W variant class in flowering plants. ", "The histone variant H2A.W defines heterochromatin and promotes chromatin condensation in Arabidopsis The histone variant H2A.W marks heterochromatin specifically and acts in synergy with heterochromatic marks H3K9me2 and DNA methylation to maintain transposon silencing In vitro, H2A.W enhances chromatin condensation by promoting fiber-to-fiber interactions via its conserved C-terminal motif. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization.  In non-flowering land plants, we identify a new class of H2A variants and propose their possible role in the emergence of the H2A.W variant class in flowering plants Covalent histone modifications (e.g.", "The histone variant H2A.W marks heterochromatin specifically and acts in synergy with heterochromatic marks H3K9me2 and DNA methylation to maintain transposon silencing. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization. Histone chaperones escort histones, and play key functions during nucleosome assembly/disassembly and in nucleosome structure configuration. Here we focus on plant histone H2A/H2B chaperones, particularly members of the NUCLEOSOME ASSEMBLY PROTEIN-1 (NAP1) and FACILITATES CHROMATIN TRANSCRIPTION (FACT) families, discussing their molecular features, properties, regulation and function. We further discuss roles of NAP1 and FACT in chromatin-based processes, such as transcription, DNA replication and repair. Future major challenges remain in order to define in more detail the overlapping and specific roles of various members of the NAP1 family as well as differences and similarities between NAP1 and FACT family members, and to identify and characterize their partners as well as new families of chaperones to understand histone variant incorporation and chromatin target specificity.", " In non-flowering land plants, we identify a new class of H2A variants and propose their possible role in the emergence of the H2A.W variant class in flowering plants In vitro, H2A.W enhances chromatin condensation by promoting fiber-to-fiber interactions via its conserved C-terminal motif. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization.", "The histone variant H2A.W defines heterochromatin and promotes chromatin condensation in Arabidopsis", "Histone variants play crucial roles in gene expression, genome integrity, and chromosome segregation. The histone variant H2A.W marks heterochromatin specifically and acts in synergy with heterochromatic marks H3K9me2 and DNA methylation to maintain transposon silencing. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization. Histone chaperones escort histones, and play key functions during nucleosome assembly/disassembly and in nucleosome structure configuration. Covalent histone modifications (e.g. ubiquitination, phosphorylation, methylation, acetylation) and H2A variants (H2A.Z, H2A.X and H2A.W) are also discussed in view of their crucial importance in modulating nucleosome organization and function.", "The histone variant H2A.W marks heterochromatin specifically and acts in synergy with heterochromatic marks H3K9me2 and DNA methylation to maintain transposon silencing. In vitro, H2A.W enhances chromatin condensation by promoting fiber-to-fiber interactions via its conserved C-terminal motif. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization."], "type": "summary", "id": "58ab1f209ef3c34033000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "The histone variant H2A.W defines heterochromatin and promotes chromatin condensation in Arabidopsis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24995981", "endSection": "title"}, {"offsetInBeginSection": 235, "offsetInEndSection": 403, "text": "The histone variant H2A.W marks heterochromatin specifically and acts in synergy with heterochromatic marks H3K9me2 and DNA methylation to maintain transposon silencing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24995981", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 669, "text": "In vitro, H2A.W enhances chromatin condensation by promoting fiber-to-fiber interactions via its conserved C-terminal motif. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24995981", "endSection": "abstract"}, {"offsetInBeginSection": 629, "offsetInEndSection": 795, "text": " In non-flowering land plants, we identify a new class of H2A variants and propose their possible role in the emergence of the H2A.W variant class in flowering plants", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25983206", "endSection": "abstract"}, {"offsetInBeginSection": 669, "offsetInEndSection": 913, "text": "Covalent histone modifications (e.g. ubiquitination, phosphorylation, methylation, acetylation) and H2A variants (H2A.Z, H2A.X and H2A.W) are also discussed in view of their crucial importance in modulating nucleosome organization and function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25781491", "endSection": "abstract"}]}, {"body": "Does mTOR regulate the translation of MAPKAPK2?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26280535"], "ideal_answer": ["Yes. mTOR regulates the translation of the MK2 (also known as MAPKAPK2) kinase through 4EBP1.  In turn, MAPKAPK2 phosphorylates the RNA-binding protein ZFP36L1 during senescence, inhibiting its ability to degrade the transcripts of numerous senescence-associated secretory phenotype (SASP) components. Consequently, mTOR inhibition or constitutive activation of ZFP36L1 impairs the non-cell-autonomous effects of senescent cells in both tumour-suppressive and tumour-promoting contexts."], "exact_answer": "yes", "type": "yesno", "id": "58967c9978275d0c4a000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280535", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1073, "text": "Senescent cells secrete a combination of factors collectively known as the senescence-associated secretory phenotype (SASP). The SASP reinforces senescence and activates an immune surveillance response, but it can also show pro-tumorigenic properties and contribute to age-related pathologies. In a drug screen to find new SASP regulators, we uncovered the mTOR inhibitor rapamycin as a potent SASP suppressor. Here we report a mechanism by which mTOR controls the SASP by differentially regulating the translation of the MK2 (also known as MAPKAPK2) kinase through 4EBP1. In turn, MAPKAPK2 phosphorylates the RNA-binding protein ZFP36L1 during senescence, inhibiting its ability to degrade the transcripts of numerous SASP components. Consequently, mTOR inhibition or constitutive activation of ZFP36L1 impairs the non-cell-autonomous effects of senescent cells in both tumour-suppressive and tumour-promoting contexts. Altogether, our results place regulation of the SASP as a key mechanism by which mTOR could influence cancer, age-related diseases and immune responses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280535", "endSection": "abstract"}]}, {"body": "Which bacteria cause diphtheria?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26607400", "http://www.ncbi.nlm.nih.gov/pubmed/25887321", "http://www.ncbi.nlm.nih.gov/pubmed/24106714", "http://www.ncbi.nlm.nih.gov/pubmed/22583953", "http://www.ncbi.nlm.nih.gov/pubmed/25578079"], "ideal_answer": ["Diphtheria is caused by the bacteria:\n1) Corynebacterium ulcerans and \n2) Corynebacterium diphtheriae."], "exact_answer": [["Corynebacterium ulcerans", "C. ulcerans"], ["Corynebacterium diphtheriae", "C. diphtheriae"]], "type": "list", "id": "58b548d722d3005309000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 256, "text": "Corynebacterium ulcerans is a zoonotic pathogen that can produce diphtheria toxin and causes an illness categorized as diphtheria in the European Union because its clinical appearance is similar to that of diphtheria caused by Corynebacterium diphtheriae. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607400", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 444, "text": "The zoonotic bacterium Corynebacterium ulcerans may be pathogenic both in humans and animals: toxigenic strains can cause diphtheria or diphtheria-like disease in humans via diphtheria toxin, while strains producing the dermonecrotic exotoxin phospholipase D may lead to caseous lymphadenitis primarily in wild animals. Diphtheria toxin-positive Corynebacterium ulcerans strains have been isolated mainly from cattle, dogs and cats.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25887321", "endSection": "abstract"}, {"offsetInBeginSection": 523, "offsetInEndSection": 619, "text": "Corynebacterium diphtheriae, a pathogenic bacterium that causes diphtheria, has been performed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106714", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Corynebacterium ulcerans 0102 carries the gene encoding diphtheria toxin on a prophage different from the C. diphtheriae NCTC 13129 prophage.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22583953", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 299, "text": "Corynebacterium ulcerans can cause a diphtheria-like illness, especially when the bacterium is lysogenized with a tox gene-carrying bacteriophage that produces diphtheria toxin. Acquisition of toxigenicity upon phage lysogenization is a common feature of C. ulcerans and C. diphtheriae. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22583953", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 235, "text": "Corynebacterium ulcerans (toxigenic C. ulcerans) produces the diphtheria toxin, which causes pharyngeal and cutaneous diphtheria-like disease in people, and this bacterium is commonly detected in dogs and cats that are reared at home. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25578079", "endSection": "abstract"}]}, {"body": "What chromosome is affected in Turner's syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26757887"], "ideal_answer": ["Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome", "Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome.", "Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome. ", "turner's syndrome (ts) is a chromosomal defect with partial or total absence of the x chromosome."], "exact_answer": [["X"]], "type": "factoid", "id": "58bca2f302b8c6095300000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26757887", "endSection": "abstract"}]}, {"body": "What is the aim of the TRAP assay?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26965413", "http://www.ncbi.nlm.nih.gov/pubmed/26683936", "http://www.ncbi.nlm.nih.gov/pubmed/25225832", "http://www.ncbi.nlm.nih.gov/pubmed/24528514", "http://www.ncbi.nlm.nih.gov/pubmed/23288413", "http://www.ncbi.nlm.nih.gov/pubmed/23913300", "http://www.ncbi.nlm.nih.gov/pubmed/23296661"], "ideal_answer": ["Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP)."], "exact_answer": [["Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP)."]], "type": "factoid", "id": "58cd7af402b8c6095300003e", "snippets": [{"offsetInBeginSection": 285, "offsetInEndSection": 452, "text": "Positive activity by the telomerase repeat amplification protocol (TRAP) was identified in cell extracts of Escherichia coli expressing a sequence-optimized hTERT gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26965413", "endSection": "abstract"}, {"offsetInBeginSection": 793, "offsetInEndSection": 1031, "text": "The regulatory role of PCDH10 in telomerase activity was confirmed by a telomeric repeat amplification protocol (TRAP) assay, and the biological functions of it were characterized by in vitro proliferation, migration, and invasion assays.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26683936", "endSection": "abstract"}, {"offsetInBeginSection": 847, "offsetInEndSection": 947, "text": "TRAP assay is a standard method for detecting telomerase activity in various tissues or cell lines. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25225832", "endSection": "abstract"}, {"offsetInBeginSection": 630, "offsetInEndSection": 679, "text": "Telomerase activity was determined by TRAP assay.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24528514", "endSection": "abstract"}, {"offsetInBeginSection": 805, "offsetInEndSection": 858, "text": "The telomerase activity was evaluated by TRAP assay. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288413", "endSection": "abstract"}, {"offsetInBeginSection": 470, "offsetInEndSection": 1178, "text": "The telomeric repeat amplification protocol (TRAP) represents an easy and rapid method for detection of telomerase activity in cells. A non-telomeric TS primer is extended by telomerase in the first step followed by the PCR amplification of the products. The PCR step renders this protocol very sensitive to detect telomerase activity at the single cell level making it compatible with the analysis of tumor samples. When run on a polyacrylamide gel, the PCR product is a characteristic ladder of bands due to the repetitive nature of telomeric DNA sequence. The densitometric analysis of the ladder allows the TRAP assay to be used for comparative quantification of telomerase activity in different samples.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23913300", "endSection": "abstract"}, {"offsetInBeginSection": 189, "offsetInEndSection": 371, "text": "Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23296661", "endSection": "abstract"}]}, {"body": "Describe clinical applications of the PIM2 scoring system.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26744626", "http://www.ncbi.nlm.nih.gov/pubmed/25996320", "http://www.ncbi.nlm.nih.gov/pubmed/24868211", "http://www.ncbi.nlm.nih.gov/pubmed/25396011", "http://www.ncbi.nlm.nih.gov/pubmed/23940977", "http://www.ncbi.nlm.nih.gov/pubmed/24051223", "http://www.ncbi.nlm.nih.gov/pubmed/24339640", "http://www.ncbi.nlm.nih.gov/pubmed/23429969"], "ideal_answer": ["The Pediatric Index of Mortality 2 (PIM2) is one of the most commonly used scoring systems to predict mortality in patients admitted to pediatric intensive care units. The PIM2 score adequately discriminates survivors from non-survivor"], "type": "summary", "id": "589a245678275d0c4a000023", "snippets": [{"offsetInBeginSection": 433, "offsetInEndSection": 731, "text": "In this study, we examine if transfusion is an independent predictor of mortality, or if outcomes are merely a result of the initial severity as predicted by Pediatric Risk of Mortality (PRISM) III, Pediatric Index of Mortality (PIM2), and day 1 Pediatric Logistic Organ Dysfunction (PELOD) scores.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26744626", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "INTRODUCTION: The Pediatric Index of Mortality 2 (PIM2) is one of the most commonly used scoring systems to predict mortality in patients admitted to pediatric intensive care units (PICU) in Argentina.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996320", "endSection": "abstract"}, {"offsetInBeginSection": 1451, "offsetInEndSection": 1533, "text": "CONCLUSIONS: The PIM2 score adequately discriminates survivors from non-survivors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996320", "endSection": "abstract"}, {"offsetInBeginSection": 1286, "offsetInEndSection": 1373, "text": "PIM2 scoring did not explain the outcome adequately, suggesting need for recalibration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24868211", "endSection": "abstract"}, {"offsetInBeginSection": 1214, "offsetInEndSection": 1436, "text": "CONCLUSION: PIM2 scoring system show adequate discriminatory function and well calibrated for the case mix of patients in PICU of Fayoum, Egypt. It can be used as beneficial tool for evaluation of risk adjusted mortality. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25396011", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "The aim of the study was to explore the association between Glasgow Coma Scale (GCS), Paediatric Index of Mortality (PIM2) and Injury Severity Score (ISS), and the long-term outcome of children with injuries.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23940977", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Pediatric index of mortality 2 score as an outcome predictor in pediatric Intensive Care Unit in India.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24339640", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "BACKGROUND AND AIMS: Pediatric index of mortality (PIM) 2 score is one of the severity scoring systems being used for predicting outcome of patients admitted to intensive care units (ICUs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24339640", "endSection": "abstract"}, {"offsetInBeginSection": 1356, "offsetInEndSection": 1434, "text": "CONCLUSION: PIM2 score discriminated well between survivors and death at PICU.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24339640", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "OBJECTIVE: A study to validate and calibrate Pediatric Index of Mortality-2 (PIM2) in children admitted to our pediatric intensive care unit (PICU).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23429969", "endSection": "abstract"}, {"offsetInBeginSection": 1205, "offsetInEndSection": 1304, "text": "CONCLUSION: PIM2 is a good index for prediction of mortality in our pediatric intensive care unit. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23429969", "endSection": "abstract"}]}, {"body": "Do histone variant mH2A (macro-H2A) levels decrease upon differentiation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23463008", "http://www.ncbi.nlm.nih.gov/pubmed/23077180", "http://www.ncbi.nlm.nih.gov/pubmed/22449192", "http://www.ncbi.nlm.nih.gov/pubmed/21552206"], "ideal_answer": ["MacroH2A.1 was found to be present at low levels upon the establishment of pluripotency in the inner cell mass and epiblast, but it was highly enriched in the trophectoderm and differentiated somatic cells later in mouse development. Chromatin immunoprecipitation revealed that macroH2A.1 is incorporated in the chromatin of regulatory regions of pluripotency genes in somatic cells such as mouse embryonic fibroblasts and adult neural stem cells, but not in embryonic stem cells. In addition, overexpression of macroH2A isoforms prevented efficient reprogramming of epiblast stem cells to na\u00efve pluripotency.", "1 was found to be present at low levels upon the establishment of pluripotency in the inner cell mass and epiblast, but it was highly enriched in the trophectoderm and differentiated somatic cells later in mouse development.", "Histone variant macroH2A confers resistance to nuclear reprogramming Histone variant macroH2A marks embryonic differentiation in vivo and acts as an epigenetic barrier to induced pluripotency.", "Resistance to reprogramming is associated with incorporation of the histone variant macroH2A, which is retained on the Xi of differentiated cells, but absent from the Xi of EpiSCs. The histone variant macroH2A acts as a component of an epigenetic multilayer that heritably maintains the silent X chromosome and has been shown to restrict tumor development.", "Through manipulation of macroH2A isoforms, we further demonstrate that macroH2A2 is the predominant barrier to reprogramming. In particular, we find macroH2A isoforms to be highly enriched at target genes of the K27me3 demethylase, Utx, which are reactivated early in iPS reprogramming", "MacroH2A.1 was found to be present at low levels upon the establishment of pluripotency in the inner cell mass and epiblast, but it was highly enriched in the trophectoderm and differentiated somatic cells later in mouse development. Histone variant macroH2A marks embryonic differentiation in vivo and acts as an epigenetic barrier to induced pluripotency."], "exact_answer": "no", "type": "yesno", "id": "58ab1f6c9ef3c34033000002", "snippets": [{"offsetInBeginSection": 268, "offsetInEndSection": 393, "text": "Through manipulation of macroH2A isoforms, we further demonstrate that macroH2A2 is the predominant barrier to reprogramming.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23463008", "endSection": "abstract"}, {"offsetInBeginSection": 532, "offsetInEndSection": 691, "text": "In particular, we find macroH2A isoforms to be highly enriched at target genes of the K27me3 demethylase, Utx, which are reactivated early in iPS reprogramming", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23463008", "endSection": "abstract"}, {"offsetInBeginSection": 880, "offsetInEndSection": 1121, "text": " Therefore, we propose that macroH2A isoforms provide a redundant silencing layer or terminal differentiation 'lock' at critical pluripotency genes that presents as an epigenetic barrier when differentiated cells are challenged to reprogram.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23463008", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Histone variant macroH2A confers resistance to nuclear reprogramming", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21552206", "endSection": "title"}, {"offsetInBeginSection": 871, "offsetInEndSection": 1051, "text": "Resistance to reprogramming is associated with incorporation of the histone variant macroH2A, which is retained on the Xi of differentiated cells, but absent from the Xi of EpiSCs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21552206", "endSection": "abstract"}, {"offsetInBeginSection": 580, "offsetInEndSection": 758, "text": "We highlight the role of macroH2A in the establishment and maintenance of differentiated states and we discuss its still poorly recognized function in transcriptional activation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22449192", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Histone variant macroH2A marks embryonic differentiation in vivo and acts as an epigenetic barrier to induced pluripotency.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23077180", "endSection": "title"}, {"offsetInBeginSection": 603, "offsetInEndSection": 836, "text": "MacroH2A.1 was found to be present at low levels upon the establishment of pluripotency in the inner cell mass and epiblast, but it was highly enriched in the trophectoderm and differentiated somatic cells later in mouse development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23077180", "endSection": "abstract"}, {"offsetInBeginSection": 837, "offsetInEndSection": 1083, "text": "Chromatin immunoprecipitation revealed that macroH2A.1 is incorporated in the chromatin of regulatory regions of pluripotency genes in somatic cells such as mouse embryonic fibroblasts and adult neural stem cells, but not in embryonic stem cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23077180", "endSection": "abstract"}, {"offsetInBeginSection": 1326, "offsetInEndSection": 1455, "text": "In addition, overexpression of macroH2A isoforms prevented efficient reprogramming of epiblast stem cells to na\u00efve pluripotency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23077180", "endSection": "abstract"}]}, {"body": "Which annotated database of A-to-I RNA editing is available?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24163250"], "ideal_answer": ["RADAR is a rigorously annotated database of A-to-I RNA editing. RADAR includes a comprehensive collection of A-to-I RNA editing sites identified in humans (Homo sapiens), mice (Mus musculus) and flies (Drosophila melanogaster), together with extensive manually curated annotations for each editing site. RADAR also includes an expandable listing of tissue-specific editing levels for each editing site, which will facilitate the assignment of biological functions to specific editing sites.", "The identification of A-to-I RNA editing sites has been dramatically accelerated in the past few years by high-throughput RNA sequencing studies. RADAR includes a comprehensive collection of A-to-I RNA editing sites identified in humans (Homo sapiens), mice (Mus musculus) and flies (Drosophila melanogaster), together with extensive manually curated annotations for each editing site."], "exact_answer": [["RADAR"]], "type": "factoid", "id": "587e1a01fc7e8dd84f000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "RADAR: a rigorously annotated database of A-to-I RNA editing", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163250", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "We present RADAR--a rigorously annotated database of A-to-I RNA editing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163250", "endSection": "abstract"}, {"offsetInBeginSection": 107, "offsetInEndSection": 678, "text": "The identification of A-to-I RNA editing sites has been dramatically accelerated in the past few years by high-throughput RNA sequencing studies. RADAR includes a comprehensive collection of A-to-I RNA editing sites identified in humans (Homo sapiens), mice (Mus musculus) and flies (Drosophila melanogaster), together with extensive manually curated annotations for each editing site. RADAR also includes an expandable listing of tissue-specific editing levels for each editing site, which will facilitate the assignment of biological functions to specific editing sites", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163250", "endSection": "abstract"}]}, {"body": "Could divalent metal transporter 1 deficiency lead to anemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27331785", "http://www.ncbi.nlm.nih.gov/pubmed/26047847", "http://www.ncbi.nlm.nih.gov/pubmed/25562168", "http://www.ncbi.nlm.nih.gov/pubmed/22580996"], "ideal_answer": ["Yes, divalent metal transporter 1 (DMT1) deficiency could result in anemia, as DMT1 is a major iron transporter required for iron absorption and erythropoiesis. DMT1 deficiency impairs erythroid differentiation and induces apoptosis of erythroid cells."], "exact_answer": "yes", "type": "yesno", "id": "58bd672d02b8c60953000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "The divalent metal transporter 1 (DMT1) is a major iron transporter required for iron absorption and erythropoiesis. Loss of DMT1 function results in microcytic anemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27331785", "endSection": "abstract"}, {"offsetInBeginSection": 621, "offsetInEndSection": 891, "text": "Dysfunction of human DMT1 is associated with several pathologies such as iron deficiency anemia hemochromatosis, Parkinson's disease and Alzheimer's disease, as well as colorectal cancer and esophageal adenocarcinoma, making DMT1 an attractive target for drug discovery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26047847", "endSection": "abstract"}, {"offsetInBeginSection": 17, "offsetInEndSection": 233, "text": "Deficiency of the divalent metal transporter 1 (DMT1) leads to hypochromic microcytic anemia. We have previously shown that DMT1 deficiency impairs erythroid differentiation and induces apoptosis of erythroid cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25562168", "endSection": "abstract"}, {"offsetInBeginSection": 1315, "offsetInEndSection": 1516, "text": "We propose that DMT1 deficiency negatively affects metabolism and life span of mature erythrocytes; two other aspects of defective erythropoiesis which contribute to the pathophysiology of the disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25562168", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 217, "text": "Hypochromic microcytic anemia associated with ineffective erythropoiesis caused by recessive mutations in divalent metal transporter 1 (DMT1) can be improved with high-dose erythropoietin supplementation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22580996", "endSection": "abstract"}]}, {"body": "Does the hERG gene code for a protein which is part of a sodium channel?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26775140", "http://www.ncbi.nlm.nih.gov/pubmed/26659724"], "ideal_answer": ["The hERG AKA Human ether-a-go-go-related gene coded for a protein subunit of a potassium channel that conducts delayed rectifier K(+) current"], "exact_answer": "no", "type": "yesno", "id": "58bdc76102b8c60953000013", "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 115, "text": " The human ether-\u00e0-go-go-related gene (hERG 1a) potassium channel is critical for cardiac repolarization", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775140", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Human ether-a-go-go-related gene (hERG) channels conduct delayed rectifier K(+) current. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26659724", "endSection": "abstract"}]}, {"body": "What is the function of calcium-sensing receptor (CaSR)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26386835", "http://www.ncbi.nlm.nih.gov/pubmed/26608608", "http://www.ncbi.nlm.nih.gov/pubmed/26261299", "http://www.ncbi.nlm.nih.gov/pubmed/23856267", "http://www.ncbi.nlm.nih.gov/pubmed/21566074"], "ideal_answer": ["The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis.\nThe CaSR is a key regulator for such diverse processes as hormone secretion, gene expression, inflammation, proliferation, differentiation, and apoptosis. Due to this pleiotropy, the CaSR is able to regulate cell fate and is implicated in the development of many types of benign or malignant tumours of the breast, prostate, parathyroid, and colon."], "exact_answer": [["The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis."]], "type": "factoid", "id": "58cd7fed02b8c6095300003f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26386835", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 261, "text": "The calcium-sensing receptor (CaSR) plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary calcium excretion. The CaSR is ubiquitously expressed, implying a wide range of functions regulated by this receptor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26608608", "endSection": "abstract"}, {"offsetInBeginSection": 689, "offsetInEndSection": 1037, "text": "The CaSR is a key regulator for such diverse processes as hormone secretion, gene expression, inflammation, proliferation, differentiation, and apoptosis. Due to this pleiotropy, the CaSR is able to regulate cell fate and is implicated in the development of many types of benign or malignant tumours of the breast, prostate, parathyroid, and colon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26608608", "endSection": "abstract"}, {"offsetInBeginSection": 168, "offsetInEndSection": 326, "text": "Extracellular calcium-sensing receptor (CaSR) and ovarian cancer gene receptor 1 (OGR1) are two GPCRs that sense extracellular Ca(2+) and H(+), respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26261299", "endSection": "abstract"}, {"offsetInBeginSection": 91, "offsetInEndSection": 179, "text": " The calcium-sensing receptor (CASR) plays a key role in maintaining calcium homeostasis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21566074", "endSection": "abstract"}]}, {"body": "Is lenvatinib effective for renal cell carcinoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27047959", "http://www.ncbi.nlm.nih.gov/pubmed/27267515", "http://www.ncbi.nlm.nih.gov/pubmed/27621699", "http://www.ncbi.nlm.nih.gov/pubmed/27690664", "http://www.ncbi.nlm.nih.gov/pubmed/26482279"], "ideal_answer": ["Yes, combination of lenvatinib and everolimus is approved to treat advanced or metastatic renal cell carcinoma."], "exact_answer": "yes", "type": "yesno", "id": "589a245778275d0c4a000024", "snippets": [{"offsetInBeginSection": 221, "offsetInEndSection": 406, "text": "However, the combination of lenvatinib, a multitargeted agent that inhibits VEGF as well as FGF receptors, and everolimus demonstrated promising results in a randomized phase II trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27047959", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "The FDA has approved the combination of lenvatinib and everolimus to treat advanced or metastatic renal cell carcinoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267515", "endSection": "abstract"}, {"offsetInBeginSection": 1386, "offsetInEndSection": 1642, "text": "Moreover, a recent Phase II study demonstrated a significant benefit for the second-line combination treatment with everolimus plus lenvatinib (a novel TKI) in terms of progression-free survival and overall survival compared to the single-agent everolimus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27621699", "endSection": "abstract"}, {"offsetInBeginSection": 769, "offsetInEndSection": 1030, "text": "We then discuss two recently approved growth factor receptor antagonists i.e. cabozantinib and lenvatinib, and a recently approved checkpoint inhibitor, nivolumab, and issues pertaining to drug development, and future directions in treatment of metastatic RCC. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690664", "endSection": "abstract"}, {"offsetInBeginSection": 2654, "offsetInEndSection": 2878, "text": "INTERPRETATION: Lenvatinib plus everolimus and lenvatinib alone resulted in a progression-free survival benefit for patients with metastatic renal cell carcinoma who have progressed after one previous VEGF-targeted therapy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26482279", "endSection": "abstract"}]}, {"body": "Which proteins form part of the NRD complex in S. cerevisiae?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25877920", "http://www.ncbi.nlm.nih.gov/pubmed/21211720", "http://www.ncbi.nlm.nih.gov/pubmed/10545197", "http://www.ncbi.nlm.nih.gov/pubmed/9804427"], "ideal_answer": ["The purification of an ATR complex allowed identification of chromodomain-helicase-DNA-binding protein 4 (CHD4) as an ATR-associated protein by tandem mass spectrometric sequencing. CHD4 (also called Mi-2beta) is a component of a histone-deacetylase-2 (HDAC2)-containing complex, the nucleosome remodeling and deacetylating (NRD) complex. Endogenous ATR, CHD4, and HDAC2 are shown to coimmunoprecipitate, and ATR and HDAC2 coelute through two biochemical purification steps. Other members of the NRD complex, HDAC1, MTA1, and MTA2, are also detectable in ATR immunoprecipitates. Sen1 of S. cerevisiae is a known component of the NRD complex implicated in transcription termination of nonpolyadenylated as well as some polyadenylated RNA polymerase II transcripts.  We now show that Pcf11, a component of the cleavage and polyadenylation complex (CPAC), is also generally required for NRD-dependent transcription termination through the action of its C-terminal domain (CTD)-interacting domain (CID)."], "exact_answer": [["Chd2"], ["Chd4"], ["Hdac2"], ["Mta1"], ["Mta2"], ["Sen1"], ["Pcf11"]], "type": "list", "id": "58adb9919ef3c34033000004", "snippets": [{"offsetInBeginSection": 1007, "offsetInEndSection": 1314, "text": "This activity is derived from the CHD3 and CHD4 proteins which contain helicase/ATPase domains found in SWI2-related chromatin remodelling factors, and facilitates the deacetylation of oligonucleosomal histones in vitro. We refer to this complex as the nucleosome remodelling and deacetylating (NRD) complex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9804427", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Molecular association between ATR and two components of the nucleosome remodeling and deacetylating complex, HDAC2 and CHD4", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10545197", "endSection": "title"}, {"offsetInBeginSection": 265, "offsetInEndSection": 602, "text": "The purification of an ATR complex allowed identification of chromodomain-helicase-DNA-binding protein 4 (CHD4) as an ATR-associated protein by tandem mass spectrometric sequencing. CHD4 (also called Mi-2beta) is a component of a histone-deacetylase-2 (HDAC2)-containing complex, the nucleosome remodeling and deacetylating (NRD) complex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10545197", "endSection": "abstract"}, {"offsetInBeginSection": 604, "offsetInEndSection": 843, "text": "Endogenous ATR, CHD4, and HDAC2 are shown to coimmunoprecipitate, and ATR and HDAC2 coelute through two biochemical purification steps. Other members of the NRD complex, HDAC1, MTA1, and MTA2, are also detectable in ATR immunoprecipitates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10545197", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Sen1 of S. cerevisiae is a known component of the NRD complex implicated in transcription termination of nonpolyadenylated as well as some polyadenylated RNA polymerase II transcripts. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211720", "endSection": "abstract"}, {"offsetInBeginSection": 167, "offsetInEndSection": 401, "text": "We now show that Pcf11, a component of the cleavage and polyadenylation complex (CPAC), is also generally required for NRD-dependent transcription termination through the action of its C-terminal domain (CTD)-interacting domain (CID).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25877920", "endSection": "abstract"}]}, {"body": "Which R / bioconductor package is used for performing SNP enrichment analysis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26685307"], "ideal_answer": ["traseR is an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs in LD."], "exact_answer": [["traseR"]], "type": "factoid", "id": "587e3129c32c812009000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26685307", "endSection": "title"}, {"offsetInBeginSection": 668, "offsetInEndSection": 916, "text": "Here, we present traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs in LD", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26685307", "endSection": "abstract"}]}, {"body": "Which disease is associated with mutations in SLC40A1 gene?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25744502", "http://www.ncbi.nlm.nih.gov/pubmed/26059880", "http://www.ncbi.nlm.nih.gov/pubmed/24644245", "http://www.ncbi.nlm.nih.gov/pubmed/23943237", "http://www.ncbi.nlm.nih.gov/pubmed/24714983", "http://www.ncbi.nlm.nih.gov/pubmed/21411349", "http://www.ncbi.nlm.nih.gov/pubmed/21175851", "http://www.ncbi.nlm.nih.gov/pubmed/21199650", "http://www.ncbi.nlm.nih.gov/pubmed/19937651", "http://www.ncbi.nlm.nih.gov/pubmed/20691492"], "ideal_answer": ["Mutations in the SLC40A1 gene, which encodes the cellular iron exporter ferroportin, are associated with the autosomal dominant hemochromatosis type 4 or Ferroportin disease. The patients characteristically have hyperferritinemia and iron overload."], "type": "summary", "id": "58bd6c5802b8c60953000012", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "Ferroportin disease is a rare type of autosomal dominantly inherited hemochromatosis caused with mutations in the ferroportin gene (SLC40A1). The patients characteristically have hyperferritinemia but normal transferin saturations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25744502", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Novel gain of function mutation in the SLC40A1 gene associated with hereditary haemochromatosis type 4.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26059880", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 294, "text": "Here we report the case of a 69-year-old Chinese Han woman who presented with liver cirrhosis, diabetes mellitus, skin hyperpigmentation, hyperferritinaemia and high transferrin saturation. Subsequent genetic analyses identified a novel heterozygous mutation (p.Cys326Phe) in the SLC40A1 gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26059880", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "A novel mutation in the SLC40A1 gene associated with reduced iron export in vitro.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24644245", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 302, "text": "Ferroportin disease is an inherited disorder of iron metabolism and is caused by mutations in the ferroportin gene (SLC40A1). We present a patient with hyperferritinemia, iron overload in the liver with reticuloendothelial distribution and also in the spleen, and under treatment with erythropheresis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24644245", "endSection": "abstract"}, {"offsetInBeginSection": 825, "offsetInEndSection": 1037, "text": "These findings and the iron overload phenotype of the patient suggest that the novel mutation c.386T>C (p.L129P) in the SLC40A1 gene has incomplete penetrance and causes the classical form of ferroportin disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24644245", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 353, "text": "Ferroportin (FPN) mediates iron export from cells and this function is modulated by serum hepcidin. Mutations in the FPN gene (SLC40A1) lead to autosomal dominant iron overload diseases related either to loss or to gain of function, and usually characterized by normal or low transferrin saturation versus elevated transferrin saturation, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23943237", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 501, "text": "Hemochromatosis type 4 is a rare form of primary iron overload transmitted as an autosomal dominant trait caused by mutations in the gene encoding the iron transport protein ferroportin 1 (SLC40A1). SLC40A1 mutations fall into two functional categories (loss- versus gain-of-function) underlying two distinct clinical entities (hemochromatosis type 4A versus type 4B). However, the vast majority of SLC40A1 mutations are rare missense variations, with only a few showing strong evidence of causality. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24714983", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 274, "text": "p.C282Y mutation and rare variants in the HFE gene have been associated with hereditary hemochromatosis (HH). HH is also caused by mutations in other genes, such as the hemojuvelin (HJV), hepcidin (HAMP), transferrin receptor 2 (TFR2) and ferroportin (SLC40A1). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21411349", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Two novel mutations in the SLC40A1 and HFE genes implicated in iron overload in a Spanish man.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21175851", "endSection": "title"}, {"offsetInBeginSection": 19, "offsetInEndSection": 239, "text": "Ferroportin disease is characterized by iron overload. It has an autosomal-dominant pattern of inheritance and has been associated with mutations in the SLC40A1 gene, which encodes the cellular iron exporter ferroportin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21199650", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 335, "text": "Mutations in the SLC40A1 gene, which encodes ferroportin, are associated with autosomal dominant hemochromatosis. Ferroportin is inhibited directly by hepcidin, a key iron-regulatory peptide, and functional consequences of SLC40A1 mutations account for observed phenotypic differences in patients with ferroportin disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19937651", "endSection": "abstract"}, {"offsetInBeginSection": 489, "offsetInEndSection": 618, "text": "The entire coding sequence of the SLC40A1 gene was sequenced in a pedigree, presenting with autosomal dominant hyperferritinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19937651", "endSection": "abstract"}, {"offsetInBeginSection": 940, "offsetInEndSection": 1097, "text": "A novel SLC40A1 mutation p.R489K segregated with iron overload in a family with clinical and histopathological signs of macrophage-type ferroportin disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19937651", "endSection": "abstract"}, {"offsetInBeginSection": 1405, "offsetInEndSection": 1881, "text": "We report a novel pathological SLC40A1 variant associated with abnormal cell surface expression of ferroportin due to intracellular retention of the mutant protein. These findings predict macrophage-type ferroportin disease, the phenotype observed in this kindred. Study of the molecular cell biology of ferroportin and its mutants is key to understanding the pathogenesis of this increasingly recognized form of hemochromatosis, which responds poorly to conventional therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19937651", "endSection": "abstract"}, {"offsetInBeginSection": 19, "offsetInEndSection": 386, "text": "Classical ferroportin disease is characterized by hyperferritinemia, normal transferrin saturation, and iron overload in macrophages. A non-classical form is characterized by additional hepatocellular iron deposits and a high transferrin saturation. Both forms demonstrate autosomal dominant transmission and are associated with ferroportin gene (SLC40A1) mutations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20691492", "endSection": "abstract"}]}, {"body": "Does Yersinia pestis causes a respiratory infection?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25691593"], "ideal_answer": ["Inhalation of Yersinia pestis results in primary pneumonic plague."], "exact_answer": "yes", "type": "yesno", "id": "58caf86f02b8c60953000030", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 140, "text": "Inhalation of Yersinia pestis results in primary pneumonic plague, a highly lethal and rapidly progressing necrotizing pneumonia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25691593", "endSection": "abstract"}]}, {"body": "Does HuR bind to the untranslated regions (UTRs) of mRNAs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27941336", "http://www.ncbi.nlm.nih.gov/pubmed/25841336", "http://www.ncbi.nlm.nih.gov/pubmed/25265983", "http://www.ncbi.nlm.nih.gov/pubmed/24687854", "http://www.ncbi.nlm.nih.gov/pubmed/23312841", "http://www.ncbi.nlm.nih.gov/pubmed/23389914"], "ideal_answer": ["Yes, the RNA-binding protein HuR binds at 3' untranslated regions (UTRs) of target transcripts, thereby protecting them against degradation."], "exact_answer": "yes", "type": "yesno", "id": "58ce69cd1f5fb2b734000003", "snippets": [{"offsetInBeginSection": 115, "offsetInEndSection": 347, "text": "HuR is also overexpressed during tumourigenesis and is abnormally present within the cytoplasm, where it binds to AU-rich elements in the 3'UTRs of target mRNA and post-transcriptionally regulates the expression of its target genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27941336", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 220, "text": "Human antigen R (HuR) is a ubiquitous 32 kDa protein comprising three RNA Recognition Motifs (RRMs), whose main function is to bind Adenylate and uridylate Rich Elements (AREs) in 3' UnTranslated Regions (UTRs) of mRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25841336", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 147, "text": "Human antigen R (HuR) is a ubiquitously expressed RNA-binding protein that modulates gene expression at the post-transcriptional level.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25265983", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "The RNA-binding protein HuR binds at 3' untranslated regions (UTRs) of target transcripts, thereby protecting them against degradation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24687854", "endSection": "abstract"}, {"offsetInBeginSection": 619, "offsetInEndSection": 812, "text": "ELAV/Hu proteins bind to AU-rich elements (ARE) in mRNAs and regulate their stability from splicing to translation, and the ubiquitous HuR protein has been implicated in cancerous cell growth. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23312841", "endSection": "abstract"}, {"offsetInBeginSection": 240, "offsetInEndSection": 381, "text": "This is achieved by altered expression of the proteins TTP and HuR, which bind 3' untranslated region (UTR) elements in cancer-related genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23389914", "endSection": "abstract"}]}, {"body": "List drug that were evaluated in the CHAMP trial for migraine.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27039826", "http://www.ncbi.nlm.nih.gov/pubmed/23594025"], "ideal_answer": ["Childhood and Adolescent Migraine Prevention (CHAMP) trial evaluated effectiveness of amitriptyline and topiramate in the prevention of migraine in children and adolescents."], "exact_answer": [["amitriptyline"], ["topiramate"]], "type": "list", "id": "589a245a78275d0c4a000026", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 284, "text": "OBJECTIVE: To describe baseline headache characteristics of children and adolescents participating in a multicenter, randomized, double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo for the prevention of migraine (CHAMP Study).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27039826", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "title"}, {"offsetInBeginSection": 651, "offsetInEndSection": 998, "text": "METHODS: CHAMP is a double-blinded, placebo-controlled, multicenter, comparative effectiveness study of amitriptyline and topiramate for the prevention of episodic and chronic migraine, designed to mirror real-world practice, sponsored by the US National Institute of Neurological Disorders and Stroke/National Institutes of Health (U01NS076788). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "abstract"}, {"offsetInBeginSection": 1292, "offsetInEndSection": 1524, "text": "The subjects will be randomized in a 2:2:1 (amitriptyline: topiramate: placebo) ratio. Doses are weight based and will be slowly titrated over an 8-week period to a target dose of 1\u2009mg/kg of amitriptyline and 2\u2009mg/kg of topiramate. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "abstract"}, {"offsetInBeginSection": 1667, "offsetInEndSection": 1850, "text": "CONCLUSIONS: The goal of the CHAMP study is to obtain level 1 evidence for the effectiveness of amitriptyline and topiramate in the prevention of migraine in children and adolescents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "abstract"}]}, {"body": "Is H4K20 methylation associated with DNA replication?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26598646", "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "http://www.ncbi.nlm.nih.gov/pubmed/27268234", "http://www.ncbi.nlm.nih.gov/pubmed/23345616", "http://www.ncbi.nlm.nih.gov/pubmed/23924899", "http://www.ncbi.nlm.nih.gov/pubmed/23152447", "http://www.ncbi.nlm.nih.gov/pubmed/20735237"], "ideal_answer": ["We employed genetic, cytological, and genomic approaches to better understand the role of PR-Set7 and H4K20 methylation in regulating DNA replication and genome stability in Drosophila cells. Thus, coordinating the status of H4K20 methylation is pivotal for the proper selection of DNA replication origins in higher eukaryotes. The methylation state of lysine 20 on histone H4 (H4K20) has been linked to chromatin compaction, transcription, DNA repair and DNA replication. Histone turnover is often associated with various histone modifications such as H3K56 acetylation (H3K56Ac), H3K36 methylation (H3K36me), and H4K20 methylation (H4K20me). We review the signaling pathways and functions associated with a single residue, H4K20, as a model chromatin and clinically important mark that regulates biological processes ranging from the DNA damage response and DNA replication to gene expression and silencing. <CopyrightInformation>\u00a9 2016 by The American Society for Biochemistry and Molecular Biology, Inc.</C In particular, the methylation states of H3K4, H3K36 and H4K20 have been associated with establishing active, repressed or poised origins depending on the timing and extent of methylation. 5BrC and 5ClC may cause aberrant methylation of cytosine during DNA replication and mimic the endogenous methylation signal associated with gene silencing.", "H4K20 methylation regulates quiescence and chromatin compaction. H4K20 methylation status plays a direct role in recruiting ORC through the binding properties of ORC1 and ORCA/LRWD1. Thus, coordinating the status of H4K20 methylation is pivotal for the proper selection of DNA replication origins in higher eukaryotes.  Intense research during the past few years has revealed histone H4 lysine 20 methylation (H4K20me) as critically important for the biological processes that ensure genome integrity, such as DNA damage repair, DNA replication and chromatin compaction.", "The methylation state of lysine 20 on histone H4 (H4K20) has been linked to chromatin compaction, transcription, DNA repair and DNA replication. Disruption of these H4K20-specific histone methyltransferases leads to genomic instability, demonstrating the important functions of H4K20 methylation in genome maintenance.", "Thus, coordinating the status of H4K20 methylation is pivotal for the proper selection of DNA replication origins in higher eukaryotes. The methylation state of lysine 20 on histone H4 (H4K20) has been linked to chromatin compaction, transcription, DNA repair and DNA replication."], "exact_answer": "yes", "type": "yesno", "id": "58adbe999ef3c34033000005", "snippets": [{"offsetInBeginSection": 923, "offsetInEndSection": 1178, "text": "It seems likely that continued study of the methylation of H4K20 will yield extremely valuable insights concerning the regulation of histone modifications before and during cell division and the impact of these modifications on subsequent gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735237", "endSection": "abstract"}, {"offsetInBeginSection": 505, "offsetInEndSection": 629, "text": "Aberrant rereplication correlates with decreased levels of H4K20me1 and increased levels of H4K20 trimethylation (H4K20me3).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152447", "endSection": "abstract"}, {"offsetInBeginSection": 980, "offsetInEndSection": 1255, "text": "Consistent with this, H4K20 methylation status plays a direct role in recruiting ORC through the binding properties of ORC1 and ORCA/LRWD1. Thus, coordinating the status of H4K20 methylation is pivotal for the proper selection of DNA replication origins in higher eukaryotes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152447", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "H4K20 methylation regulates quiescence and chromatin compaction.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23924899", "endSection": "title"}, {"offsetInBeginSection": 371, "offsetInEndSection": 580, "text": "Mass spectrometry analysis of histone modifications reveals that H4K20me2 and H4K20me3 increase in quiescence and other histone modifications are present at similar levels in proliferating and quiescent cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23924899", "endSection": "abstract"}, {"offsetInBeginSection": 581, "offsetInEndSection": 726, "text": "Analysis of cells in S, G2/M, and G1 phases shows that H4K20me1 increases after S phase and is converted to H4K20me2 and H4K20me3 in quiescence. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23924899", "endSection": "abstract"}, {"offsetInBeginSection": 898, "offsetInEndSection": 1249, "text": "Overexpression of Suv4-20h1, the enzyme that creates H4K20me2 from H4K20me1, results in G2 arrest, consistent with a role for H4K20me1 in mitosis. The results suggest that the same lysine on H4K20 may, in its different methylation states, facilitate mitotic functions in M phase and promote chromatin compaction and cell cycle exit in quiescent cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23924899", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23345616", "endSection": "title"}, {"offsetInBeginSection": 360, "offsetInEndSection": 611, "text": " Intense research during the past few years has revealed histone H4 lysine 20 methylation (H4K20me) as critically important for the biological processes that ensure genome integrity, such as DNA damage repair, DNA replication and chromatin compaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23345616", "endSection": "abstract"}, {"offsetInBeginSection": 820, "offsetInEndSection": 994, "text": "Disruption of these H4K20-specific histone methyltransferases leads to genomic instability, demonstrating the important functions of H4K20 methylation in genome maintenance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23345616", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Both H4K20 mono-methylation and H3K56 acetylation mark transcription-dependent histone turnover in fission yeast.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27268234", "endSection": "title"}, {"offsetInBeginSection": 121, "offsetInEndSection": 291, "text": "Histone turnover is often associated with various histone modifications such as H3K56 acetylation (H3K56Ac), H3K36 methylation (H3K36me), and H4K20 methylation (H4K20me).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27268234", "endSection": "abstract"}, {"offsetInBeginSection": 974, "offsetInEndSection": 1121, "text": "These results together indicate that H4K20me1 as well as H3K56Ac are bona fide marks for transcription-dependent histone turnover in fission yeast.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27268234", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Methylation of histone H4 lysine 20 by PR-Set7 ensures the integrity of late replicating sequence domains in Drosophila.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "endSection": "title"}, {"offsetInBeginSection": 453, "offsetInEndSection": 636, "text": "However, these studies were limited to only a handful of mammalian origins, and it remains unclear how PR-Set7 and H4K20 methylation impact the replication program on a genomic scale.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "The methylation state of lysine 20 on histone H4 (H4K20) has been linked to chromatin compaction, transcription, DNA repair and DNA replication. Monomethylation of H4K20 (H4K20me1) is mediated by the cell cycle-regulated histone methyltransferase PR-Set7", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "endSection": "abstract"}, {"offsetInBeginSection": 828, "offsetInEndSection": 1066, "text": " We find that deregulation of H4K20 methylation had no impact on origin activation throughout the genome. Instead, depletion of PR-Set7 and loss of H4K20me1 results in the accumulation of DNA damage and an ATR-dependent cell cycle arrest.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "endSection": "abstract"}, {"offsetInBeginSection": 610, "offsetInEndSection": 875, "text": "We review the signaling pathways and functions associated with a single residue, H4K20, as a model chromatin and clinically important mark that regulates biological processes ranging from the DNA damage response and DNA replication to gene expression and silencing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598646", "endSection": "abstract"}]}, {"body": "What is LedPred?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26628586"], "ideal_answer": ["LedPred is an R/bioconductor package to predict regulatory sequences using support vector machines. LedPred is provided as an R/Bioconductor package connected to an online server to avoid installation of non-R software. Due to the heterogeneous CRM feature integration, LedPred excels at the prediction of regulatory sequences in Drosophila and mouse datasets compared with similar SVM-based software."], "type": "summary", "id": "587e392d2420191125000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "LedPred: an R/bioconductor package to predict regulatory sequences using support vector machines", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26628586", "endSection": "title"}, {"offsetInBeginSection": 316, "offsetInEndSection": 803, "text": "Here, we present LedPred, a flexible SVM workflow that predicts new regulatory sequences based on the annotation of known CRMs, which are associated to a large variety of feature types. LedPred is provided as an R/Bioconductor package connected to an online server to avoid installation of non-R software. Due to the heterogeneous CRM feature integration, LedPred excels at the prediction of regulatory sequences in Drosophila and mouse datasets compared with similar SVM-based software.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26628586", "endSection": "abstract"}]}, {"body": "What is the connection between furin and hepcidin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24808863", "http://www.ncbi.nlm.nih.gov/pubmed/23390091", "http://www.ncbi.nlm.nih.gov/pubmed/19610021", "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "http://www.ncbi.nlm.nih.gov/pubmed/17905609"], "ideal_answer": ["The iron-regulatory peptide hepcidin is synthesized in the liver as an 84-aa pre-pro-hormone maturated by proteolysis through a consensus furin cleavage site to generate the bioactive 25-aa peptide secreted in the circulation. The hepatic prohormone convertase furin mediates the posttranslational processing of hepcidin."], "type": "summary", "id": "58bebc4c02b8c60953000015", "snippets": [{"offsetInBeginSection": 101, "offsetInEndSection": 213, "text": "Hepcidin is mainly produced by the liver as a propeptide and processed by furin into the mature active peptide. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24808863", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Implication of the proprotein convertases in iron homeostasis: proprotein convertase 7 sheds human transferrin receptor 1 and furin activates hepcidin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23390091", "endSection": "title"}, {"offsetInBeginSection": 1074, "offsetInEndSection": 1276, "text": "Analysis of primary hepatocytes from mice lacking furin, PC5, PACE4, or PC7 revealed that hepcidin, which limits iron availability in the circulation, is specifically generated by furin and not by PC7. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23390091", "endSection": "abstract"}, {"offsetInBeginSection": 1433, "offsetInEndSection": 1604, "text": "Among the PC family members, only furin activates hepcidin in hepatocytes, and uniquely the full-length membrane-bound PC7 can directly shed hTfR1 by cleavage at Arg100 \u2193.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23390091", "endSection": "abstract"}, {"offsetInBeginSection": 595, "offsetInEndSection": 815, "text": "The human hepcidin gene contains three exons that encode a 72-aa precursor (pro-hepcidin) with a characteristic furin cleavage site immediately N-terminal to the 25-aa major hepcidin species found in plasma and urine [3]", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19610021", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "title"}, {"offsetInBeginSection": 17, "offsetInEndSection": 392, "text": "The iron-regulatory peptide hepcidin is synthesized in the liver as an 84-aa pre-pro-hormone maturated by proteolysis through a consensus furin cleavage site to generate the bioactive 25-aa peptide secreted in the circulation. This peptide regulates iron export from enterocytes and macrophages by binding the membrane iron exporter, ferroportin, leading to its degradation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 1293, "offsetInEndSection": 1451, "text": "Our results demonstrate that pro-hepcidin lacks biological activity, unless fully maturated by a furin-dependent process to yield the bioactive 25-aa peptide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17905609", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 327, "text": "Hepcidin is encoded as an 84 amino acid prepropeptide containing a typical N-terminal 24 amino acid endoplasmic reticulum targeting signal sequence, and a 35 amino acid proregion (pro) with a consensus furin cleavage site immediately followed by the C-terminal 25 amino acid bioactive iron-regulatory hormone (mature peptide). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17905609", "endSection": "abstract"}, {"offsetInBeginSection": 1129, "offsetInEndSection": 1238, "text": "In conclusion, the hepatic prohormone convertase furin mediates the posttranslational processing of hepcidin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17905609", "endSection": "abstract"}]}, {"body": "What is Beh\u00e7et's disease", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27914129"], "ideal_answer": ["Behet's disease (BD) is a complex chronic relapsing inflammatory disorder of unknown etiology.", "Beh\u00e7et's disease (BD) is a complex chronic relapsing inflammatory disorder of unknown etiology.", "Beh\u00e7et's disease (BD) is a complex chronic relapsing inflammatory disorder of unknown etiology. ", "beh\u00e7et's disease (bd) is a complex chronic relapsing inflammatory disorder of unknown etiology."], "type": "summary", "id": "58cb305c02b8c60953000032", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Beh\u00e7et's disease (BD) is a complex chronic relapsing inflammatory disorder of unknown etiology. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914129", "endSection": "abstract"}]}, {"body": "What is the role of IL-18BP?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26782741", "http://www.ncbi.nlm.nih.gov/pubmed/26850179", "http://www.ncbi.nlm.nih.gov/pubmed/26898120", "http://www.ncbi.nlm.nih.gov/pubmed/25182570", "http://www.ncbi.nlm.nih.gov/pubmed/27914933", "http://www.ncbi.nlm.nih.gov/pubmed/25548255", "http://www.ncbi.nlm.nih.gov/pubmed/25807634", "http://www.ncbi.nlm.nih.gov/pubmed/25692120"], "ideal_answer": ["IL-18 binding protein (IL-18BP) is a natural inhibitor of IL-18. The balance between IL-18 and IL-18BP has an important role in the inflammatory setting."], "exact_answer": [["IL-18 binding protein (IL-18BP) is a natural inhibitor of IL-18. The balance between IL-18 and IL-18BP has an important role in the inflammatory setting."]], "type": "factoid", "id": "58cd90c202b8c60953000040", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Interleukin 18--binding protein ameliorates liver ischemia--reperfusion injury.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850179", "endSection": "title"}, {"offsetInBeginSection": 1549, "offsetInEndSection": 1719, "text": " IL-18BP exhibited anti-inflammatory, antioxidant, and protective effects in I/R-mediated hepatic injury via regulating some liver enzyme activities and cytokine levels. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850179", "endSection": "abstract"}, {"offsetInBeginSection": 308, "offsetInEndSection": 1012, "text": "Because of IL-18's potential pro-inflammatory and tissue destructive effects, its biological activities are tightly controlled in the body by its naturally occurring antagonist called IL-18BP. The antagonist is produced in the body both constitutively and in response to an increased production of IL-18 as a negative feedback mechanism. Under physiological conditions, most of IL-18 in the circulation is bound with IL-18BP and is inactive. However, an imbalance in the production of IL-18 and its antagonist (an increase in the production of IL-18 with a decrease, no increase or an insufficient increase in the production of IL-18BP) has been described in many chronic inflammatory diseases in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26898120", "endSection": "abstract"}, {"offsetInBeginSection": 377, "offsetInEndSection": 441, "text": "L-18 binding protein (IL-18BP) is a natural inhibitor of IL-18. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182570", "endSection": "abstract"}, {"offsetInBeginSection": 681, "offsetInEndSection": 761, "text": "Platelets also contain the IL-18 antagonist, the IL-18-Binding Protein (IL-18BP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914933", "endSection": "abstract"}, {"offsetInBeginSection": 614, "offsetInEndSection": 762, "text": "The natural inhibitor IL-18BP , whose production is enhanced by IFN-\u03b3 and IL-27, further regulates IL-18 activity in the extracellular environment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25548255", "endSection": "abstract"}, {"offsetInBeginSection": 147, "offsetInEndSection": 224, "text": "IL-18 binding protein (IL-18BP) is a naturally occurring inhibitor of IL-18. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25807634", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 374, "text": "IL-18 binding protein (IL-18BP) is a natural inhibitor of IL-18. The balance between IL-18 and IL-18BP has an important role in the inflammatory setting.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25692120", "endSection": "abstract"}]}, {"body": "Describe crowned dens syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25910825", "http://www.ncbi.nlm.nih.gov/pubmed/26008686", "http://www.ncbi.nlm.nih.gov/pubmed/26370870", "http://www.ncbi.nlm.nih.gov/pubmed/25196626", "http://www.ncbi.nlm.nih.gov/pubmed/24926265", "http://www.ncbi.nlm.nih.gov/pubmed/23932725", "http://www.ncbi.nlm.nih.gov/pubmed/24703344", "http://www.ncbi.nlm.nih.gov/pubmed/24715874", "http://www.ncbi.nlm.nih.gov/pubmed/24891867", "http://www.ncbi.nlm.nih.gov/pubmed/25243939", "http://www.ncbi.nlm.nih.gov/pubmed/23392827", "http://www.ncbi.nlm.nih.gov/pubmed/23806762", "http://www.ncbi.nlm.nih.gov/pubmed/23569451", "http://www.ncbi.nlm.nih.gov/pubmed/22303531", "http://www.ncbi.nlm.nih.gov/pubmed/19834710", "http://www.ncbi.nlm.nih.gov/pubmed/22470810", "http://www.ncbi.nlm.nih.gov/pubmed/21799227", "http://www.ncbi.nlm.nih.gov/pubmed/19727898", "http://www.ncbi.nlm.nih.gov/pubmed/20051747", "http://www.ncbi.nlm.nih.gov/pubmed/19783114", "http://www.ncbi.nlm.nih.gov/pubmed/20960401", "http://www.ncbi.nlm.nih.gov/pubmed/20646716", "http://www.ncbi.nlm.nih.gov/pubmed/19668044", "http://www.ncbi.nlm.nih.gov/pubmed/18056506", "http://www.ncbi.nlm.nih.gov/pubmed/17361376", "http://www.ncbi.nlm.nih.gov/pubmed/15316123", "http://www.ncbi.nlm.nih.gov/pubmed/15497527", "http://www.ncbi.nlm.nih.gov/pubmed/12614858", "http://www.ncbi.nlm.nih.gov/pubmed/10879718", "http://www.ncbi.nlm.nih.gov/pubmed/8748801", "http://www.ncbi.nlm.nih.gov/pubmed/19210868", "http://www.ncbi.nlm.nih.gov/pubmed/24842523", "http://www.ncbi.nlm.nih.gov/pubmed/27818601", "http://www.ncbi.nlm.nih.gov/pubmed/27733419"], "ideal_answer": ["Crowned dens syndrome is a rare form of \"crown-like\" calcifications around the dens and often presents with recurrent neck pain, stiffness of neck, increased erythrocyte sedimentation rate, and episodes of fever."], "type": "summary", "id": "589a245e78275d0c4a000029", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "BACKGROUND: Patients with crowned dens syndrome (CDS), which is pseudogout of the atlantoaxial junction induced by \"crown-like\" calcifications around the dens, present with symptoms of severe neck pain, rigidity, and high fever. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25910825", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "BACKGROUND CONTEXT: Crowned dens syndrome (CDS) is a rare form of calcium phosphate crystal depositions and often presents with recurrent neck pain, stiffness of neck, increased erythrocyte sedimentation rate, and episodes of fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26008686", "endSection": "abstract"}, {"offsetInBeginSection": 73, "offsetInEndSection": 295, "text": "A CT scan revealed calcification of the transverse ligament and crown-like calcification around the odontoid process. According to the clinical and radiological findings, she was diagnosed with crowned dens syndrome (CDS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26370870", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 285, "text": "Crystal deposition in the cervical spine around the odontoid process may lead to acute neck pain. This rare condition is called crowned dens syndrome and should be considered in the differential diagnosis of a possible etiology for fever, headache and cervical pain of unknown origin. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25196626", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 352, "text": "Crowned dens syndrome (CDS), related to microcrystalline deposition in the periodontoid process, is the main cause of acute or chronic cervical pain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24926265", "endSection": "abstract"}, {"offsetInBeginSection": 71, "offsetInEndSection": 292, "text": "Axial calcium pyrophosphate dihydrate deposition disease (CPDD) is well known for cervical spine involvement with the crowned dens syndrome but other localisations are probably underdiagnosed in sterile spondylodiscitis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23932725", "endSection": "abstract"}]}, {"body": "Which protein mediates gene loop formation in the yeast S. cerevisiae?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24124207", "http://www.ncbi.nlm.nih.gov/pubmed/22081613", "http://www.ncbi.nlm.nih.gov/pubmed/21835917", "http://www.ncbi.nlm.nih.gov/pubmed/19602510", "http://www.ncbi.nlm.nih.gov/pubmed/18550805", "http://www.ncbi.nlm.nih.gov/pubmed/17803944"], "ideal_answer": ["Moreover, looping is dependent upon the general transcription factor TFIIB: the E62K (glutamic acid 62 --> lysine) form of TFIIB adversely affects looping at every gene tested, including BLM10, SAC3, GAL10, SEN1, and HEM3. TFIIB crosslinks to both the promoter and terminator regions of the PMA1 and BLM10 genes, and its association with the terminator, but not the promoter, is adversely affected by E62K and by depletion of the Ssu72 component of the CPF 3' end processing complex, and is independent of TBP.", "Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB. TFIIB crosslinks to both the promoter and terminator regions of the PMA1 and BLM10 genes, and its association with the terminator, but not the promoter, is adversely affected by E62K and by depletion of the Ssu72 component of the CPF 3' end processing complex, and is independent of TBP", "Gene looping, defined as the interaction of the promoter and the terminator regions of a gene during transcription, requires transcription factor IIB (TFIIB).", "A transcription-independent role for TFIIB in gene looping."], "exact_answer": [["TFIIB"]], "type": "factoid", "id": "58adc1ff9ef3c34033000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "A transcription-independent role for TFIIB in gene looping.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17803944", "endSection": "title"}, {"offsetInBeginSection": 290, "offsetInEndSection": 510, "text": "Moreover, looping is dependent upon the general transcription factor TFIIB: the E62K (glutamic acid 62 -->lysine) form of TFIIB adversely affects looping at every gene tested, including BLM10, SAC3, GAL10, SEN1, and HEM3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17803944", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 798, "text": "TFIIB crosslinks to both the promoter and terminator regions of the PMA1 and BLM10 genes, and its association with the terminator, but not the promoter, is adversely affected by E62K and by depletion of the Ssu72 component of the CPF 3' end processing complex, and is independent of TBP", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17803944", "endSection": "abstract"}, {"offsetInBeginSection": 962, "offsetInEndSection": 1066, "text": "We present a high-resolution genome-wide map of TFIIB locations that implicates 3' NFRs in gene looping.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18550805", "endSection": "abstract"}, {"offsetInBeginSection": 837, "offsetInEndSection": 1107, "text": "Instead, activators physically interacted with the general transcription factor TFIIB when the genes were activated and in a looped configuration. TFIIB cross-linked to both the promoter and the terminator regions during the transcriptionally activated state of a gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19602510", "endSection": "abstract"}, {"offsetInBeginSection": 1292, "offsetInEndSection": 1428, "text": " We propose that the activators facilitate gene looping through their interaction with TFIIB during transcriptional activation of genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19602510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Gene looping, defined as the interaction of the promoter and the terminator regions of a gene during transcription, requires transcription factor IIB (TFIIB).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21835917", "endSection": "abstract"}, {"offsetInBeginSection": 159, "offsetInEndSection": 272, "text": "We have earlier demonstrated association of TFIIB with the distal ends of a gene in an activator-dependent manner", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21835917", "endSection": "abstract"}, {"offsetInBeginSection": 1578, "offsetInEndSection": 1698, "text": "Furthermore, TFIIB interaction with the CF1 complex and Pap1 is crucial for gene looping and transcriptional regulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21835917", "endSection": "abstract"}, {"offsetInBeginSection": 70, "offsetInEndSection": 226, "text": "TFIIB also cross-links to terminator regions and is required for gene loops that juxtapose promoter-terminator elements in a transcription-dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22081613", "endSection": "abstract"}, {"offsetInBeginSection": 1125, "offsetInEndSection": 1252, "text": "These results define a novel, functional interaction between TFIIB and Ssl2 that affects start site selection and gene looping.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22081613", "endSection": "abstract"}, {"offsetInBeginSection": 249, "offsetInEndSection": 361, "text": "Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24124207", "endSection": "abstract"}]}, {"body": "Does CRISPR inversion of CTCF sites alter genome topology?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26276636"], "ideal_answer": ["Yes. CRISPR inversion of CTCF sites alters genome topology."], "exact_answer": "yes", "type": "yesno", "id": "587e440f2420191125000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "CRISPR Inversion of CTCF Sites Alters Genome Topology and Enhancer/Promoter Function", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26276636", "endSection": "title"}, {"offsetInBeginSection": 258, "offsetInEndSection": 1185, "text": "To test the functional significance of this observation, we combined CRISPR/Cas9-based genomic-DNA-fragment editing with chromosome-conformation-capture experiments to show that the location and relative orientations of CBSs determine the specificity of long-range chromatin looping in mammalian genomes, using protocadherin (Pcdh) and \u03b2-globin as model genes. Inversion of CBS elements within the Pcdh enhancer reconfigures the topology of chromatin loops between the distal enhancer and target promoters and alters gene-expression patterns. Thus, although enhancers can function in an orientation-independent manner in reporter assays, in the native chromosome context, the orientation of at least some enhancers carrying CBSs can determine both the architecture of topological chromatin domains and enhancer/promoter specificity. These findings reveal how 3D chromosome architecture can be encoded by linear genome sequences", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26276636", "endSection": "abstract"}]}, {"body": "Which are the causes of the Koebner phenomenon?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25046469", "http://www.ncbi.nlm.nih.gov/pubmed/15854039", "http://www.ncbi.nlm.nih.gov/pubmed/12195563", "http://www.ncbi.nlm.nih.gov/pubmed/10348006", "http://www.ncbi.nlm.nih.gov/pubmed/21715249"], "ideal_answer": ["The causes of the Koebner phenomenon are:\n1) Lichen sclerosus\n2) Vitiligo\n3) Psoriasis and \n4) Physical stress."], "exact_answer": [["Lichen sclerosus"], ["Vitiligo"], ["Psoriasis"], ["Physical stress"], ["Lichen planus"]], "type": "list", "id": "58bfcb8702b8c60953000016", "snippets": [{"offsetInBeginSection": 205, "offsetInEndSection": 284, "text": "Lichen sclerosus has been reported at sites of injury as a Koebner phenomenon. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25046469", "endSection": "abstract"}, {"offsetInBeginSection": 1260, "offsetInEndSection": 1504, "text": "Therefore, lower expression of keratinocyte-derived factors, including SCF, in vitiliginous keratinocytes, which could result from keratinocyte apoptosis, might be responsible for passive melanocyte death and may explain the Koebner phenomenon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15854039", "endSection": "abstract"}, {"offsetInBeginSection": 88, "offsetInEndSection": 300, "text": "Deprivation of survival factors causes the apoptosis of melanocytes. Vitiligo often develops following physical trauma, even if this is minor. The exact mechanism of the Koebner phenomenon in vitiligo is unclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15854039", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "First described in 1877 as the appearance of psoriatic lesions in the uninvolved skin of psoriatic patients as a consequence of trauma, the Koebner phenomenon has since been described in numerous diseases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12195563", "endSection": "abstract"}, {"offsetInBeginSection": 983, "offsetInEndSection": 1210, "text": "The Koebner phenomenon is known to occur (lichen sclerosus occurs in skin already scarred or damaged), so trauma, injury, and sexual abuse have been suggested as possible triggers of symptoms in genetically predisposed people. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10348006", "endSection": "abstract"}, {"offsetInBeginSection": 764, "offsetInEndSection": 948, "text": "The triggering role of physical stress is seen in the \"deep Koebner\" phenomenon, which causes inflammation in the synovial membrane and in enthesis, resulting in peripheral arthritis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715249", "endSection": "abstract"}]}, {"body": "What is the function of the DGAT1 gene product?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25687632"], "ideal_answer": ["Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in the acyl-CoA-dependent triacylglycerol biosynthesis", "Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in the acyl-CoA-dependent triacylglycerol biosynthesis. . . . . ", "Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in the acyl-CoA-dependent triacylglycerol biosynthesis.", "Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in the acyl-CoA-dependent triacylglycerol biosynthesis, the enzyme catalyzes a key step in lipid biosynthesis.", "diacylglycerol acyltransferase 1 (dgat1) catalyzes the final step in the acyl-coa-dependent triacylglycerol biosynthesis."], "type": "summary", "id": "58cbf1f402b8c60953000036", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in the acyl-CoA-dependent triacylglycerol biosynthesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25687632", "endSection": "abstract"}]}, {"body": "Which disease(s) are caused by HEX A deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20100466", "http://www.ncbi.nlm.nih.gov/pubmed/15108204", "http://www.ncbi.nlm.nih.gov/pubmed/25606403", "http://www.ncbi.nlm.nih.gov/pubmed/9073025", "http://www.ncbi.nlm.nih.gov/pubmed/7717398", "http://www.ncbi.nlm.nih.gov/pubmed/2220809"], "ideal_answer": ["Mutations in the HEX A gene, encoding the alpha-subunit of beta-hexosaminidase A (Hex A), are the cause of Tay-Sachs disease as well as of juvenile, chronic, and adult GM2 gangliosidoses."], "type": "summary", "id": "58cea0768acda34529000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Tay-Sachs disease (TSD) is a recessively inherited neurodegenerative disorder due to mutations in the HEXA gene resulting in a beta-hexosaminidase A (Hex A) deficiency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100466", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Rapid identification of HEXA mutations in Tay-Sachs patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100466", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "Tay-Sachs disease (TSD) is a recessively inherited neurodegenerative disorder caused by mutations in the HEXA gene resulting in \u03b2-hexosaminidase A (HEX A) deficiency and neuronal accumulation of GM2 ganglioside.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25606403", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "Tay-Sachs disease is a genetically determined neurodegenerative disorder, resulting from mutations of the hexosaminidase (Hex) A gene coding for the alpha-subunit of beta-D-N-acetyl-hexosaminidase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9073025", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Tay-Sachs disease (TSD) results from mutations in HEXA that cause Hex A deficiency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7717398", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Mutations in the HEX A gene, encoding the alpha-subunit of beta-hexosaminidase A (Hex A), are the cause of Tay-Sachs disease as well as of juvenile, chronic, and adult GM2 gangliosidoses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2220809", "endSection": "abstract"}]}, {"body": "Which two drugs were compared in the ARISTOTLE Trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26447668", "http://www.ncbi.nlm.nih.gov/pubmed/26839066", "http://www.ncbi.nlm.nih.gov/pubmed/25547937", "http://www.ncbi.nlm.nih.gov/pubmed/25854636", "http://www.ncbi.nlm.nih.gov/pubmed/24281250"], "ideal_answer": ["Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial compared apixaban and warfarin."], "exact_answer": [["apixaban"], ["warfarin"]], "type": "list", "id": "589a246178275d0c4a00002b", "snippets": [{"offsetInBeginSection": 262, "offsetInEndSection": 465, "text": "METHODS: We analyzed patients from ARISTOTLE, a randomized trial of 18,201 patients with atrial fibrillation comparing the effects of apixaban versus warfarin on the risk of stroke or systemic embolism. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26447668", "endSection": "abstract"}, {"offsetInBeginSection": 138, "offsetInEndSection": 469, "text": " In this study we evaluated the relationship between inflammatory biomarkers at baseline and future risk of cardiovascular events in the Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.METHODS: The ARISTOTLE trial randomised 18,201 patients with AF to apixaban or warfarin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26839066", "endSection": "abstract"}, {"offsetInBeginSection": 1391, "offsetInEndSection": 1562, "text": "Moreover, apixaban was associated with decreased all-cause mortality (RR 0.89, 95% CI 0.81 to 0.99) although this finding was driven by the results of the ARISTOTLE trial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25547937", "endSection": "abstract"}, {"offsetInBeginSection": 671, "offsetInEndSection": 880, "text": "Compared with warfarin, apixaban (in the ARISTOTLE trial) and edoxaban (in the ENGAGE-AF trial) were shown to be superior or non-inferior, respectively, for reduction in stroke or SE risk in patients with AF. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854636", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 434, "text": "METHODS: A decision-analytic Markov model was constructed to assess the cost-effectiveness of apixaban versus warfarin, based on data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF (ARISTOTLE) trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24281250", "endSection": "abstract"}]}, {"body": "Which histone mutation is associated with gliomas?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26957305", "http://www.ncbi.nlm.nih.gov/pubmed/27034984", "http://www.ncbi.nlm.nih.gov/pubmed/27701736", "http://www.ncbi.nlm.nih.gov/pubmed/25525250"], "ideal_answer": ["Pediatric central nervous system tumors are the most common solid tumor of childhood. Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3.", "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3. Genome-wide analyses indicate a resetting of the transformed precursors to a developmentally more primitive stem cell state, with evidence of major modifications of histone marks at several master regulator genes.", "some of these molecular changes with clinicopathological utility have been used for the first time in the most recent edition of the world health organization (who) classification of cns tumours to define entities like ependymoma, rela fusion-positive or diffuse midline glioma, h3 k27m-mutant.", "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3"], "exact_answer": [["K27M in H3.3"]], "type": "factoid", "id": "58bac71222d3005309000013", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "abstract"}, {"offsetInBeginSection": 359, "offsetInEndSection": 546, "text": "We show that H3.3K27M expression synergizes with p53 loss and PDGFRA activation in neural progenitor cells derived from human embryonic stem cells, resulting in neoplastic transformation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "abstract"}, {"offsetInBeginSection": 436, "offsetInEndSection": 730, "text": "Some of these molecular changes with clinicopathological utility have been used for the first time in the most recent edition of the World Health Organization (WHO) classification of CNS tumours to define entities like ependymoma, RELA fusion-positive or diffuse midline glioma, H3 K27M-mutant.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27701736", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 828, "text": "The recent discovery of somatic oncogenic mutations affecting chromatin regulation in pediatric high-grade glioma has markedly improved our understanding of disease pathogenesis, and these findings have stimulated the development of novel therapeutic approaches targeting epigenetic regulators for disease treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27034984", "endSection": "abstract"}]}, {"body": "What is the purpose of HaploReg v4?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26657631"], "ideal_answer": ["HaploReg v4 enables the systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease."], "type": "summary", "id": "587f60f892a5b8ad44000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657631", "endSection": "title"}, {"offsetInBeginSection": 725, "offsetInEndSection": 1351, "text": "Since first launching the website in 2011, we have greatly expanded HaploReg, increasing the number of chromatin state maps to 127 reference epigenomes from ENCODE 2012 and Roadmap Epigenomics, incorporating regulator binding data, expanding regulatory motif disruption annotations, and integrating expression quantitative trait locus (eQTL) variants and their tissue-specific target genes from GTEx, Geuvadis, and other recent studies. We present these updates as HaploReg v4, and illustrate a use case of HaploReg for attention deficit hyperactivity disorder (ADHD)-associated SNPs with putative brain regulatory mechanisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657631", "endSection": "abstract"}]}, {"body": "Which virus type causes Molluscum contagiosum?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22688765", "http://www.ncbi.nlm.nih.gov/pubmed/21228810", "http://www.ncbi.nlm.nih.gov/pubmed/21802105", "http://www.ncbi.nlm.nih.gov/pubmed/10500212", "http://www.ncbi.nlm.nih.gov/pubmed/10502526"], "ideal_answer": ["Molluscum contagiosum virus (MCV) is a human poxvirus that causes tumor-like skin lesions."], "exact_answer": [["human poxvirus"]], "type": "factoid", "id": "58bfd0db02b8c60953000017", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Molluscum contagiosum virus (MCV), a poxvirus pathogenic for humans, replicates well in human skin in vivo, but not in vitro in standard monolayer cell cultures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22688765", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Molluscum contagiosum virus (MCV) is a poxvirus that causes tumor-like skin lesions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21228810", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Molluscum contagiosum poxvirus (MCV) type 1 and type 2 encode two chemokine-like proteins MC148R1 and MC148R2. I", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21802105", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Molluscum contagiosum virus (MCV) is a common, human poxvirus that causes small papular skin lesions that persist for long periods without signs of inflammation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10500212", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 311, "text": "All poxviruses studied encode a type 1B topoisomerase that introduces transient nicks into DNA and thereby relaxes DNA supercoils. Here we present a study of the protein domains of the topoisomerase of the poxvirus molluscum contagiosum (MCV), which allows us to specify DNA contacts made by different domains. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502526", "endSection": "abstract"}]}, {"body": "What tissue is most affected in Ehlers-Danlos syndromes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26958560"], "ideal_answer": ["the ehlers-danlos syndromes (eds) are a group of connective tissue disorders characterized by triad of joint hypermobility, skin extensibility, and tissue fragility.", "The Ehlers-Danlos syndromes (EDS) are a group of connective tissue disorders characterized by triad of joint hypermobility, skin extensibility, and tissue fragility.", "The Ehlers-Danlos syndromes (EDS) are a group of connective tissue disorders characterized by triad of joint hypermobility, skin extensibility, and tissue fragility. "], "exact_answer": [["connective tissue"]], "type": "factoid", "id": "58cdb41302b8c60953000042", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "The Ehlers-Danlos syndromes (EDS) are a group of connective tissue disorders characterized by triad of joint hypermobility, skin extensibility, and tissue fragility. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26958560", "endSection": "abstract"}]}, {"body": "What is Mondor's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26971966", "http://www.ncbi.nlm.nih.gov/pubmed/24989360", "http://www.ncbi.nlm.nih.gov/pubmed/25667776", "http://www.ncbi.nlm.nih.gov/pubmed/25530373"], "ideal_answer": ["Mondor's disease is a rare benign and self-limiting condition characterized by thrombophlebitis of the superficial veins of the anterolateral thoracoabdominal wall and genital area."], "type": "summary", "id": "589a246778275d0c4a00002f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "INTRODUCTION: Mondor's disease is a rare superficial thrombophlebitis, historically involving the thoracic venous system of women. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26971966", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Mondor's disease is a rare benign and self-limiting condition characterized by thrombophlebitis of the superficial veins of the anterolateral thoracoabdominal wall.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24989360", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Mondor's disease is a rare condition characterized by a superficial thrombophlebitis that can occur in the thoracoabdominal and genital areas. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25667776", "endSection": "abstract"}, {"offsetInBeginSection": 1419, "offsetInEndSection": 1680, "text": "CONCLUSION: Penile Mondor disease is a rare complication that can be successfully treated with medical therapy and conservative approach. Our series showed that penile Mondor's disease does not lead to permanent deformation of the penis or erectile dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25530373", "endSection": "abstract"}]}, {"body": "How are immediate early genes (IEG) defined?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19581597", "http://www.ncbi.nlm.nih.gov/pubmed/15507712", "http://www.ncbi.nlm.nih.gov/pubmed/11222693", "http://www.ncbi.nlm.nih.gov/pubmed/8783263"], "ideal_answer": ["this class of genes is experimentally defined by their transcription following primary infection or reactivation in the presence of inhibitors of protein synthesis. Immediate-early (IE) genes are the first class of viral genes expressed after primary infection or reactivation.", "this class of genes is experimentally defined by their transcription following primary infection or reactivation in the presence of inhibitors of protein synthesis.", "Immediate-early (IE) genes are the first class of viral genes expressed after primary infection or reactivation.", "Immediate-early (IE) genes are the first class of viral genes expressed after primary infection or reactivation. this class of genes is experimentally defined by their transcription following primary infection or reactivation in the presence of inhibitors of protein synthesis. . . . ", "Immediate-early (IE) genes are the first class of viral genes expressed after primary infection or reactivation. This class of genes is experimentally defined by their transcription following primary infection or reactivation in the presence of inhibitors of protein synthesis.", "Immediate-early (IE) genes are the first class of viral genes expressed after primary infection or reactivation. this class of genes is experimentally defined by their transcription following primary infection or reactivation in the presence of inhibitors of protein synthesis."], "type": "summary", "id": "58c2556302b8c6095300001f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Immediate-early (IE) genes are the first class of viral genes expressed after primary infection or reactivation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15507712", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 354, "text": "this class of genes is experimentally defined by their transcription following primary infection or reactivation in the presence of inhibitors of protein synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15507712", "endSection": "abstract"}]}, {"body": "Which library is used for fixed-length approximate string matching?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27832739"], "ideal_answer": ["libFLASM is a free open-source C++ software library for solving fixed-length approximate string matching under both the edit and the Hamming distance models."], "exact_answer": [["libFLASM"]], "type": "factoid", "id": "587f7a69d8d850a152000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "libFLASM: a software library for fixed-length approximate string matching.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27832739", "endSection": "title"}, {"offsetInBeginSection": 862, "offsetInEndSection": 1737, "text": "We present and make available libFLASM, a free open-source C++ software library for solving fixed-length approximate string matching under both the edit and the Hamming distance models. Moreover we describe how fixed-length approximate string matching is applied to solve real problems by incorporating libFLASM into established applications for multiple circular sequence alignment as well as single and structured motif extraction. Specifically, we describe how it can be used to improve the accuracy of multiple circular sequence alignment in terms of the inferred likelihood-based phylogenies; and we also describe how it is used to efficiently find motifs in molecular sequences representing regulatory or functional regions. The comparison of the performance of the library to other algorithms show how it is competitive, especially with increasing distance thresholds.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27832739", "endSection": "abstract"}, {"offsetInBeginSection": 1750, "offsetInEndSection": 2164, "text": "Fixed-length approximate string matching is a generalisation of the classic approximate string matching problem. We present libFLASM, a free open-source C++ software library for solving fixed-length approximate string matching. The extensive experimental results presented here suggest that other applications could benefit from using libFLASM, and thus further maintenance and development of libFLASM is desirable", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27832739", "endSection": "abstract"}]}, {"body": "Which disease the skin condition Necrobiosis lipoidica diabeticorum is associated to?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25266162", "http://www.ncbi.nlm.nih.gov/pubmed/24575162", "http://www.ncbi.nlm.nih.gov/pubmed/19715570", "http://www.ncbi.nlm.nih.gov/pubmed/19380665"], "ideal_answer": ["Necrobiosis lipoidica diabeticorum (NLD) is a rare, granulomatous inflammatory skin disease of unknown origin, sometimes associated with diabetes mellitus."], "exact_answer": [["Diabetes mellitus"]], "type": "factoid", "id": "58bfd8e902b8c60953000018", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "Necrobiosis lipoidica diabeticorum (NLD) is a chronic condition, which is characterized by single or multiple lesions on the legs, and occurs in 0.3% of patients with diabetes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25266162", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 221, "text": "Necrobiosis lipoidica (NL) is a rare chronic granulomatous dermatitis that usually appears in the lower extremities. It affects about 0.3-1.2% of diabetic patients, the majority of whom have type 1 diabetes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24575162", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 244, "text": "A 32-year-old woman with type 2 diabetes mellitus suffering from morbid obesity with BMI 45,14\u2009kg/m(2) was operated on. Not only the type 2DM but also one of its complication known as necrobiosis lipoidica diabeticorum remitted postoperatively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23762652", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 616, "text": "Necrobiosis lipoidica is a granulomatous skin disease of unknown etiology, associated mainly with diabetes mellitus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23762652", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 133, "text": "Necrobiosis lipoidica diabeticorum is a rare disease of unclear etiology, that occurs in about 1% of diabetic patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715570", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 168, "text": "Necrobiosis lipoidica diabeticorum (NLD) is a rare, granulomatous inflammatory skin disease of unknown origin, sometimes associated with diabetes mellitus. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19380665", "endSection": "abstract"}]}, {"body": "Is Doxorubicin cardiotoxic?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27735842"], "ideal_answer": ["Doxorubicin (DOXO) is widely used to treat solid tumors. However, its clinical use is limited by side effects including serious cardiotoxicity due to cardiomyocyte damage", "Doxorubicin (DOXO) is widely used to treat solid tumors. However, its clinical use is limited by side effects including serious cardiotoxicity due to cardiomyocyte damage. "], "exact_answer": "yes", "type": "yesno", "id": "58cdb80302b8c60953000043", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Doxorubicin (DOXO) is widely used to treat solid tumors. However, its clinical use is limited by side effects including serious cardiotoxicity due to cardiomyocyte damage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27735842", "endSection": "abstract"}]}]}